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SUMMARY 
 
Eosinophilic inflammation, imbalance of eicosanoid production and bacterial infection has been considered 
crucial factors in the pathophysiology of upper airway diseases. The aim of this work was to study the 
regulation of the eicosanoid pathway and its relation with the eosinophilic inflammatory process in chronic 
rhinosinusitis/nasal polyposis. Subsequently we investigated the possible role of an immune response against 
Staphylococcus aureus in the regulation of these inflammatory mechanisms in nasal tissue and structural 
cells. 
 
Our first objective was to develop a reliable and accurate real-time PCR methodology for mRNA 
quantification of the two spliced receptor variants of the IL-5 receptor alpha. Extensive work has covered the 
regulation of the IL-5 receptor at protein level. However, the lack of a sensitive gene expression assay 
difficult the detection of small changes at its transcription level. We developed an assay with efficiency 
higher than 95% and a coefficient of variation less than 25% that allowed us to study the regulation of the 
splice variants of this receptor and confirm previous results from protein analysis.  
 
Furthermore, we analyzed the expression stability of internal reference genes and the influence of tissue 
degradation in their expression profile in chronic rhinosinusitis/ nasal polyp tissue. This work showed that 
the stability of reference genes is different in chronic rhinosinusitis and nasal polyp mucosa. We were able to 
select adequate internal reference genes for accurate and reliable gene expression studies in these tissues. 
 
Once the previous objectives were achieved, we study the eicosanoid and eicosanoid receptors regulation in 
chronic rhinosinusitis/ nasal polyposis and their possible role in aspirin intolerance. Here we showed that 
CysLTs and CysLTs receptor expression increased with severity of inflammation, in contrast to PGE2 that 
was down-regulated and inversely related to inflammation. Results of these studies suggest that changes in 
eicosanoid production may occur in chronic rhinosinusitis in absence of aspirin sensitivity syndrome and that 
they may not be specific but a parallel phenomenon linked to inflammation. Furthermore, EP2 and EP4 
receptor expression was increased in chronic rhinosinusitis and nasal polyp subjects in contrast to EP1 and 
EP3, which were down regulated in the polyp group, suggesting a distinctive role of these receptors in the 
pathophysiology of nasal polyposis.  
 
Finally, based on our previous findings and parallel work of our group, we studied the influence of S. aureus 
enterotoxins in the regulation of both eosinophilic inflammatory and eicosanoid pathways. We first show that 
nasal polyposis/aspirin intolerance was associated with increased concentrations of eosinophil-related 
mediators, as well as of IgE antibodies to S. aureus enterotoxins. Furthermore, eicosanoid release evaluated 
in nasal polyp patients showed an increase of leukotrienes and lipoxin A4 in patients with immune response 
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against S. aureus enterotoxins, which seem to be correlated to the enterotoxin-derived inflammatory reaction 
and unrelated to asthma and allergy conditions.  
 
These findings were extended to structural cells (fibroblasts). These in vitro experiments demonstrated that 
S. aureus enterotoxin B could regulate the production of PGE2 and influence important cell physiological 
mechanisms like growth and migration. The results of our studies provide new insights about the molecular 
interactions and the role of bacterial infection in the regulation of two crucial inflammatory mechanisms 
operating in airway human diseases, the eicosanoid biosynthetic and the eosinophilic pathways 
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SAMENVATTING 
  
Eosinofiele inflammatie, verstoord evenwicht in de productie van eicosanoïden en bacteriële infectie worden 
beschouwd als cruciale factoren in de pathofysiologie van aandoeningen van de bovenste luchtwegen. Dit 
werk had als doel de regulatie van de eicosanoïde pathway en zijn relatie met het eosinofiele inflammatoire 
proces bij chronische rhinosinusitis/nasale polypose te bestuderen. Verder onderzochten we ook de 
mogelijke rol van de immuunrespons tegen S. aureus in de regulatie van deze inflammatoire processen in 
nasaal weefsel en structurele cellen. 
  
Ons eerste doel was het ontwikkelen van een betrouwbare en accurate real-time PCR methodologie voor 
mRNA kwantificering van de twee spliced varianten van de IL-5 alfa receptor. Intensief onderzoek ging uit 
naar de regulatie van deze receptor op proteïne niveau. Het gebrek aan een gevoelige gen-expressie 
analysemethode bemoeilijkte echter de detectie van kleine veranderingen op transcriptie niveau. We 
slaagden er uiteindelijk in een methode te ontwikkelen met een efficiëntie groter dan 95% en een 
variatiecoëfficiënt lager dan 25%, die ons eveneens toeliet de vroegere resultaten van proteïneanalysen te 
bevestigen.  
 
Bovendien analyseerden we de expressiestabiliteit van interne referentiegenen en de invloed van 
weefseldegradatie op hun expressiepatroon in chronisch rhinosinusitis-/neuspoliepweefsel. Dit werk toonde 
aan dat de stabiliteit van referentiegenen verschillend is in de mucosa van chronische rhinosinusitis en nasale 
polypose. Bij deze studies konden we de beste interne referentiegenen selecteren voor accurate en 
betrouwbare gen-expressies in deze weefsels. 
 
Eens deze doelstellingen bereikt werden, gingen we over tot onderzoek naar de regulatie van eicosanoïden en 
eicosanoïdreceptoren bij chronische rhinosinusitis/nasale polypose en hun mogelijke rol bij aspirine-
overgevoeligheid. We toonden aan dat de expressie van CysLTs en CysLTs receptoren toeneemt met de 
ernst van inflammatie, in tegenstelling tot PGE2, dat was down-gereguleerd en omgekeerd gerelateerd   aan 
de ernst van inflammatie. De resultaten van deze studie suggereren dat veranderingen in 
eicosanoïdproductie kunnen voorkomen bij chronische rhinosinusitis in afwezigheid van 
aspirinegevoeligheid en dat zij geen specifiek maar een parallel fenomeen zouden zijn gelinkt aan eosinofiele 
inflammatie. Bovendien was de expressie van de EP2 en EP4 receptoren verhoogd bij chronische 
rhinosinusitis, in tegenstelling tot EP1 en EP3, die down-gereguleerd waren bij patiënten met nasale polypose. 
Dit suggereert een specifieke rol van deze receptoren in de pathophysiologie van nasale polypose.   
 
Op basis van deze bevindingen, en in de lijn van het onderzoek van ons labo, gingen we ook de invloed na 
van S. aureus enterotoxines op de regulatie van eosinofiele inflammatoire en eicosanoïde pathways. We 
  
 
 
 
 
- 20 - 
toonden aan dat nasale polypose/aspirine-overgevoeligheid geassocieerd is met verhoogde concentraties van 
eosinofiel-gerelateerde mediatoren, alsook van IgE antilichamen tegen S. aureus enterotoxines. We konden 
echter geen directe impact aantonen van deze enterotoxines op de manifestatie van aspirine-
overgevoeligheid. Daarnaast konden we vaststellen dat de release van eicosanoïden bij patiënten met nasale 
polypose en immuunrespons tegen S. aureus enterotoxines, zich kenmerkt door een toename aan 
leukotrienen en lipoxin A4. Die zijn op hun beurt gecorreleerd aan de enterotoxine-gemedieerde 
inflammatoire reactie, maar niet gerelateerd aan astma en allergie.  
 
We breidden onze bevindingen uit naar structurele cellen (fibroblasten). Met een in-vitro experiment toonden 
we aan dat S. aureus enterotoxine B de productie van PGE2 kan reguleren en belangrijke cellulaire 
fysiologische mechanismen zoals groei en migratie kan beïnvloeden. De resultaten van onze studies brengen 
nieuwe inzichten in de moleculaire interacties en in de rol van bacteriële infectie in de regulatie van twee 
cruciale inflammatoire mechanismen bij humane luchtwegpathologie: de eosinofiele en de eicosanoïde 
biosynthetische pathway. 
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RÉSUMÉ 
 
L’inflammation éosinophilique, un déséquilibre dans la production d’éicosanoïdes et l’infection bactérienne 
ont été considérés comme des facteurs cruciaux dans la physiopathologie des maladies des voies respiratoires 
supérieures. Le but de ce travail était d’étudier la régulation des voies des éicosanoïdes et de sa relation avec 
les processus d’inflammation éosinophilique dans la sinusite chronique/polypose naso-sinusienne. Par la 
suite, nous avons investigués la réponse immunologique possible contre S. aureus dans la régulation des 
mécanismes inflammatoires des tissus nasaux et des cellules structurelles. 
 
Notre premier objectif était de développer une méthode reproductible et précise de real time PCR pour la 
quantification d’ARNm de deux variantes scindées d’un récepteur. Un travail important a décrit la régulation 
de ce récepteur au niveau protéïque. Cependant, le manque de test sensible pour l’expression génique a rendu 
difficile la détection de petits changements au niveau transcriptionnel. Nous avons développé un test avec 
une efficacité supérieure à 95 % et un coefficient de variation inférieur à 25 % qui nous permet de confirmer 
les résultats précédents de l’analyse protéique.  
 
De plus, nous avons analysé la stabilité d’expression des gènes de référence internes et l’influence du 
dommage tissulaire sur leur profil d’expression dans la sinusite chronique et la polypose nasosinusienne. Ce 
travail a démontré que la stabilité des gènes de référence est différente dans la sinusite chronique et la 
polypose naso-sinusienne. Nous sommes capables de sélectionner les meilleurs gènes de référence internes 
pour des études d’expression géniques reproductibles et précis dans ces tissus. 
 
Une fois les premiers objectifs atteints, nous avons étudié la régulation des éicosanoïdes et de leur récepteurs 
dans la sinusite chronique /polypose naso-sinusienne et de leur rôle possible dans l’intolérance à l’aspirine. 
Nous avons démontré ici, que l’expression des CysLTs et de leurs récepteurs CysLTs augmentait avec la 
sévérité de l’inflammation, au contraire de la PGE2 qui était sous exprimée et inversément corrélée à 
l’inflammation. De manière intéressante, l’expression des récepteurs EP2 et EP4 était augmentée dans la 
sinusite chronique à la différence des récepteurs EP1 et EP3 qui sont sous exprimés chez les patients 
polypeux. Les résultats de ces études suggèrent des changements dans la production d’éicosanoïdes dans la 
sinusite chronique en absence d’intolérance d’aspirine et qu’ils ne sont pas spécifiques mais seraient un 
phénomène parallèle lié à l’inflammation. 
 
Enfin, basés sur nos résultats précédents et sur des travaux parallèles dans notre groupe, nous nous sommes 
posés la question de l’influence des entérotoxines de S. aureus dans la régulation, d’une part, de 
l’inflammation éosinophilique et, d’autre part, de la cascade éicosanoïque. Nous avons d’abord montré que la 
polypose naso-sinusienne/ intolérance à l’aspirine était associée à des concentrations plus élevées de 
médiateurs éosinophiliques, ainsi que des anticorps IgE contre les entérotoxines du S. aureus. Cependant, 
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nous n’avons pas trouvé d’impact direct de ces entérotoxines sur la manifestation de l’intolérance à 
l’aspirine. De plus, la libération d’éicosanoïdes évaluée chez des patients polypeux montrait une 
augmentation de leucotriènes et de LXA4 chez les patients ayant une réponse immunitaire contre les 
entérotoxines de S.aureus qui semble corrélée à la réaction inflammatoire entérotoxine-dérivée et non relatée 
à l’asthme ou des conditions allergiques.  
 
Ces  éléments furent étendus aux cellules structurelles de type fibroblaste. Cette expérimentation in vitro a 
démontré que l’entérotoxine B du S. aureus peut réguler la production de PGE2 et influencer des mécanismes 
importantes telles les croissances et la migration. Les résultats de nos études proposent une vision nouvelle 
des interactions moléculaires et du rôle de l’infection bactérienne dans la régulation de deux mécanismes 
inflammatoires cruciaux intervenant dans les maladies respiratoires humaines: la biosynthèse des 
éicosanoïdes et la marche éosinophilique. 
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CHAPTER 1 
 
CHRONIC RHINOSINUSITIS AND NASAL POLYPOSIS, 
DEFINITION AND IMMUNOLOGICAL ASPECTS 
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CLINICAL DEFINITION, HISTOMORPHOLOGY AND DIAGNOSIS 
 
Chronic rhinosinusitis 
 
Rhinosinusitis is a group of disorders characterized by inflammation of the mucosa of the nose and paranasal 
sinuses with a prevalence rate of about 10- 30% of the population in Europe and 15% of the population in the 
USA (Moss et al., 1986). Rhinosinusitis can be classified according to the temporal course of the disease 
(duration and frequency of episodes) as: a) acute rhinosinusitis, b) recurrent acute or chronic rhinosinusitis, 
and c) acute exacerbations of chronic sinusitis (Lanza et al., 1997). 
 
Chronic rhinosinusitis has been defined as an inflammatory reaction of the paranasal mucous membrane, 
which might be based on viral or bacterial infections and is mainly characterized by an accumulation of 
inflammatory cells in the lamina propria, with some unspecific lesions such as edema, fibrosis or epithelial 
degradation (Van Cauwenberge et al., 2004). Diagnosis of chronic rhinosinusitis is based on the presence of 
typical sings such as discoloured nasal drainage arising from the nasal passages, oedema, or erythema of the 
middle meatus that persist longer than 12 weeks or more. This accompanied by a pathologic CT- scan 
showing diffuse mucosal thickening, opacification or swelling of the ethmoidal and maxillary mucosa with 
bilateral obstruction of the osteomeatal complex, but without polyp formation visible during nasal endoscopy 
or during surgery (Benninger et al., 2003). 
 
Chronic rhinosinusitis/ nasal polyposis 
 
Nasal polyposis is defined as a multifactorial disease consisting of tissue (nasal and sinus mucosa) 
infiltration by inflammatory cells, predominantly eosinophils, and the formation of pseudocysts with plasma 
exudation and albumin retention (Van Cauwenberge et al., 2004). Clinically, its diagnosis is based on an 
endoscopy and CT- scan of the paranasal sinuses showing the presence of endoscopically visible bilateral 
polyps growing from the middle nasal meatus into the nasal cavities, and affecting ethmoidal and maxillary 
sinuses (Benninger et al., 2003). The typical history of a patient having nasal polyps is a “cold” that persist 
over months or years, with nasal obstruction and discharge as the most prominent symptoms. After some 
time, hyposmia or anosmia and additional complaints appear (Drake e al., 1984).  
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CO- MORBIDITIES 
 
Asthma 
 
The association between sinusitis and asthma has been appreciated since long. Up to 70% of asthmatic 
patients also suffer from chronic rhinosinusitis (Annesi-Maesano et al., 1999) and there is circumstantial 
evidence that chronic rhinosinusitis may be linked to chronic lung disease, especially severe asthma (Rossi et 
al., 1994). However, the mechanisms by which sinusitis influences asthma are not well understood. This link 
between these diseases is supported by studies showing that abnormal sinus radiography are frequent in 
patients with asthma exacerbations, and that drug management of sinusitis (Rossi et al., 1994) or sinus 
surgery results in a significant improvement in asthma symptoms (Senior et al., 1999). In addition, nasal 
polyposis can also be frequently found in association with lower tract respiratory disorders, such as asthma 
and non-specific bronchial hyperreactivity (Lamblin et al., 1997). Up to 70% of patients with nasal polyposis 
have been reported to have asthma (Larsen et al., 1996). In addition, several studies have demonstrated the 
manifestation of bronchial hyper-reactivity in nasal polyp patients, even in those with no history of asthma 
(Kordash et al., 1975). Interestingly, patients with nasal polyposis and asymptomatic bronchial 
hyperreactivity have an eosinophilic inflammation similar to that observed in asthmatic patients with nasal 
polyposis, whereas patients with nasal polyposis without bronchial hyperreactivity do not have eosinophilic 
lower airways inflammation (Lamblin et al., 1999). 
 
Aspirin intolerance 
 
The aspirin intolerance triad is defined as a steroid-dependent asthma and nasal polyposis (rhinosinusitis) 
that starts with a prolonged episode of nasal congestion, rhinorrea, and hyposmia with persistent mucosal 
inflammation, followed by nasal polyposis, bronchial asthma and then aspirin intolerance after ingestion of 
aspirin and other non-steroidal anti-inflammatory drugs (Samter et al., 1968). About 80% of the patients 
registered at the European Network on Aspirin-Induced Asthma (AIANE) complain of nasal blockage 
accompanied by rhinorrhea and about 50% of patients are dependent on systemic and inhaled corticosteroids 
(Szczeklik et al., 1999). Between 40 and 80% of patients with aspirin intolerance, suffer from polyposis, and 
about 15% of polyp patients have been reported as aspirin intolerants (Settipane et al., 1996). Clinically, 
aspirin-intolerant rhinosinusitis is characterised by an increased eosinophil count in blood, nasal and 
bronchial mucosa (Szczeklik et al., 1999). This pathology has been often associated with allergy and high 
levels of local IgE (Zhu et al., 1997), however, an IgE-mediated mechanism has not been demonstrated, and 
atopy does not seem to influence the risk to develop the disease (Szczeklik et al., 2000). In addition, 
alterations in arachidonic acid metabolism have been suggested as one of the main factors driving the disease 
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(Szczeklik et al., 1999). The intake of aspirin inhibits the constitutively expressed cyclooxygenase-1 (COX-
1) and the inducible cyclooxygenase-2 (COX-2) enzymes. This inhibition results in a decrease of 
spontaneous synthesis of anti-inflammatory prostanoids like prostaglandin E2 (PGE2) leading to an enhanced 
5- lipoxygenase (5-LOX) activity (Pavord et al., 1995). Overexpression of leukotriene C4 synthase (LTC4S) 
has been demonstrated in eosinophils and mast cells, resulting in an overproduction of cysteinyl leukotrienes 
(Cys-LTs), which may be released into the airways causing nasal congestion, rhinorrhoea, 
bronchoconstriction and induce eosinophilia (Cowburn et al., 1998). So far, due to the lack of a validated 
clinical laboratory test, the diagnosis of this syndrome is based on oral, bronchial, or nasal provocation tests 
(Schapowal et al., 1995). In addition, there are conservative treatment possibilities consisting of 1) avoidance 
of aspirin and other non-steroidal antinflammatory drugs (NSAIDs), 2) oral and/ or topical 
glucocorticosteroids, 3) leukotriene receptor antagonists or leukotriene synthesis inhibitors and 4) in selected 
cases, aspirin desensitization. The course of the disease is independent from aspirin intake, indicating that 
factors other than aspirin could be responsible for this disease, which, with a few exceptions, remains present 
during the whole life. 
 
Allergy 
 
Several hypotheses have been postulated in order to explain the possible role of allergy in rhinosinusitis and 
nasal polyposis. Most of them tried to explain the link between allergy, tissue edema and sinus obstruction 
and inflammation, but without succeeding due to the lack of presence of sinusitis in some patients with 
seasonal rhinitis. However, later, it was suggested that perennial allergic (and non-allergic) rather than 
seasonal rhinitis might predispose to sinusitis (Berrettini et al. 1999). Due to the similarity of the clinical 
symptoms (late-onset asthma, elevated local IgE in polyp fluid and a pronounced tissue eosinophilia) 
between allergic rhinitis and nasal polyposis, allergy has also been considered a possible cause of nasal 
polyposis. However, the low percentage of atopic compared to non-atopic patients manifesting the disease 
(Caplin et al., 1971 and Settipane et al., 1996) and the lack of association between nasal polyp symptoms and 
skin prick test positivity exclude this theory.  Accordingly, so far allergy does not seem to be a predisposing 
factor for rhinosinusitis or nasal polyposis. 
 
Cystic fibrosis 
 
This is an autosomal recessive genetic disorder considered as one of the most common fatal inherited 
diseases. The cause of the disease is related to a mutation in the gene regulating the chloride transport in 
epithelial cells affecting the apical chloride transport, leading to an increase of mucus secretion (Yamaya et 
al., 1991). It has been suggested, that mutations in the gene responsible for cystic fibrosis may be associated 
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with the development of chronic rhinosinusitis or nasal polyposis (Wang et al. 2000). Approximately 10% to 
20% of cystic fibrosis patients have been eventually reported to require surgical treatment of their sinuses 
(Batsakis et al., 1996). Additonally, sinusitis is frequently detected in radiological investigations of patients 
with cystic fibrosis and the incidence of nasal polyps in this group of patients range from 6% to 48% (Cepero 
et al., 1987). In addition, bacteriology of maxillary sinuses has demonstrated bacterial infection in 95 % of 
all cases. The predominant organisms are Pseudomonas aeruginosa, Staphylococcus aureus, Hemophilus 
influenzae and anaerobes (Hadfield et al., 2000). Unfortunately, the response of these patients to 
antimicrobial therapy often is insufficient when compared to non- cystic fibrosis patients. However, it has 
been showed that the size of polyp is reduced when nasal corticosteroids are used (Hadfield et al., 2000). 
Finally, surgery is another alternative for these patients. However, because of the persistent nature of the 
disease it only offers a transient effect. Surgery should only be performed in case of sufficient symptomsand 
followed by a post- operative follow- up. 
 
PATHOMECHANISMS AND IMMUNOLOGICAL ASPECTS 
 
Chronic rhinosinusitis 
 
The mucosal lining in chronic sinusitis is characterized by basement membrane thickening, goblet cell 
hyperplasia, subepithelial edema, and mononuclear cell infiltration. In contrast to nasal polyposis, tissue 
eosinophilia is not a hallmark of chronic sinusitis without polyp formation. The chronic rhinosinusitis 
mucosa shows neutrophils as main inflammatory cells with only a few eosinophils, mast cells and basophils.  
 
Studies of the cytokine profile in this disease have shown high levels of interleukin-1 beta (IL-1β) in some 
extravascular polymorphonuclear cells (PMNs) and mononuclear lymphocytes, and suggests that this 
cytokine induce the expression of ICAM-1 and E- selectin and stimulate the infiltration of PMNs in chronic 
rhinosinusitis (Tokushige et al., 1994). Interleukine-3 (IL-3) and interleukin-8 (IL-8) seem also to play a 
dominant role in this pathology. IL-3 displays multi-colony-stimulating factor activities and stimulates the 
differentiation and activation of macrophages, neutrophils, mast cells and eosinophils (Rudack et al., 1998). 
Its role in this disease may be related to local defense mechanisms and in the repair of chronically inflamed 
sinus mucosa by inducing the release of various mediators (Persson et al., 1997). In addition, the contribution 
of this cytokine to the development of fibrosis and mucosa thickening has been also suggested (Persson et 
al., 1997). IL-8 has been demonstrated in nasal discharge from chronic sinusitis patients (Rhyoo et al., 1999) 
and constitutes a potent neutrophil chemoattractant. TGF-1β mRNA and protein levels are also high and 
related to fibrosis in chronic rhinosinusitis patients compared to normal nasal mucosa and nasal polyp tissue 
(Watelet et al., 2004). Although great efforts have been done to elucidate the cytokine and molecular pattern 
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involved in the manifestation of chronic rhinosinusitis little has been achieved. In the future, more structural 
and functional studies are needed to finally define the causative factors of this disease. 
 
Chronic rhinosinusitis/ nasal polyposis 
 
Although a large number of studies have been focused on the pathophysiology of nasal polyposis, a full 
understanding of the underlying mechanisms has not been achieved yet. Recent insights suggest regulation of 
eosinophil chemotaxis, activation, and survival, together with histopathology changes (such as pseudocyst 
formation) as main factors contributing to the disease. Histomorphologically, polyp tissue reveals frequent 
epithelial damage, a thickened basement membrane, and edematous to sometimes fibrotic stromal tissue, 
with a reduced number of vessels and glands (Kakoi et al., 1987). The stroma of mature polyps is mainly 
characterized by edema and pseudocystic formations surrounded by fibroblasts and infiltrating inflammatory 
cells, predominantly activated eosinophils, which are present in about 80% of nasal polyps (Stoop et al., 
1993) and are localized mainly around the vessels, glands and beneath of the mucosal epithelium (Kakoi et 
al., 1987). In addition, albumin and other plasma proteins have also been found deposited within the 
pseudocysts, adjacent to the eosinophil infiltration, which suggests a central deposition of plasma proteins, 
regulated by the subepithelial eosinophilic inflammation, as a pathogenetic principle of polyp formation and 
growth (Persson, 1991). 
 
An increased production of cytokines/chemokines like granulocyte/macrophage colony-stimulating factor 
(GM-CSF), interleukin-5 (IL-5), RANTES and eotaxin have been demonstrated in the nasal polyp tissue. 
This can actively contribute to migration and survival of eosinophils and extracellular matrix breakdown 
(Mullol et al., 1995; Bachert et al., 2000). IL-5 is one of the key cytokines in the pathophysiology of nasal 
polyposis. This cytokine is significantly increased in nasal polyp patients compared to healthy subjects and 
its expression has been found to correlate with eosinophilic cationic protein (ECP) in the polyp tissue 
suggesting its autocrine role in the activation of eosinophils (Bachert et al., 2001). This role for this cytokine 
was later supported by the finding that treatment of eosinophil-infiltrated polyp tissue with neutralizing anti-
IL-5 monoclonal antibody, resulted in eosinophil apoptosis and decreased tissue eosinophilia (Simon et al., 
1997). Furthermore, recent studies have shown that nasal polyps also express high levels of RANTES and 
eotaxin, which are potent eosinophil chemoattractants (Bartels et al., 1997).  
 
Adhesion molecules like intercellular adhesion molecule (ICAM-1), E-selectin and P-selectin are also highly 
expressed in nasal polyp endothelium (Symon et al., 1994) and have been suggested as crucial factors 
implicated in the development of nasal polyps.  In 1995, Jahnsen and col., reported an elevated expression of 
VCAM-1 in nasal polyp tissue vessels that correlated with the number of eosinophils. This phenomenon was 
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later observed to be decreased after treatment with topical glucocorticosteroids (Tingsgaard et al., 1999), 
emphasizing the importance of the adhesion molecules in the migration, activation and functionality of 
eosinophils (Palframan et al., 1998) and hence their potential role in nasal polyp formation. 
 
Within the nasal polyp structure we can find also a large quantity of extracellular fluid contributing to edema 
formation. Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis and vascular 
permeability and has been found highly expressed in the polyp tissue. This factor together with transforming 
growth factor-beta (TGF-β) has been shown to contribute to the edema and increased angiogenesis in nasal 
polyps (Wittekindt et al., 2002). In addition, TGF-β can modulate fibroblast function contributing to 
eosinophil infiltration and stromal fibrosis (Lee et al., 2003). More, other mediators like albumin, histamine 
and immunoglobulins (IgE and IgG) are increased in nasal polyps (Bachert et al, 2000). Local IgE 
production can contribute to the increased recurrence of nasal polyps after surgical polypectomy via the IgE-
mast cell-FcεRI cascade (Settipane et al., 1996). Finally, interactions between mast cells, T-cells, epithelial 
cells and fibroblasts play a crucial role in the persistent eosinophilic inflammation observed in polyps 
(Pawankar et al., 2003). In summary, although nasal polyposis has been defined as a multifactorial disease, 
chronic persistent inflammation seems to be the major factor driven- disease irrespective of the aetiology. 
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CHAPTER 2 
 
ARACHIDONIC ACID (EICOSANOID) METABOLISM 
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GENERAL OVERVIEW 
 
The term eicosanoid stems from the greek word “eikos”, meaning twenty, and refers to a collective group of 
compounds that have twenty carbon atoms. Eicosanoids are a very important group of compounds regulating 
crucial body functions and they include the prostaglandins (PGs), prostacyclins, thromboxanes (TXs), and 
leukotrienes (LTs). The study of these molecules, which culminate in the discovery of one of the most 
important pathways for lipid mediators began in 1930 when Burr discovered the essential fatty acids (Burr et 
al., 1930) and Von Euler in 1934 identified a factor with fatty acid properties and vasodepressor and smooth 
muscle–stimulating activity that was termed “prostaglandin (Von Euler, 1935). Thirty years later Bergström 
and Samuelsson linked these observations to the structures of the “classical” prostaglandins and 
demonstrated that they were produced from an essential fatty acid: the arachidonic acid (AA) (Bergström et 
al., 1964), initiating in this way the era of eicosanoid research. In 1971, Vane discovered that analgesic, 
antipyretic and anti-inflammatory aspirin-like drugs could inhibit prostaglandin biosynthesis (Vane, 1971) 
and soon thereafter, the platelet pro-aggregator and vasoconstrictor molecule thromboxane A2 was 
elucidated, followed by the isolation of its antagonist, a vascular wall-synthesized prostacyclin. In addition, 
the Nobel Prize for the identification of 100 eicosanoids was awarded in 1982, which strongly pushed 
forward the research in this field. Furthermore, Serhan et al. identified lipoxins, also derivatives of the 
arachidonic acid cascade (Serhan et al., 1984).  
 
All mammalian cells except erythrocytes synthesize eicosanoids. These molecules function locally at the site 
of synthesis at minute concentrations and a receptor-mediated G-protein linked signalling pathway mediates 
their action. They have antagonistic roles like hormones, and regulate most of physiological functions such 
as blood pressure, inflammatory responses (Busse, 1998), uterine contractions during birth (Olson, 2003), 
pain, the release of gastric acid (Halter et al., 1991), the constriction and dilation of airways in the lungs and 
blood vessels (Holgate et al., 2003) and many others.  Two main pathways (Figure 1) are involved in the 
biosynthesis of eicosanoids: 1) the prostaglandins and thromboxanes, synthesized by the cyclic pathway and 
2) the LTs and lipoxins by the linear pathway. The cyclic pathway is initiated through the action of 
prostaglandin G/H synthases (also called prostaglandin endoperoxide synthetase), which possesses two 
activities, cyclooxygenase (COX) and peroxidase. The linear pathway is initiated through the action of 
lipoxygenases, with the enzyme 5-LOX giving rise to the LTs and the 15-LOX responsible for the 
production of lipoxins.  
 
LEUKOTRIENES BIOSYNTHETIC PATHWAY 
 
Leukotrienes are predominantly produced by inflammatory cells like polymorphonuclear leukocytes, 
macrophages, and mast cells. Immune complexes, bacterial peptides, and other stimuli may activate the 
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biosynthesis of these compounds.  Biosynthesis of LTs is initiated with the translocation of cytosolic 
phospholipase A2 (cPLA2) to the nuclear membrane with the consequent release of AA (Clark et al., 1991), 
which can be further converted to leukotriene A4 (LTA4) by the enzyme 5-lipoxygenase (5-LOX) (Peters- 
Golden et al., 2001) as shown in figure 2.  5-LOX, a non- heme iron dioxygenase, and the key enzyme in this 
cascade, can translocate from either the nuclear or cytoplasmic compartment depending on the cell type 
(Peters-Golden et al., 2001). The translocation of this enzyme seems to occur via the 5-LOX activating 
protein (FLAP), which is a  nuclear envelope integral protein that acts as an AA transfer protein (Funk, 
2001) for conversion to LTA4 (Mancini et al., 1993; Rouzer et al., 1986). At that stage, LTA4 can  undergo  3  
different types of transformation depending on the cellular context: a) cytoplasmic and /or b) nuclear 
hydrolytic attack by leukotriene A4 hydrolase (LTA4H) to yield leukotriene B4 (LTB4) (Radmark et al., 
1984), or c) conjugation with glutathione to form leukotriene C4 (LTC4) at the nuclear envelope, reaction that 
is catalyzed by glutathione transferase LTC4 synthase (LTC4S). In this reaction, LTC4 is metabolized 
extracellularly (Yoshimoto et al., 1988 and Lam et al., 1989) and cleaved by specific enzymes to produce the 
extracellular active metabolites LTD4 and LTE4 (Bergström et al., 1981), comprising the cysLTs, described 
many years ago as “slow-reacting substance of anaphylaxis”. 
Figure 1. Arachidonic acid cascade leading to the formation of peptide (cysteinyl) leukotrienes, lipoxins,  
                 prostaglandins and tromboxanes. 
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PROSTAGLANDINS BIOSYNTHETIC PATHWAY 
 
Prostaglandins are formed by most cells in the body and act as autocrine and paracrine lipid mediators (i.e., 
they signal at or immediately adjacent to their site of synthesis) (Funk, 2001). These molecules are not stored 
but rather synthesized de novo from membrane-released AA after cell activation by mechanical trauma, 
cytokines, growth factors, and other stimuli.  
 
Prostaglandin’s synthesis (Figure 3) starts at the endoplasmic reticulum and nuclear membrane when AA 
released by cPLA2 is metabolized by prostaglandin H synthase-1 or cyclooxygenase 1 (COX–1) and/ or 
prostaglandin H synthase- 2 or cyclooxygenase- 2 (COX– 2) to form first prostaglandin G2 (PGG2) and after 
prostaglandin H2 (PGH2) (Rocca et al., 2002). Then, cell-specific prostaglandin synthases catalyze the 
conversion of PGH2 to biologically active end products known as prostanoids. These prostanoids include: 
prostaglandin E2 (PGE2) produced by microsomal prostaglandin E synthase (Jakobsson et al., 1999); 
prostaglandin F2 (PGF2a), prostaglandin D2 (PGD2) by PG synthases found in the uterus, prostaglandin I2  
 
Figure 2. Leukotriene’s biosynthetic pathway, according to Funk, 2001. 
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(PGI2) by  prostacyclin  synthase,  located  in the  brain and and tromboxane A2 (TXA2) by tromboxane 
synthase located in platelets, macrophages and mast cells (Helliwell et al. 2004). 
 
Interestingly, although both cyclooxygenases isozymes catalyze the same reactions and share approximately 
60% structural and atomic homology, they are encoded by two different genes located on distinct 
chromosomes and have different functions even within the same cell type (FitzGerald et al., 2001). COX-1 is 
thought to be expressed constitutively in gastric mucosa, kidney, platelets, and vascular endothelial cells and 
COX-1-dependent prostaglandin production is thought to control a number of physiologic ‘‘housekeeping’’ 
functions in the body. The concentration of this isoform remains relatively stable, although small changes in 
expression can occur after stimulation with hormones, growth factors or during development (Smith et al., 
2001). The expression of COX-2, in contrast, has been shown to be inducible in different cell types in 
response to pro-inflammatory stimuli like cytokines, endotoxins, growth factors or tumor promoters (Smith 
et al., 2001). Although constitutive expression of this enzyme has been found in certain regions of the brain, 
Figure 3. Prostaglandin’s biosynthetic pathway and actions according to Funk, 2001. 
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reproductive tissues, kidney and thymus (Smith et al., 2001); COX-2- dependent prostaglandins play a major 
role in regulating inflammatory and cell proliferation events (Rocca et al., 1999). 
 
LIPOXINS BIOSYNTHETIC PATHWAY 
 
Biosynthesis of lipoxins (LXs) occurs via cell-cell interactions and depends on the cells and enzymes present 
therein and can be subjected to modulation by cytokines. In addition, these compounds can also be 
synthesized when the precursor molecules 15- hydroperoxyeicosatetraenoic acids (15-HETEs) accumulate 
within the cell membrane, in the absence of transcellular lipoxygenase activity (Brezinski et al., 1990). There 
are three biosynthetic pathways, which end in the formation of these molecules (Figure 4). The first of the 
major routes involves the activities of the 5-LOX and 12-LOX enzymes. 5-LOX, present in cells of myeloid 
lineage (e.g. polymorphonuclear neutrophils) generates LTA4 from AA, which is taken up by platelets and 
metabolized to form lipoxin (LXA4) through the oxygenase activity of 12-LOX present in these cells 
(Edenius et al., 1990; Serhan et al., 1990). A second route is via the action of 15-LOX present in epithelial 
cells and monocytes (Serhan et al., 1984). In this reaction, molecular oxygen is inserted into carbon 15 of 
AA (C20:4), predominantly in the S configuration to yield the 15(S)- hydroperoxyeicosatetraenoic acid 
(15(S)- HETE) that serve as a substrate for neutrophil 5-LOX that through the actions of epoxide hydrolases 
in leukocytes convert it to LXA4 and LXB4 (Serhan et al., 1984).  
 
The third and additional route of LXs formation is via the aspirin-triggered 15-epi-LX (ATLs) pathway 
(Claria et al., 1995). In this pathway, aspirin induces acetylation of COX-2 enzyme and shifts its function as 
endoperoxidase to a lipoxygenase activity. This event promotes the conversion of arachidonate to 15-HETE 
that carries its C15 alcohol in the R but not in the S configuration (15(R)-HETE). This metabolite is then 
released from endothelial and epithelial cells and may be transformed by leukocyte 5-LOX to generate 15-
epi-LXA4 or 15-epi-LXB4 (Claria et al., 1995). During the last 2 decades, significant efforts have been 
directed towards identifying the physiological actions of these molecules, and after extensive in vivo and in 
vitro studies, they have been generally identified as endogenous anti-inflammatory “braking signals” maybe 
with antagonist properties to pro-inflammatory eicosanoids (Hugh et al., 1995).  
 
EICOSANOID RECEPTORS 
 
Eicosanoid signalling operates through lipid G- protein- coupled receptors (GPCRs), which structures and 
the encoding proteins are now known for human, mouse, and rat (Brink et al., 2003). According to the 
International Union of Pharmacology (IUPHAR), leukotriene receptors are classified in three main groups: 
the BLT receptors, which biological activities are related to LTB4 and related hydroxyacids and are classified 
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as chemoattractants, the CysLTs receptors related belonging to the nucleotide receptor family, the lipoxin 
receptors (ALX) also included in the chemoattractant receptor class along with formyl peptide receptors 
(FPL) and the prostanoid receptors in an apart class. (Figure 5, Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Transcellular biosynthesis of lipoxins and aspirin- triggered lipoxins. 
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Table 1. Nomenclature of the human cloned eicosanoid receptors, according to the International Union of 
Pharmacology (IUPHAR).   
 
Receptor IUPHAR  
name 
IUPHAR  
code 
Non- selective  
ligand 
Gene/ 
chromosome 
Accession 
number 
(Swiss- Prot) 
Leukotriene B4  
receptor 1 
BLT1 2.1 :BLT :1 :BLT1 LTB4 14q11.2-q12 Q15722  
Leukotriene B4  
receptor 2 
BLT2 2.1 :BLT :2 :BLT2 LTB4 14q11.2-q12 Q9NPC1  
Cysteinyl leukotriene 
receptor 1 
CysLT1 2.1 :CLT :1 :CLT1 LTC4/LTD4/LTE4 Xq13-q21 Q9Y271  
Cysteinyl leukotriene 
receptor 2 
CysLT2 2.1 :CLT :2 :CLT2 LTC4/LTD4/LTE4 13q14.2 Q9NS75  
Lipoxin receptor ALX 2. :ALX LXA4/ fMLP 19q13.3 P25090  
 
Figure 5. The major receptor families for lipid mediators indicated in a phylogenic 
tree according to Brink et al., (2003). 
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Leukotriene B4 (BLT) receptors  
 
The leukotriene B4 (BLT) receptors (BLT1 and BLT2) are G protein-coupled seven transmembrane domain 
receptors (Tager et al., 2003). They have 45% amino acid identity, however, some differences in G protein- 
coupling mediating different cellular events, have been observed. Additionally, the affinity and specificity 
for LTB4 binding is also different. BLT1 is a high-affinity receptor specific for LTB4, whereas BLT2 is a low-
affinity receptor that can also binds other eicosanoids including 12(S)- HETE, 12(S)- HPETE, 15(S)- HETE 
(Yokomizo et al., 2001). Northern and dot blot analyses have revealed that the distribution of BLT1 and 
BLT2 expression differs significantly.  Whereas human BLT1 is expressed primarily in leukocytes, human 
BLT2 is present in most human tissues (spleen > liver, ovary, peripheral blood leukocytes, pancreas > heart, 
prostate, testis, small intestine, kidney, lung, colon, thymus, muscle, placenta) (Yokomizo et al., 2000; 
Tryselius et al., 2000; Kamohara et al., 2000; Wang et al., 2000). Further investigation of mRNA expression 
of these receptors in human peripheral blood leukocytes has demonstrated that neutrophils and eosinophils 
express significant amounts of both BLT1 and BLT2, whereas mononuclear cells express BLT2 but minimal 
BLT1 (Kamohara et al., 2000). Expression of BLT receptors can be up-regulated during inflammation; 
however, specific inflammatory stimuli responsible for their induction have not yet been fully characterized. 
So far, it has been demonstrated that IFN-γ and glucocorticoids can increase BLT1 expression in human 
leukocytes (Huang et al., 1998); and dexamethasone can induce its transcription in peripheral blood 
neutrophils (Stankova et al., 2002). Finally, BLT1 and BLT2 may play a crucial role in host defense and in 
many inflammatory diseases by mediating LTB4 activities like inflammatory cell recruitment, activation of 
inflammatory cell effector functions, and prolongation of inflammatory cell survival (Tager et al., 2003). 
 
Cysteinyl leukotrienes (CysLT) receptors  
 
Cysteinyl leukotriene (CysLTs) receptors are seven trans-membrane-spanning receptors that couple to G 
proteins and activate intracellular signalling pathways in response to their endogenous ligands LTC4, LTD4 
and LTE4 (Lynch et al., 1999; Heise et al., 2000). Biochemical studies have shown that these receptors share 
38% amino acid identity and have very low homology in the extreme carboxyl termini (Brink et al., 2003). 
Originally, classification of CysLT receptors was based on the intolerance to the so-called “classical” 
antagonists including:  montelukast (Singulair) (Jones et al., 1995), zafirlukast (Accolate) (Krell et al., 1990 
and Garcia-Marcos et al., 2003), pranlukast (Onon, Azlaire) (Obata et al., 1992 and Keam et al., 2003), 
pobilukast (Hay et al., 1987) and MK571 (Jones et al., 1989). Accordingly, two main groups of these 
receptors have been identified: CysLT1 receptor class, intolerant to the classical antagonists and CysLT2 
class, which mediates effects not inhibited by the classical antagonists (Tudhope et al., 1994). A few years 
ago, molecular biology techniques have confirmed these previous pharmacological findings and allowed the 
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cloning of two distinct receptors in humans, hCysLT1 (Lynch et al., 1999) and hCysLT2 (Takasaki et al., 
2000). However, the available literature and research data suggest the existence of additional classes or 
subclasses for both receptors (Ravasi et al., 2002) but additional investigation is required to expand the 
current classification. Several studies have demonstrated the presence of intracellular CysLTs receptors 
(Bandeira- Melo et al., 2003). It is known that enzymes involved in leukotriene synthesis are located not only 
in the nuclear envelope but also inside the nucleus of many cells suggesting that lipoxygenases metabolites 
might not only activate cell surface receptors but also act locally at intracellular receptors such as 
peroxisome proliferative- activated receptors (PPARs) (Peters-Golden et al., 2001). However, although some 
in vitro studies performed with LTB4 support this hypothesis, there is no information concerning the action 
of CysLTs on these intracellular receptors. 
 
Expression pattern and distribution of CysLT1 and CysLT2 receptors vary considerably between tissues and 
organism species (Nicosia et al. 2000).  Human CysLT1 receptor is highly expressed in peripheral blood 
leukocytes, lung, pancreas small intestine and a few other tissues as showed in table 2. Expression of mRNA 
and protein of this receptor have been also detected in peribronchial smooth muscle cells ad interstitial 
macrophages (Figueroa et al., 2001) but also in peripheral blood monocytes, eosinophils, 
monocytes/macrophages, B-lymphocytes and CD34+ granulocytic precursor cells. However, low or no 
expression has been observed in neutrophils or T-lymphocytes (Mita et al., 2001). Expression of hCysLT2 
receptor is also high in spleen and peripheral blood leukocytes, however differently to the hCysLT1 it is also 
expressed in heart, adrenal glands and brain (Table 2). Eosinophils also express this receptor but in higher 
levels as compared to hCysLT1 and expression in monocytes, neutrophils and T- cells have been also 
observed (Mita et al., 2001). However, in contrast to hCysLT1, this receptor is weakly expressed in lung 
smooth muscles (Heise et al., 2000).  
 
According to different studies it seems that both T-helper 1 (Th1) and T-helper (Th2) cytokines can regulate 
CysLTs receptor expression. This is supported by early experiments showing that receptor binding to LTD4 
can be enhanced by IL-5 in HL-60 cells differentiated into eosinophils (Thivierge et al., 2000). In addition, 
IL-4 and IL-13 were also able to induce CysLT1 expression in human monocytes and macrophages 
(Thivierge et al., 2001) and IFN-γ was able to increase both CysLT1 and CysLT2 expression in human airway 
smooth muscle cells (Amrani et al. 2001).  
 
However, although many efforts are being doing, research concerning the regulation of CysLTs receptor 
expression remains in the infancy stage. Not only pharmacological studies but also characterization of the 
promoter regions and transcription factors of these receptors will greatly help elucidate signalling pathways 
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involved in receptor regulation. That will have a big implication in the understanding of the pathogenesis 
involving the action of these molecules especially in airway diseases. 
 
Lipoxin (ALX) receptors   
 
Deduced amino acid sequences indicated that ALX belongs to the GPCR superfamily, but also on the basis 
of its nucleotide sequence, it is a member of the chemokine receptor superfamily, with the ability to bind 
both lipid and peptide ligands (Chiang et al., 2000; Christophe et al. 2001 and 2002). ALXR is the  first non-
prostanoid  eicosanoid  GPCRs receptor  recognized  at  the  molecular level (Fiore et al., 1993, 1994) and 
identified as the only inhibitory or anti-inflammatory receptor that acts via an agonist (LXA4) and has a role 
as a "stop signal" (Fiore et al., 1994; Serhan, 1994, 1997; Takano et al., 1997). LXB4, in contrast do not act 
via the ALX receptor interacts with a specific receptor present on human leukocytes (Maddox et al., 1996). 
Its cDNA sequence has not been cloned yet and is considered as a putative receptor. In addition to this data it 
has been also shown that LXA4 can bind a CysLTs receptor (Gronert et al., 2001) and at a third type: the aryl 
hydrocarbon receptor (AhR), which is a ligand-activated transcription factor regulating genes implicated in 
xenobiotic metabolism and lipoxin degradation (Schaldach et al., 1999). 
        
  Table 2. Expression profile of human CysLT1 and CysLT2 receptors (Addapted from Hui, 2002). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue hCysLT1 hCysLT2 
 Expression level Expression level 
Lung   
Bronchial smooth muscle cells ++ + 
Interstitial macrophages ++ ++ 
Peripheral blood leukocytes   
Eosinophils ++ ++ 
Monocytes/macrophages + + 
Neutrophils ± + 
B lymphocytes + ? 
T lymphocytes ± + 
CD 34+ precursor cells + ? 
Mast cells + ? 
Spleen ++ ++ 
Heart and coronary vessels ? ++ 
Brain ? ++ 
Adrenal glands ? ++ 
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Expression of ALXR has been described in monocytes (Maddox et al., 1997), basolateral membrane of 
gastrointestinal epithelial cells (Kucharzik at al., 2003), synovial fibroblasts (Sodin-Semrl et al., 2000), 
bronchial epithelial cells (Bonnans et al. 2003), and mesangial cells (McMahon et al., 2002). This receptor 
can be regulated at the transcription level by cytokines including IL-1, IL-13 and IFN-γ (Sodin-Semrl et al., 
2000). As we state before, responses evoked through ALXR have been observed in response to either lipid or 
peptide ligands (Chiang et al., 2000; Fiore et al., 1993) where many of them are chemotactic and elicit pro-
inflammatory responses in human leukocytes. An example is that stimulation of ALXR by serum amyloid A 
(SAA) induces IL-8 secretion in human neutrophils (He et al., 2003). 
 
However, LXA4 activation of the same receptor does not induce IL-8 secretion but decreases the SAA-
induced IL-8 secretion, suggesting that SAA and LXA4 may compete for a common binding site on the 
ALXR (He et al., 2003). The functional significance of multiple lipid and peptide ligand binding at the 
ALXR remains uninvestigated. And the fact that this ALXR can switch recognition as well as function from 
stimulatory to inhibitory, raises the possibility that activation of this receptor by LX or ATL can protect the 
host from deleterious PMN-induced responses associated with innate immune responses.  
 
Prostanoid receptors 
 
These receptors belong to the family of G protein-coupled rhodopsin-type receptor with 7 putative 
transmembrane domains (Hirata et al. 1991). Eight types and subtypes of the prostanoid receptors have been 
until now identified (Table 3). They include the human and mouse PGD receptor (DP); the mouse, rat, and 
human PGE receptor EP1 subtype; the mouse and human PGE receptor EP2 subtype; the mouse, human, rat, 
rabbit, and bovine PGE receptor EP3 subtype; the mouse, human, and rat PGE receptor EP4 subtype; the 
mouse, human, bovine, rat, and sheep PGF receptor (FP); the mouse, human, and rat PGI receptor (IP) and 
the mouse, rat, and bovine TXA (TP) receptor (Narumiya et al. 1999). Analysis of amino acid sequences has 
shown that particular motifs are specifically conserved among the prostanoid receptors (Narumiya et al. 
1999). However, despite the presence of these conserved sequences, overall homology among the prostanoid 
receptors is quite limited, ranging from ~20 to 30%. In contrast, the homology of a given type or subtype of 
receptor among various species is considerably higher, oscillating between 70 and 97% (Narumiya et al. 
1999). With exception of the human DP and EP2, the chromosomal localizations of the genes encoding the 
human prostanoid receptors have been determined and have been mapped to chromosome bands 19p13.1, 
1p31.2, 5p13.1, 1p31.1, 19q13.3, and 19p13.3 (Duncan et al. 1995 and Nusing et al., 1993). Each of the 
prostanoid receptors shows a selective response in tissues and ligand-binding specificity that distinguishes it 
from the others (Narumiya et al. 1999). 
  
 
 
 
 
 
- 50 - 
Several pharmacological and biochemical studies combined with molecular biology approaches have shown 
that each prostanoid receptor is specifically distributed in the body and that expression levels are variable 
among tissues. Human DP receptor has been detected at low levels in the small intestine (Boie et al. 1995) 
and in specific cells in the brain (Oida et al., 1997). Among the prostanoid receptors, the EP3 and EP4 
receptors are widely distributed throughout the human body. In contrast, the distribution of EP1 is restricted 
to several organs, such as the kidney, lung, and stomach (Watabe et al., 1993). EP2 is the least abundant 
among these receptors and is effectively induced in response to stimuli like LPS, IFN-γ and hormones 
(Katsuyama et al., 1997; Lim et al., 1997). Earlier ligand- binding studies (Powell et al., 1974 and Rao, 
1973) have indicated that FP is most abundantly expressed in the corpus luteum, although also in the kidney, 
stomach glands and in fibroblastic cell lines such as NIH-3T3 (Arakawa et al., 1996). IP mRNA is most 
abundantly expressed in neurons, in which it was co- localized with the mRNA for preprotachykinin A, a 
precursor of substance P, indicating that this receptor may be involved in the mediation of pain. In some 
neurons, IP mRNA can be also co-expressed with the mRNA of EP receptor subtypes, suggesting that these 
receptors play overlapping roles in transmission of pain sensation. In addition, IP is also expressed in 
megakaryocytes and the smooth muscles of arteries, afferent arterioles of the glomerulus, in the thymus and 
spleen (Oida et al., 1995). Finally, northern blot analysis have shown that TP is abundantly expressed in 
tissues rich in vasculatures such as the lung, kidney, and heart, but also in immune-related organs such as the 
thymus and spleen (Namba et al., 1994). This receptor is also highly expressed by immature thymocytes such 
as CD4-, CD8- and CD4+, CD8+ cells. Also it was shown that TP receptor agonist can induce apoptotic cell 
death of immature thymocytes in a receptor-dependent manner, suggesting its role in thymocyte 
differentiation and development, in addition to its well-known roles in the cardiovascular and respiratory 
systems (Ushikubi et al., 1993). 
              Table 3. Expression profile of prostanoid receptors on human immune cells. 
Type Subtype Cells expressing the receptors 
DP  Neutrophils 
EP EP1 B lymphocytes, 
 EP2 B lymphocytes, eosinophils, neutrophils 
 EP3 B- lymphocytes, T- lymphocytes, macrophages / monocytes
 EP4 B lymphocytes 
FP   
IP  T- lymphocytes 
TP  Macrophages / monocytes, eosinophils 
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PHYSIOLOGICAL IMPLICATIONS OF EICOSANOIDS ON CHRONIC RHINOSINUSITIS/ 
NASAL POLYPOSIS 
In the past two decades, it has been apparent that eicosanoids play an important role in certain airway 
inflammatory conditions like rhinosinusitis, nasal polyposis, allergic rhinitis and asthma. The implication of 
LTs and prostaglandins in these diseases has been extensively investigated. Although, the regulatory 
mechanism governing the production of these molecules is not 100% clear, the use of anti-LTs, LTs- 
receptor antagonists and alternative to cyclooxygenase inhibitors has been of great help in the management 
of airway diseases. Interactions in eicosanoid pathway in paranasal sinus diseases and especially nasal 
polyposis have been demonstrated by several studies. Baenkler and col. (Baenkler et al., 1996) observed an 
altered pattern of the lipoxygenase and cyclooxygenase pathways when nasal tissue becomes irritated. These 
authors also observed a remarkable increase of CysLTs by polypous tissue upon arachidonic acid 
stimulation, in contrast to only slightly elevated PGE2 release when compared to normal tissue, suggesting 
the involvement of these metabolites in the pathogenesis of nasal polyps. In addition, an interesting work by 
Klapan et al., (1995), showed that patients with post- operative recurrences had significantly lower of PGE2 
but higher TXA2 and LTC4 compared to subjects without polyp recurrence. In this study, LTC4 levels were 
correlated with the rate of recurrence suggesting a possible prognostic value of these molecules for nasal 
polyp recurrence.  
Differential regulation of CysLTs receptors has also been suggested as crucial factor in the pathophysiology 
of chronic inflammatory airway diseases. An elevated number of nasal inflammatory leukocytes bearing 
CysLT1 has been observed in chronic rhinosinusitis-aspirin intolerant patients compared with their aspirin 
counterparts (Sousa et al., 2002). However, a study performed with CysLT1 receptor antagonist montelukast 
showed that improvement of therapy was not associated with a number of clinical parameters evaluated 
including aspirin intolerance; introducing a controversial speculation about the role of these receptors in the 
development of the disease (Ragab et al., 2001). Furthermore, CysLT1 receptor expression has been localized 
in big number of inflammatory cells within the nasal mucosa (Sousa et al., 2002) and increased levels of this 
receptor have been also reported on neutrophils and eosinophils on the nasal lavages from patients with 
allergic rhinitis (Figueroa et al., 2003). 
Studies with LTs receptor antagonist have concluded that anti- leukotrienes therapy might play a significant 
role in controlling polyposis and symptoms secondary to sinonasal disease, and they might be an important 
alternative to long-term oral steroid therapy and repeated surgery (Parnes et al., 2000). In contrast to CysLTs, 
controversial results about LTB4 and BLT receptors have been reported in several studies. The levels of these 
molecules have been found increased in nasal polyp patients with allergy in comparison to non- allergic 
subjects (Pinto et al., 1997); but no differences were observed between aspirin intolerant compared to 
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tolerant subjects (Sousa et al., 2002). Until now, no clear mechanism regulating the synthesis of these 
molecules in airway has been demonstrated. However, neutrophils, the major LTB4 producing cells are able 
to interact with other cell types, especially epithelial cells, influencing the qualitative and quantitative profile 
of leukotriene production (Maclouf et al., 1988).  
Furthermore, cyclooxygenase metabolic pathway has been suggested to be different in nasal polyp patients. 
That was first suggested by Mullol and col. (Mullol et al., 2002), who demonstrated that basal COX-1 
mRNA is spontaneously up- regulated in cultured normal mucosa but not in nasal polyps. In addition, 
spontaneous cytokine induction of COX-2 mRNA expression was up- regulated in both cultures but delayed 
in nasal polyp compared to normal mucosa. Similar results were found by Gosepath et al., (2004), who 
observed a down- regulation of COX-2 expression in epithelial cells of nasal polyp tissue compared to 
normal mucosa. These authors suggested that prostanoid metabolism might play a crucial role in the 
pathogenesis of inflammatory nasal diseases and in the formation of nasal polyps.  
 
Additionally, there are still molecules with a big controversial role in the pathogenesis of chronic 
inflammatory diseases, the lipoxins. Lipoxins are generally associated with anti-inflammatory effects and 
have been reported to reduce leukocyte infiltration (McMahon et al., 2004). However, certain di- 
hydroxyeicosatetraenoic acids (HETEs), which are precursors of these molecules, may have also pro-
inflammatory effects, specifically neutrophilic and eosinophilic chemotaxis (Maddox et al., 1996). Chopped 
human nasal polyps have been shown to have a high capacity to produce LXA4 after incubation with 
exogenous LTA4 in presence of polymorphonuclear granulocytes (Edenius et al., 1990). In addition, severity 
of asthma has been associated with increased expression and activation of 15- LO enzyme, collagen 
deposition and eosinophil accumulation (Chu et al., 2002). Interestingly, the levels and capacity of producing 
these molecules are decreased in aspirin intolerant patients (Sanak et al., 2000) suggesting that maybe a 
particular regulation event of this pathway, operating only in these patients, is involved in the pathogenesis 
of this disease. Although extensive studies are going on in this field, the specific role of these molecules and 
their regulation in sinunasal diseases remains largely unclear. 
 
Finally, implication of eicosanoid differential regulation in aspirin intolerance syndrome has also gained a lot 
of attention since 1987 when Jung and co- workers (Jung et al., 1987) showed that LTC4 and LTB4 
concentrations were higher in nasal polyp and more in those with aspirin intolerance.  In 1993, Kowalski 
reported an increase of LTC4 concentration after aspirin provocation in nasal lavages of chronic 
rhinosinusitis aspirin- intolerant patients; suggesting that production of lipoxygenase products of arachidonic 
acid may induce glandular secretions contributing to the clinical symptoms observed in aspirin intolerance 
syndrome (Kowalski et al., 1993).  Andrew Szczeklik’s group showed in 1996, that aspirin challenge 
significantly depressed PGE2 and thromboxane B2 in aspirin- tolerant and intolerant patients but increased 
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PGD2, PGF2α and PGF9α and 11β-PGF2 only in aspirin- intolerant subjects (Szczeklik et al., 1996). Later, 
this group also showed that eicosanoid metabolism disturbances in terms of  urinary LTE4  and serum 
9α,11β-PGF2 after aspirin provocation, is more severe in patients with bronchial and nasal responses than in 
subjects with only bronchial or nasal symptoms (Swierczynska et al., 2003). 
 
In other hand, Pinto et al. (1997) corroborated these results showing high levels of LTs in nasal polyp tissue 
and turbinates from patients with allergic rhinitis and a decreased cyclooxygenase/ lipoxygenase ratio in 
patients with aspirin intolerance.  Cowburn and col. extended these observations by showing that intake of 
lysine-aspirin in aspirin- intolerant subjects resulted in an additional release of CysLTs into the 
bronchoalveolar fluid and in a bronchial responsiveness that correlated with the number of cells expressing 
LTC4 synthase enzyme (Cowburn et al., 1998).  
 
Furthermore, a significant increase of CysLTs and lower PGE2 release after aspirin challenge was observed 
in nasal polyp tissue and peripheral blood from aspirin- intolerant subjects compared to normal mucosa from 
controls (Schmid et al., 1999). Taking this one-step further, Picado et al., (1999, 2003), looked at the 
regulation of the cyclooxygenase pathway in patients with rhinosinusitis and aspirin intolerance. Their 
results showed no differences in COX-1 mRNA expression between nasal mucosa and nasal polyps from 
patients with and without aspirin intolerance. However, COX-2 mRNA expression and NF-κΒ activity, in 
nasal polyp tissue from aspirin intolerant subjects, was markedly lower than in polyps from patients without 
intolerance, suggesting that an inadequate regulation of these inflammatory pathways may be involved in the 
manifestation of this syndrome. Of interest, a functional polymorphism in the promoter region COX-2 gene 
was observed in aspirin- intolerant patients. This polymorphism resulted in increased capacity of monocytes 
to produce prostaglandins and was associated with the severity of the disease and the need of corticosteroids 
(Szczeklik et al., 2004). 
 
Recently, a study from our group analyzed the basal tissue levels of chronic rhinosinusitis/nasal polyp tissue 
in patients with and without aspirin intolerance. In this work, we showed that changes in tissue eicosanoid 
production may occur in chronic rhinosinusitis in absence of clinical aspirin intolerance and they may not be 
specific but represent a secondary phenomenon linked to the inflammatory process in these patients (Pérez- 
Novo et al., 2005). Summarizing all these findings, it seems that the occurrence of chronic rhinosinusitis/ 
nasal polyposis probably represent a result of different chronic inflammatory stimuli regulated in part by the 
arachidonic acid pathway. 
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DEFINITION 
 
Superantigens (SAgs) are toxins of microbial or viral origin that cross-link antigen-presenting cells (APCs) 
and T-cells by binding simultaneously to the immunoreceptors major histocompatibility complex (MHC) 
class II (Dellabona et al., 1990) and the T-cell receptors (TCRs) (Choi et al., 1990). These molecules have an 
extreme ability to activate (D4+, CD-8+) T- cells polyclonally (White et al., 1989) when presented on MHC 
class II, and in contrast to conventional antigens, they are not processed and presented as short peptides.  
 
IMMUNOLOGY 
 
Conventional antigens are processed within antigen-presenting cells (APCs) into peptide fragments that are 
loaded into the peptide-binding groove of the major histocompatibility complex (MHC class II) class II 
molecule for presentation at the cell surface to T- cells. This mechanism allows that T- cells will only 
respond if they recognize the class II molecule through CD4 and the specific peptide being presented and 
only a small number of the host’s T-cell repertoire (0.001 %) will be activated (Figure 5). By contrast, SAgs 
bind as intact proteins, directly to the immunoreceptors of MHC class II molecule outside the peptide-
binding groove (Fischer et al. 1989) and T-cell receptor (TCRs), at the variable part of the TCR β-chain 
(TCR-Vβ), which are sites away from conventional peptide-binding sites (Figure 6).  SAgs binding causes a 
massive T-cell proliferation (up to 20% of all host’ T cells), release of large amounts of the cytokines IL-2, 
TNF-α and IFN-γ, IL-1) (Langford et al. 1978) and cytotoxic reactions towards target cells (Dohlsten et al., 
1991). 
The most well characterized bacterial SAgs are the ones produced by Staphylococcus aureus and 
Streptococcus pyogenes. S. aureus secrete more than 10 different SAgs (Peterson et al., 2004) named 
staphylococcal enterotoxins (SEs) A, B, C1-3, D, E, G, H, I, J, K, L, M, N, O, P, Q and toxic shock 
syndrome toxin-1 (TSST-1) as shown in Table 4. However, each strain of these bacteria generally produces a 
certain repertoire of SAgs that is all bacterial strains do not produce all different types of SAgs (Jarraud et al. 
2001). 
SUPERANTIGEN PRESENTATION BY MHC CLASS II MOLECULES 
 
All structurally characterized SAgs can adopt a very similar three-dimensional fold; however they can be 
presented by MHC class II in three distinct ways [Li et al., 2001; Jardetzky et al., 1994). According to this 
ability to bind MHC class II, SAgs may be divided into three groups 1) the single α-chain-binding SAgs (e.g. 
SEB), 2) the single β-chain-binding SAgs (e.g. SEH) or 3) the ones capable of cross-links two MHC class II 
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molecules by binding one α- and one β-chain (e.g. SEA) (Jardetzky et al., 1994 and Petersson et al. 2001), 
two α- chains (e.g. SED) or two β- chains (e.g. SPE-C) (Roussel et al., 1997 and Al-Daccak et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPERANTIGEN INTERACTIONS WITH T- CELL RECEPTOR (TCR) 
 
A hallmark for T-cell stimulation by SAgs has been the specificity for the Vβ part of the T-cell receptor, 
TCRV-β (Choi et al., 1990). However, SAgs possess a specific TCR-Vβ profile, that is, they specifically 
expand T- cells bearing some TCR-Vβs, while others will be excluded (Kappler et al., 1989). In this way, all 
T-cells harbouring the SAg-specific TCR-Vβ will be activated. In addition, the TCR-Vα part appears to 
influence indirectly the specificity for SAg activation of T-cells (Seth et al., 1994) through an interaction of 
Figure 6: Differences between antigen and superantigen. Antigenic peptides are processed 
within the cell and presented on the cell surface in association with class II MHC molecules. 
They then trigger the T-cell receptor on a T lymphocyte. Superantigens are not processed but 
bind to the class II MHC protein and to the V beta chain of theT cell receptor. A given 
superantigen activates a distinct class of T cells that express a certain V beta chain.  
In the case of MHC II-TCR interaction with a normally processed peptide, recognition of the 
peptide on theMHC molecule requires V alpha, J alpha, V beta, D beta and J beta segments of 
the TCR. Such an interactionoccurs at low frequency. In the case of MHC II-TCR interaction 
with an unprocessed superantigen, only a given Vbeta region is recognized. This clearly would 
occur at a much higher frequency.  
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the β-chain of MHC class II and the α-chain of TCR (Seth et al., 1994). The affinities for SAg- TCR-Vβ 
interactions are relatively low, suggesting that some sort of serial triggering may also operate in T-cell 
activation by SAgs.  
 
S. aureus DERIVED ENTEROTOXINS AS SUPERANTIGENS 
 
Staphylococcal SAgs are structurally related heat-stable proteins of approximately 27 kDa molecular mass 
defined as a group of high-molecular weight pyrogenic proteins, which have in common an extremely potent 
stimulatory activity for T-lymphocytes and γδ+ T-cells, B-cells, macrophages, antigen presenting cells, 
eosinophils and epithelial cells (Fleischer, 1994). Effect of S. aureus SAgs on T- lymphocytes has been 
mainly studied on skin inflammatory diseases. Stimulation of PBMCs from atopic dermatitis patients with 
SEA and SEB showed a significantly stronger response to these enterotoxins SEA or SEB compared to the 
response obtained from the controls subjects. In addition, this response was accompanied by an enhance of 
the expression of specific Vβ segments which displayed distinct patterns, suggesting a polyclonal T- cell 
proliferation induced by enterotoxins (Yudate et al., 1996). 
 
Additionally, studies in vivo on patients with this disease, showed that application of SEB on the skin of 
normal individuals and affected individuals resulted in a selective accumulation of T-cells expressing SEB-
reactive TCR-Vβ segments and in an inflammatory reaction; suggesting that S. aureus superantigen-induced 
T-cell activation is involved in the pathogenesis and may exacerbate and sustain the inflammation in 
inflammatory skin diseases (Skov et al., 2000; Strange et al., 1996). However, compared with studies on 
lymphocytes, just a few studies have been focused in the effects of staphylococcal SAgs on other pro-
inflammatory cell types, like eosinophils, macrophages, mast cells, and epithelial cells, which are known to 
play crucial roles in the pathogenesis of inflammatory airway disease. Several studies performed on 
eosinophils have described these cells as accessory cells, which in presence of certain cytokines can increase 
the expression of HLA-DR (a MHC class II molecule) and a subsequent proliferation of resting (CD4+) T- 
cells in response to enterotoxins stimulation (Mawhorter et al., 1994).  In addition, it has been shown that 
SEs may also directly affect the eosinophil activity by inhibiting apoptosis and modulating important cell-
surface antigens, including the up-regulation or down- regulation of important cell surface markers (Wedi et 
al., 2002). Macrophages have been also described as accessory cells for a T-cell activation / proliferation in 
response to staphylococcal SAgs and have been found to play a crucial role in enterotoxin- induced T cell 
apoptosis (Zen et al., 1996). Additionally, other studies have suggested that these cells can be activated by 
cross- linking both MHC-I and MHC-II molecules leading to the release of important cytokines like IL-6 and 
TNF-α (Wright et al., 1999). Studies with SEB have suggested that SAgs may augment antigen-specific T-
cell responses by inducing IL-12 production in macrophages (Bright et al., 1999). Furthermore, mast cells 
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have been most widely studied in the context of allergic disease but also play a critical role in host defense 
against bacterial infection. These cells can also act as accessory cells in response to SAgs, similar to 
eosinophils and macrophages. Cord blood- derived mast cells have been shown to directly induce CD4+ T- 
cell activation through presentation of SEB and TSST-1 SAgs; phenomenon that may be critical in 
subsequent cellular activation events due to the frequent co- localization of mast and T- cells at sites of 
antigen entry (Poncet et al., 1999).  In addition, S. aureus Cowan 1 and the immunoglobulin (Ig)-binding 
protein A could induce the release of several mediators like histamine, tryptase and leukotriene C4 from 
human heart mast cells by interacting with the VH3 region of IgE, suggesting a new model for the 
pathogenetic link between bacterial infections, IgE-mediated activation of mast cells and cardiovascular 
diseases (Genovese et al., 2000).  
 
IMMUNOLOGICAL IMPLICATION OF S. aureus ENTEROTOXINS ON AIRWAY DISEASES 
 
Compared to other diseases, few studies have documented the role of S. aureus and its superantigens on 
inflammatory airway disease. Nasal carriage of S. aureus affect about 20% of the population and it has been 
identified as a risk factor for the pathogenesis of community-acquired and nosocomial infections (Kluytmans 
et al., 1997; Von Eiff et al., 2001). The factors determining the carrier or non- carrier status remain largely 
unknown. Several factors like surface glycoproteins, proteoglycans and epithelial and mucous host factors, 
have been shown to mediate the binding of S. aureus. However the molecules implicated on this interaction 
between host and bacteria have not been identified. The nasal vestibule has a complex epithelial surface that 
can be histologically classified into five distinct regions (Mygind et al., 1982). These regions range from an 
anterior hairy epidermis continuous with the skin to a moist pseudostratified columnar layer characterized by 
many ciliated cells, which have the function of transporting the mucus and entrapped particles to the 
pharynx, where they are swallowed. Cole et al. (2001) demonstrated that in nasal carriers, the highest 
concentrations of S. aureus are found immediately distal to the anterior hairy epidermis in a moist squamous 
epithelium devoid of hair, cilia, and microvilli. These authors also state that this phenomenon is due to a 
combination of defective nasal fluid and the lack of alternative mechanical clearance mechanisms resulting 
in the S. aureus colonization. Additionally in this study, a release of epithelial and neutrophil-derived host 
defense peptides into nasal secretions of carriers and acute rhinitis donor fluids (Cole et al., 2001) indicating 
that neutrophils are recruited in response to S. aureus colonization.  
 
S. aureus is present in about 60 to 70% of cases of massive nasal polyposis (Van Zele et al., 2004). It has 
been extensively suggested that S. aureus derived enterotoxins may play an important role in the 
pathogenesis of nasal polyposis. This hypothesis is based on the idea that initial injury to the lateral wall of 
the nose may result of staphylococcal derived toxins, which may induce lymphocyte activation resulting in 
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the production of both TH1 and TH2 cytokines. This cytokines, are responsible for the massive up- regulation 
and activation of lymphocytes, eosinophils, and macrophages, which are the most common inflammatory 
cells found in nasal polyposis. Recent studies, performed in tissue from patients with bilateral nasal polyps, 
have demonstrated the formation of specific IgE to S. aureus enterotoxins, which correlated with the severity 
of eosinophilic inflammation and the manifestation of asthma (Bachert et al., 2001).  These findings were 
supported  by Gevaert and col. (Gevaert et al., 2005), who demonstrated an increase of tissue localized 
polyclonal IgE formation, which was associated with the presence of IgE specific to SEs, S. aureus 
colonization and eosinophilic inflammation. Furthermore the authors showed that these enterotoxins bind to 
follicular structures and lymphoid accumulations in the nasal polyp tissue; suggesting a polyclonal B-cell 
activation because of chronic microbial colonization and release of enterotoxins, which may result in IgE 
switch and formation in these patients. Additionally, aspirin intolerance has been associated with increased 
concentrations of eosinophil-related mediators, as well as IgE antibodies to SEs in nasal polyp tissue (Pérez- 
Novo et al., 2004; Suh et al., 2004). However, although a direct impact of these bacteria with this syndrome 
could not be established, these findings suggest that staphylococcal superantigens may drive local 
eosinophilic inflammation in nasal polyp tissue, and that this is exacerbated in aspirin intolerant subjects. 
These results were later supported by a study showing an increased S. aureus colonization in nasal polyposis 
compared to chronic rhinosinusitis patients and even more when nasal polyposis appeared in combination 
with asthma and aspirin intolerance (Van Zele et al., 2004).   
 
SEs has been also suggested as a possible disease modifier for chronic obstructive pulmonary disease 
(COPD). This was evidenced in a study where the levels of IgE to SEs were significantly higher in patients 
with stable and exacerbated COPD compared to smokers and healthy subjects, and correlated with the 
clinical parameters of these patients (Rohde at al., 2004). In addition, adherence of S. aureus to components 
of the secreted mucus layer in cystic fibrosis patients has also been reported (Ulrich et al., 1998). However, 
the authors suggest that the cause for the chronic respiratory infections in CF is due to impaired mucociliary 
clearance present before any airway infection in these patients. This point to a secondary role of 
staphylococcal enterotoxins in this disease. Another evidence for the role of these enterotoxins in CF was 
shown by an in vitro experiment where B- cells from CF patients served as APC of staphylococcal SAgs for 
an immortalized T-cell line. Interestingly, this action could not be inhibited by dexamethasone, suggesting 
that the pulmonary response to superantigens may be poorly regulated in CF, leading to an exaggerated 
inflammatory response to S. aureus (Ben-Ari et al., 2000). 
 
Finally, the role of staphylococcal enterotoxins in upper airway allergic diseases is getting more and more 
attention nowadays. Sensitization to S. aureus enterotoxins has been found increased in patients with allergic 
rhinitis, which also high total serum IgE levels and manifested polyvalent sensitization (Okano et al., 2001). 
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ECP levels were elevated in allergic patients with immune response to SEs compared to patients lacking 
specific IgE to these enterotoxins. ECP, is thought to be a reliable marker of clinical severity for allergic 
disease and these findings suggest sensitization to staphylococcal enterotoxins as an important prognostic 
factor of persistent upper airway allergic diseases (Rossi et al., 2004) 
 
Table 4. Functional properties of superantigens and their associated diseases according to Proft et al., 2003.             
 
 
SAg 
MW 
(kDa) 
Crystal 
structure Zinc binding 
MHC II binding α- β 
chain 
Human TcR Vβ 
specificity Disease 
 
SEA 
27·1 + + +/+ 1·1, 5·3, 6·3, 6·4, 6·9, 
7·3, 7·4, 9·1, 23·1 
Food poisoning 
SEB 28·4 + - +/- 1·1, 3·2, 6·4, 15·1 Food poisoning 
SEC1 27·5 - - +/- 3·2, 6·4, 6·9, 12, 15·1 Food poisoning 
SEC2 27·6 + - +/- 12, 13, 14, 15, 17, 20 Food poisoning 
SEC3 27·6 + - +/- 5·1, 12 Food poisoning 
SED 26·9 + + +/+ 1·1, 5·3, 6·9, 7·4, 8·1, 
12·1 
Food poisoning 
SEE 26·8 - + +/+ 5·1, 6·3, 6·4, 6·9, 8·1 Food poisoning 
SEG 27·0 - ? ? 3, 12, 13·1, 13·2, 14, 
15 
Food poisoning 
SEH 25·2 + + -/+ ? Toxic shock syndrome 
SEI 24·9 - ? ? 1·1, 5·1, 5·3, 23 Food poisoning 
SEJ 28·5 - ? ? ? ? 
SEK 25·3 - ? ? 5·1, 5·2, 6·7 ? 
SEL 24·7 - ? ? ? ? 
SEM 24·8 - ? ? ? ? 
SEN 26·1 - ? ? ? ? 
SEO 26·7 - ? ? ? ? 
SEP 26·4 - ? ? ? ? 
SEQ 26·0 - ? ? 2·1, 5·1, 21·3 ? 
TSST 21·9 + - +/- 2·1 TSS 
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HYPOTHESIS OF WORK 
 
 
We hypothesize that alterations in the eicosanoids and their receptors expression are related to the degree of 
eosinophilic inflammation in chronic rhinosinusitis/ nasal polyposis, and Staphylococcus aureus enterotoxins 
may contribute to the pathogenesis of the disease by (directly or indirectly) affecting the eicosanoid 
metabolism.  
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RESEARCH OBJECTIVES 
 
The aim of this research work was to investigate the regulation of arachidonic acid metabolism and 
eosinophilic inflammation in chronic rhinosinusitis/nasal polyp patients and the possible role of S. aureus 
superantigens in the balance of these important pathways. 
 
As primary objective we aimed to develop an accurate and sensitive real-time PCR technique that allows 
quantifying the expression level of the two splice variants (membrane anchored and soluble) isoforms of IL-
5Rα, a molecule playing a crucial role in the regulation of eosinophil migration and activation in chronic 
inflammatory airway diseases. As second, we wanted to select a proper set of reference genes for accurate 
normalization in further gene expression studies in chronic rhinosinusitis and nasal polyp tissues. In parallel, 
we evaluated the influence of RNA degradation on the stability and expression pattern of these internal 
control genes. 
 
Once this methodology was established, we proceed to study the gene and protein expression of eicosanoids 
and eicosanoid receptors in sinonasal tissue and  evaluated their possible correlation with severity of 
eosinophilic inflammation and co-moborbidities like asthma and aspirin intolerance.  
 
Furthermore, based on the results of the previous study together with parallel data obtained from our group 
related to S. aureus colonization and the possible role of its enterotoxins in the pathogenesis of chronic 
rhinosinusitis; we decided to evaluate the link between eosinophilic inflammation and the manifestation of 
aspirin intolerance with the immune response to staphylococcal enterotoxins. This research work showed 
that although staphylococcal enterotoxins are not directly implicated in the clinical manifestation of aspirin 
intolerance syndrome they may crucially contribute to the exacerbation of eosinophilic inflammation 
observed in these patients.  
 
These findings allowed us to investigate the relationship between immune response to S. aureus enterotoxins 
(in terms of specific IgE formation), leukotrienes and lipoxins synthesis in chronic rhinosinusitis/ nasal polyp 
tissue. In this study, we found an up-regulation of eicosanoid levels in subjects with enterotoxin immune 
response that lead to the question of how these molecules could induce changes in this inflammatory 
pathway.  
 
Accordingly, the previous study was then extended to investigate the role of these enterotoxins (specifically 
enterotoxin B) on the regulation of eicosanoid metabolism on nasal tissue fibroblasts. After stimulation of 
these cells with SEB, we found that the enterotoxin differentially influence COX-2 and prostaglandin E2 
synthesis and basic cell function like cell growth and migration.  
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PART- II 
 
RESEARCH WORK 
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CHAPTER 4 
 
INTERNAL CONTROL GENES AND REAL-TIME PCR IN THE 
STUDY OF AIRWAY INFLAMMATORY PROCESS 
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Introduction 
 
Eosinophils are one of the crucial cells regulating the chronic inflammatory process in inflammatory airway 
diseases like nasal polyposis and asthma. Activation of these cells is mainly mediated by the interaction of 
the cytokine IL-5 and its receptor IL-5R. This receptor consists in an alpha and a beta chain, which play 
different roles in the inflammatory process. The alpha chain of this receptor consists in two isoforms (the 
transmembrane and the soluble forms). Alternative splicing of the gene for IL-5Rα regulates production of 
these forms. Although several studies have been evaluated the differential regulation of these receptor forms 
at the protein level, the lack of a sensitive and accurate gene expression method difficulted the study of its 
transcriptional regulation. That is why we decided to apply a novel technology: real-time PCR, to study the 
differential mRNA expression of these isoforms in chronic rhinosinusitis and nasal polyposis. The method 
established allowed us to quantify the number of molecules for each spliced variant in nasal tissue and 
peripheral blood by using a standard curve based methodology and SYBR– green as detection strategy.. 
 
Furthermore, we proceed to evaluate a set of internal control genes that could be used in posterior gene 
analysis performed in this research work. Although most of researchers known the importance of 
normalizing gene expression data, only recently it has been really demonstrated the need of analyzing the 
stability of these genes prior gene analysis experiments. In chronic rhinosinusitis and nasal polyposis this 
analysis has not been performed. In this study we demonstrated that stability of internal control genes vary in 
normal nasal mucosa, chronic rhinosinusitis and nasal polyp tissue and this variation greatly depends of the 
degradation profile of the samples. Our results showed the importance of controling RNA integrity before 
PCR based studies and provide, for the first time, a suitable set of internal control genes that can be used in 
gene expression analyses in chronic rhinosinusitis and nasal polyp tissues.   
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Impact of RNA Quality on Reference Gene Expression Stability 
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Gene expression quantification methods are important tools in the understanding of the molecular events 
underlying human diseases and in the identification of diagnostic and therapeutic targets. Generally, the 
messenger RNA (mRNA) used for these analyses is derived from human biopsies obtained after surgery. As 
a consequence, several steps during tissue handling have to be carefully controlled in order to preserve the 
quality and integrity of the RNA material. It is well known that RNA is sensitive to degradation by 
postmortem processes and inadequate sample handling or storage (1). However, RNA integrity control is 
often not systematically performed prior to (PCR-based) downstream analyses. While in the past, RNA 
quality could often not be assessed due to the limited availability of the precious sample (e.g., from 
microdisected cells or small biopsies), the advent of capillary gel electrophoresis and (sample retention) 
spectrophotometry technologies (e.g., NanoDrop® ND-1000; NanoDrop Technologies, Wilmington, DE, 
SA) has addressed this issue, allowing quality estimations using only nanograms (or even picograms) of total 
RNA (2). In addition, amplification of RNA is now an alternative method to obtain sufficient amounts to 
conduct gene expression studies when postmortem tissues are scarce; however, assessment of RNA quality 
based on the 18S and 28S ribosomal RNA bands is often not possible anymore after amplification. 
 
Furthermore, it remains to be determined whether the amplified mRNA can faithfully be used to assess RNA 
quality of the starting material. Apart from RNA quality, the choice of a proper set of reference genes for 
accurate normalization is another crucial factor with a profound impact on the reliability of the obtained gene 
expression levels (3). Reference genes are expressed constitutively in every cell; however, their expression 
can be regulated with diseases state, during cellular proliferation, due to cellular composition and by 
mitogenic stimuli (e.g., growth factors) (4, 5). Furthermore, it is now known that life styles and genetic 
make-up of individuals can influence mRNA expression (6). That is why the validation of the expression 
stability of reference genes remains an important step to ensure the accuracy and reliability of gene 
expression studies. The objective of this study was to analyze the influence of RNA degradation on the 
stability and expression pattern of different internal control genes. To this purpose, 10 commonly used 
reference genes were quantified in both intact and degraded RNA from clinical specimens obtained from 
ethmoidal and maxillary sinuses collected from patients with nasal polyposis (NP) and chronic rhinosinusitis 
(CRS). 
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Sixteen clinical tissue samples (30 mg) were homogenized in Tri-reagent buffer (Sigma, St. Louis, MO, 
USA) (1 mL/50–100 mg of tissue) in a chilled pestle mortar. Total RNA isolation and cDNA synthesis were 
performed as described previously (7). RNA quality and percent of degradation were assessed with the 
Agilent 2100 Bioanalyzer system using the RNA 6000 Nano LabChip® kit (Agilent Technologies, Palo 
Alto, CA, USA); for representative results, see Supplementary Figure S1, which can be found online at 
www.BioTechniques.com. Real-time PCR amplifications were performed in an iCycler iQ® real time PCR 
detection system (Bio-Rad Laboratories, Hercules, CA, USA) in a 25-µL volume containing 20 ng cDNA 
(total RNA equivalent) of unknown samples, 1× SYBR® Green I Master mix (Bio-Rad Laboratories), and 
300 nM specific primer pairs for 10 references genes (GAPD, UBC, SDHA, HPRT1, B2M, ACTB, YWHAZ, 
HMBS, RPLI3A, and TBP); see Supplementary Table S1 for more information. Primer sequences are 
reported previously (3) and are available in RTPrimerDB, the real-time PCR primer and probe database 
(medgen.ugent.be/ rtprimerdb/) (8). The amplification protocol consisted of 1 cycle at 95°C for 10 min 
followed by 40 cycles at 95°C for 30 s and at 60°C for 1 min. Gene expression level normalization and 
stability analysis was performed using the Microsoft® Excel® Visual Basic application geNorm as described 
previously (3). Our results show that the stability of  reference genes not only is different in CRS and NP 
ethmoidal and maxillary sinus tissues (as can be expected due to differences in cellular origin), but also 
varies within the same tissue type according to the degradation status of the samples (Figure 1). The fact that 
highly stable genes in intact RNA samples rank among the most unstable genes in degraded samples (e.g., 
ACTB in NP tissue) and vice versa (e.g., GAPD in CRS and B2M in NP) suggests that at least some genes 
show different sensitivity to RNA degradation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step* Degraded RNA 
(CRS samples) 
Intact RNA 
(CRS samples) 
Degraded RNA 
(NP samples) 
Intact RNA 
(NP samples)
1 HPRT1 GAPD HPRT1 YWHAZ 
2 YWHAZ YWHAZ ACTB B2M 
3 B2M RPL3IA RPL3IA RPL3IA 
4 TBP B2M GAPD UBC 
5 RPL3IA UBC TBP GAPD 
6 UBC HPRT1 YWHAZ HMBS 
7 ACTB TBP HMBS HPRT1 
8 GAPD ACTB SDHA SDHA 
9 HMBS- SDHA HMBS- SDHA B2M- UBc ACTB- TBP 
Reference genes ranked in order of their expression stability increasing from top
to bottom; the two most stable genes in each sample series; for example ACTB
and TBP in intact RNA from nasal polyp tissue, cannot be ranked in order
because of the required use of gene ratios for gene-stability. *: The step number 
at which the least stable gene is excluded, see right panel. 
Figure 1. Average expression stability values of remaining control genes. Expression stability (M) was 
analyzed during stepwise exclusion of the least stable control gene in the different tissue samples (the 
different steps match those in the table). CRS, chronic rhinosinusitis; NP, nasal polyp. 
Step 
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 (M
) 
    0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
1 2 3 4 5 6 7 8 9
Degraded RNA (CRS samples)
Intact RNA (CRS samples) 
Degraded RNA (NP samples) 
Intact RNA (NP samples) 
  
 
 
 
 
 
- 92 - 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bottom line is that different reference genes appear to be suitable for normalization in degraded versus 
intact RNA samples. When one has no prior knowledge of the RNA degradation status, incorrect conclusions 
could thus be drawn for the selection of proper reference genes. Furthermore, once a suitable set of reference 
genes has been selected (even based on only intact samples), the use of these genes to normalize mRNA 
content in (partially) degraded samples could lead to significant errors and misinterpretation of target gene 
expression levels information.  
 
The purpose of normalization is to remove the sampling differences (such as RNA quantity and cDNA 
synthesis efficiency) in order to identify real gene-specific variation that, for proper internal control genes, 
should be minimal. Following the approach outlined in Reference 3, we have calculated the gene-specific 
variation for each reference gene as the standard deviation of normalized expression levels. To this end, the 
raw expression values were divided by two different normalization factors, calculated as the geometric mean 
of the three most stable control genes (as determined by geNorm) in degraded or intact RNA samples. We 
Nasal polyp (NP) samples  
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Figure 2. Relative average gene-specific variation in degraded versus intact RNA samples. Gene-specific 
variation in expression was calculated after normalization using the three most stable reference genes 
according to geNorm analysis. Bars represent the ratio of the average standard deviation of normalized gene 
expression levels in degraded samples versus nondegraded samples. From left to right, nasal polyp (NP) and 
chronic rhinosinusitis (CRS) tissues samples, normalized using 2 different normalization factors. 
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subsequently determined the average gene-specific variation of all reference genes (either excluding or 
including the three normalizing reference genes) for each normalization factor, and within each tissue type, 
and plotted the ratio of the variation in degraded versus intact samples (Figure 2).  
 
It is clear that the gene-specific variation is always higher in degraded versus intact samples, with more 
pronounced differences in CRS compared to NP. Furthermore, normalization using the so-called best 
reference genes in degraded samples systematically resulted in higher gene-specific variation than using the 
best reference genes identified on the basis of intact samples. In addition, in degraded samples, relative gene 
specific variation was also higher when the three most stable genes (used for normalization) were excluded 
(Figure 2, grey bars) than when they were included (Figure 2, black bars). In contrast, in non-degraded 
samples, the inclusion or exclusion of these genes seems not to significantly affect gene specific variation. 
Using a normalization factor based on the proper internal reference genes should result in the removal of 
nonspecific variations. However, unstable reference genes cannot completely remove variation instead, they 
add more, resulting in larger so-called gene-specific variation for the tested reference genes.  
 
This analysis clearly demonstrates that most nonspecific variation was removed when the most stable control 
genes in intact RNA samples (as determined by geNorm) were used for normalization and that the gene 
expression variation in degraded RNA samples is inherently higher. While thorough RNA quality control is 
routinely being performed prior to microarray-based gene expression profiling, the same quality control is 
often considered not required or simply not performed for PCR-based quantification methods. Indeed, even 
on degraded RNA samples, a nice amplification curve can be obtained. However, in view of the observed 
difference in reference gene expression stability between intact and degraded RNA samples from the same 
tissue and the higher gene-specific variation in degraded samples, we propose performing RNA quality 
control prior to downstream quantification assays and discarding degraded samples, especially if one aims to 
accurately quantify small expression differences. Indeed, as it is of utmost importance to normalize samples 
using the same set of reference genes, our results suggest that it is inappropriate to compare degraded and 
intact samples. 
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CHAPTER 5 
 
REGULATION OF EICOSANOID METABOLISM IN CHRONIC 
RHINOSINUSITIS/ NASAL POLYPOSIS 
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Introduction  
 
Arachidonic acid cascade is one of the most controversial pathways regulating the balance of pro- and anti- 
inflammatory events during immune response. Arachidonic acid released after cell stimulation, can be 
metabolized by three different ways yielding to the production of leukotrienes, prostaglandins and lipoxins, 
which can up- or down-regulate the expression of their receptors in combination with other stimulus like 
cytokines and growth factors. Implication of this pathway in chronic rhinosinusitis/ nasal polyposis and 
especially in aspirin intolerance syndrome has been suggested; however, the precise mechanisms operating 
in these diseases remain unclear. In this chapter, we demonstrated that changes in arachidonic acid 
metabolism may occur in absence of the clinical manifestation of aspirin intolerance in patients with chronic 
rhinosinusitis and they are mainly related to the eosinophilic inflammation developed in these patients. In 
addition, we also show that the expression of CysLTs and especially prostanoid receptors follow a different 
pattern in chronic rhinosinusitis patients with and without nasal polyps, which can have a big implication in 
the attenuation of the inflammatory responses in these patients. 
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ABSTRACT 
 
Background: Eicosanoid receptors are G-protein-coupled receptors playing an important 
immunomodulatory role in airway diseases; however, there is little information on the expression of these 
receptors and their link with eosinophilic information in paranasal sinus diseases. We aimed with this study 
to investigate the tissue expression of leukotrienes and prostaglandin E2 receptors in chronic rhinosinusitis 
patients with and without nasal polyposis and the link of this regulation with the inflammatory process in 
these subjects. Methods: Samples were prepared from nasal tissue of patients with chronic rhinosinusitis 
without nasal polyps (CRS, n=11), with nasal polyps (CRS-NP, n=13) and 6 healthy subjects (Controls). 
mRNA expression of CysLT1, CysLT2, BLT1, BLT2, E- prostanoid receptors (EP1, EP2, EP3, EP4) and IL-5R 
was determined by real- time PCR. Concentrations of PGE2, LTC4/D4/E4, LTB4 and IL-5R (were determined 
by ELISA and of ECP by ImmunoCap. Protein expression and tissue localization of eicosanoid receptors and 
activated eosinophils were evaluated by immunohistochemistry. Results: CysLT1 mRNA expression was 
significantly increased in CRS-NP compared to CRS and controls, and CRS compared to controls, whereas 
CysLT2 mRNA was enhanced in both CRS groups without differences between them. In addition, levels of 
CysLT1 and CysLT2 receptors correlated to the number of activated eosinophils, IL-5R protein, ECP and 
LTC4/D4/E4 concentrations in the disease groups. PGE2 protein concentrations and prostanoid receptors EP1 
and EP3 were down-regulated in the CRS-NP tissue vs. CRS and controls, whereas EP2 and EP4 expression 
was enhanced in CRS and CRS-NP patients vs. controls. No differences in BLT receptors or LTB4 were 
observed between patients and controls. Conclusions: Contrasting to LTB4, we here show that protein and 
receptor expression for cys-leukotrienes and prostaglandin E2 is differentially regulated in CRS-NP, showing 
a parallel regulation pattern between eicosanoids and their receptors. Within the group of EP receptors, we 
found a differential shift of EP1 and EP3 molecules vs. EP2 and EP4, which may be important in the 
mechanisms operating in chronic rhinosinusitis/ nasal polyposis. 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS: 
AA:  arachidonic acid  
AAM:  arachidonic acid metabolism 
BLT1:  leukotriene B4 receptor 1 
BLT2:  leukotriene B4 receptor 2 
CRS:  chronic rhinosinusitis 
CRS-NP: chronic rhinosinusitis- nasal polyp  
CysLTs:  cysteinyl leukotrienes 
CysLT1:  cysteinyl leukotriene receptor 1 
CysLT2:  cysteinyl leukotriene receptor 2 
EG2:  eosinophil granulocyte 
EP1:  prostanoid receptor 1 
EP2:   prostanoid receptor 2 
EP3:  prostanoid receptor 3 
EP4:  prostanoid receptor 4 
Sol- IL5Rα: soluble interleukin –5 receptor alpha  
LTC4/ D4/ E4:  leukotriene C4/ D4/ E4 
LTB4:  leukotriene B4 
PGE2:  Prostaglandin E2 
Key words: prostanoid E receptors, nasal 
polyposis, chronic rhinosinusitis, 
leukotriene receptors, eosinophilic 
inflammation, eicosanoid metabolism. 
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INTRODUCTION 
 
The role of eicosanoids in the pathophysiology of chronic inflammatory airway diseases especially asthma 
have been well documented. However, the key steps in the regulation leading to the production of these 
molecules remain unclear. Eicosanoid signalling operates through lipid G- protein- coupled receptors 
(GPCRs) (1). According to the International Union of Pharmacology (IUPHAR), eicosanoid receptors are 
classified in four main groups: the BLT receptors, with biological activities related to LTB4, the cysteinyl 
leukotrienes (CysLTs) receptors related family, the lipoxin (ALX) receptors and the prostanoid receptors 
class (1). 
 
Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly in the aspirin-
sensitive syndrome. These eicosanoids mediate their biologic activities through interactions with the CysLT1 
and CysLT2 receptors, which play an important role in inducing bronchospasm, endothelial cell adherence, 
myofibroblast proliferation, bronchoconstrictions, vascular hyper-permeability, mucus secretion and 
chemokine production (2). Immunohistochemical studies have revealed that the CysLT1 receptor is 
expressed on eosinophils, mast cells, macrophages, neutrophils and vascular endothelial cells in the nasal 
mucosa (3). CysLT1 receptor has been found up- regulated in inflammatory cells from aspirin-sensitive 
patients compared to non-aspirin-sensitive patients and its down- regulation was associated to the aspirin 
sensitization performed in these patients (4). Expression of CysLTs receptors has been also demonstrated in 
key allergic and inflammatory cells from the upper airway of patients with active seasonal allergic rhinitis 
(5). Cysteinyl leukotrienes may also regulate vascular permeability in the airways, leading to airway edema. 
In vitro studies have shown that administration of CysLTs receptor antagonists markedly reduced plasma 
extravasation and vascular endothelial growth factor levels in allergen-induced asthma, indicating the role of 
CysLTs receptors in the modulation of vascular permeability (6). Genetic studies have also suggested the 
CysLT2 receptor to be one of the genes contributing to susceptibility to asthma, based on a polymorphism 
associated to the development of this disease in a Japanese population (7). In addition, a recent study 
performed in patients with chronic rhinosinusitis/ nasal polyps showed that CysLT1 expression predominates 
on inflammatory leukocytes in patients with aspirin-sensitive rhinosinusitis, but the effects of cysteinyl 
leukotrienes on glands and epithelium may be mediated predominantly through CysLT2 (8). 
 
Together with CysLTs, leukotrienes B4 receptors (BLTs) have been reported as potential molecules in the 
regulation of airway inflammation. However, in contrast to CysLTs, controversial results about LTB4 and 
BLT receptors have been reported in several studies. The human high-affinity LTB4 receptor BLT1 has been 
found in myeloid leukocytes, including neutrophils, macrophages, and eosinophils, but also T cells (9). In 
vitro studies have demonstrated that LTB4 can induce T helper type 1 and 2 cell chemotaxis and firm 
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adhesion to endothelial cells and early CD4+ and CD8+ T cell recruitment into the airway in an asthma model 
(10). Furthermore, BLT receptor- LTB4 mediated action was found to contribute to neutrophil influx into the 
airways in patients suffering from chronic obstructive pulmonary disease, suggesting its role in disease 
progression (11). However, in upper airway diseases, the levels of LTB4 and BLT receptors have been found 
increased in nasal polyp patients with allergy in comparison to non- allergic subjects (12) but no differences 
were observed between aspirin intolerant compared to tolerant subjects (13). Until now, no clear mechanism 
regulating the synthesis of these molecules in airway has been demonstrated.  
 
Although a large body of studies has been focused in the expression leukotrienes and leukotrienes receptors 
in different airway diseases; a few experiments have been conducted related to the mechanisms regulating 
prostanoid and lipoxin receptor signalling. The prostanoid receptor subfamily comprises eight members: the 
prostaglandin D (DP) receptor, the prostaglandin E2 receptors (EP1, EP2, EP3 and EP4), the prostaglandin F 
receptor (FP), the prostaglandin I receptor (IP), the tromboxane A receptor (TP), and a ninth prostaglandin 
receptor identified recently, the chemoattractant receptor homologous molecule expressed on Th2 cells 
(CRTH2) (14). The roles of prostaglandin receptors in physiology and immune system are determined by 
multiple factors including cellular context, receptor expression profile, ligand affinity, and differential 
regulation of signal transduction pathways (14). In airways, effect of PGE2 in bronchodilation and airway 
relaxation has been found to be mediated by EP2 receptor (15, 16). In addition, a study performed in wild- 
type and EP receptor-deficient mice demonstrated that interaction of PGE2 with EP1 and EP3 receptors 
induce airway constriction through activation of neural pathways, whereas activation of EP2 on airway 
smooth muscle induced bronchodilation. These results suggest that modulation of airway tone by PGE2 
involves multiple receptors mechanisms and different cell populations (17). Basal expression of EP2 and EP4 
receptors has been observed to be increased on bronchial inflammatory cells from asthmatic patients and 
may be altered in vitro on eosinophils in response to inflammatory stimuli, suggesting the 
immunomodulatory role of these receptors in asthma, (18). Furthermore, Burgess and col. have also shown a 
high expression of EP2 and EP3 receptors on smooth muscle cells from asthmatic patients compared to non- 
asthmatics.  Interestingly, cells from asthmatic subjects had increased sensitivity to proliferation inhibition 
by EP2- but not by EP3 specific agonists, suggesting the role of EP2 in airway cell proliferation process (19). 
Furthermore, recent studies have shown that EP3 knockout mice developed a more severe allergic 
inflammation than wild-type mice or mice deficient in other prostaglandin E receptor subtypes. Of interest, a 
EP3- selective agonist suppressed this reaction, suggesting this receptor as an important molecule in the 
modulation of allergic reactions (20). The aim of this study was to compare the tissue expression of CysLTs 
and PEG2 receptors in chronic rhinosinusitis with and without nasal polyps, and to study their relation with 
eosinophilic inflammation in these patients. 
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MATERIALS AND METHODS  
 
Patients and clinical diagnosis 
 
Samples from ethmoidal and maxillary sinuses were collected during functional endoscopic sinus surgery 
(FESS) procedures in the Department of Othorhinolaryngology at the Ghent University Hospital. Nasal 
tissues were obtained from 13 patients with chronic rhinosinusitis and nasal polyposis (CRS-NP) (10 males, 
3 females, age range: 30- 54 years) and 11 subjects with chronic rhinosinusitis without nasal polyposis CRS 
(8 males, 3 females, age range: 21- 53 years) who were scheduled for sinus surgery in the department of 
Othorhinolaryngology of the Ghent University Hospital. As control group (Controls), we included 6 subjects, 
who underwent septal surgery and removal of parts of the inferior turbinate due to anatomical variations, 
without any acute or chronic clinical, endoscopic or imaging signs of sinusitis or polyposis. The mean age of 
this group was 36.6 years (4 males, 2 females, age range: 21- 53 years) and none of the subjects had a history 
of atopic, sinus or lower airway disease.  
 
Diagnosis of CRS was based on the presence of typical symptoms (headache, nasal obstruction and 
discoloured nasal drainage) longer than 12 weeks and a positive CT- Scan showing swelling of the ethmoidal 
and maxillary mucosa and bilateral obstruction of the osteomeatal complex but without polyp formation, 
visible during nasal endoscopy or during surgery. Nasal polyposis was diagnosed based on symptoms history 
(nasal congestion, lost of smell, changes in sense of taste and persistent postnasal drainage), clinical 
examination, nasal endoscopy and paranasal sinuses CT- Scan, defined as presence of visible bilateral polyps 
growing from the middle meatus into the nasal cavities, and affecting the ethmoidal sinuses. In the CRS-NP 
group, 4 patients had asthma and in the CRS group, there was one patient with allergic rhinitis and one with 
asthma, none of them did manifest any aspirin clinical manifestation of intolerance to aspirin or NSAIDs. 
Diagnosis of asthma was based on clinical history, typical symptoms and lung (pulmonary) function tests 
(Spirometry and Peak Expiratory Flow), following the Global initiative for asthma (GINA) guidelines. The 
study was approved by the ethical committee of the Ghent University Hospital, and all patients gave 
informed consent before their participation. The use of any oral medication with possible impact on 
measurements of enzymes or mediators, including systemic glucocorticoids and anti-leukotrienes, was 
stopped in all subjects 4 weeks before surgery. The use of topical glucocorticoids was interrupted 2 weeks 
before surgery.  
 
Real time PCR for eicosanoid receptors 
 
Quantitative real time PCR was used to determine the mRNA levels of enzymes and receptors involved in 
the AA cascade. Nasal tissue (30 mg) was homogenized in Tri- reagent buffer (Sigma-Aldrich, MO, USA), 1 
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ml per 50-100 mg of tissue, in a chilled pestle mortar. Total RNA from homogenates was isolated using Tri-
reagent Kit following the manufacturer’s instructions (Sigma-Aldrich, MO, USA). cDNA was synthesized 
from 2 µg of total RNA using Oligo(dT)12-18, random hexamers and the Superscript RNase H- Reverse 
Transcriptase (Life Technologies, CA, USA),  as described previously (21). Amplification reactions were 
performed on an iCycler iQ Real-Time PCR Detection System (Bio-Rad laboratories, CA, USA) using 
specific primers (Table 1) designed with the Primer3 software (22). PCR reactions contained 20 ng cDNA 
(total RNA equivalent) of unknown samples, 1x SYBR Green I Master mix (Bio-Rad laboratories, CA, 
USA) and 300 nM of primer pairs in a final volume of 25 µl. PCR protocol consisted of 1 cycle at 95°C for 
10 minutes followed by 45 cycles at 95°C for 30 seconds and at 60°C for 1 minute. The expression of two 
housekeeping genes Beta actin (ACTB) and Hydroxymethyl-bilane synthase (HMBS) was used to normalize 
for transcription and amplification variations among samples and control specimens. The relative number of 
molecules of each gene, expressed in relative expression units quantified per 20 ng of cDNA sample, was 
determined by the ∆CT value method as described previously (23).  
 
Table 1. Primer sequences used for real time PCR amplification 
 
 
Eicosanoid levels 
 
Concentration of cysteinyl leukotrienes C4/D4/E4 (LTC4/D4/E4), prostaglandin E2 (PGE2) and leukotriene B4 
(LTB4) were measured by Enzyme Linked Immunoassays (ELISAs) purchased from Oxford BioMedicals 
(Oxford, USA). Sample extraction procedures for protein removal and eicosanoid stabilization were 
performed according to the provider’s instructions. Briefly, nasal or sinus tissues were first homogenized in 
ethanol (5ml/g) for LTB4 and LTC4/D4/E4, and in 15% methanol/ 0.1M sodium phosphate buffer, pH 7.5 for 
Eicosanoid 
receptors 
Forward primer (5’→ 3’) Reverse primer (5’→ 3’) Amplicon 
size 
Genbank 
Accession 
number 
EP1 GATGGTGGGCCAGCTTGTC GCCACCAACACCAGCATTG 73 bp NM_000955 
EP2 GACCGCTTACCTGCAGCTGTAC TGAAGTTGCAGGCGAGCA 73 bp NM_000956 
EP3 AAGGCCACGGCATCTCAGT TGATCCCCATAAGCTGAATGG 76 bp NM_000957 
EP4 ACGCCGCCTACTCCTACATG AGAGGACGGTGGCGAGAAT 63 bp NM_000958 
BLT1 CCTGAAAAGGTGCAGAAGC AAAAAGGGAGCAGTGAGCAA 93 bp NM_000752 
BLT2 CTTCTCATCGGGCATCACAG ATCCTTCTGGGCCTACAGGT 88 bp NM_019839 
CysLT1 TCCTTAGAATGCAGAAGTCCGTG AAATATAGGAGAGGGTCAAAGCAA 80 bp NM_006639 
CysLT2 GCTGATCATTCGGGTTCTGT GGTGATGATGATGGTGGTCA 91 bp NM_020377 
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PGE2 measurements and then centrifuged for 5 minutes at 3,000 rpm at 4°C. Supernatants were diluted in 
water, pH 3.5 and following manufacturer’s instructions (Oxford BioMedicals, Oxford, USA). The detection 
ranges for all assays were between 0.02- 10 ng/ml. The sensitivity was of 0.2 ng/ml for all assays and the 
intra- and inter- assay coefficient of variation less than 10%.  
 
 
Eosinophil inflammatory markers 
 
Soluble IL-5α receptor isoform was quantified using a real time PCR, as described previously (21). Briefly, 
a standard curve was constructed from a plasmid containing the cDNA sequence for this receptor isoform. A 
fragment of this plasmid was amplified with specific primers, purified and subsequently quantified and used 
in equimolar 10-fold dilutions to generate standard curve. Real time amplifications were performed in a 25 µl 
volume reaction containing 1X SYBR Green I Master mix (Bio- Rad laboratories, CA, USA), 300 nM of 
primer pairs and a set of primers specific for this hIL-5 Rα isoform (21). PCR protocol consisted of 1 cycle 
at 95°C for 10 minutes followed by 40 cycles at 95°C for 30 seconds and at 64°C for 1 minute. Each sample 
was tested in duplicate. The quantity of each amplicon was calculated from the values of the standard curve 
and normalized by the quantities obtained for beta actin (ACTB) and hydroxymethyl-bilane synthase 
(HMBS). 
 
Soluble IL-5α receptor protein concentrations were measured by a research ELISA as described previously 
(24) with a sensitivity of 8 pg/ ml. and an intra- and inter- assay coefficient of variation less than 10%. 
Quantification of Eosinophil Cationic Protein (ECP) was carried out, on supernatants obtained after nasal 
tissue homogenization, by the UniCAP system (Pharmacia & Upjohn, Sweden), with a detection limit of < 
0.5 µg/L and a coefficient of variation less than 10%.  
 
Number of activated eosinophils was determined by staining the eosinophil granulocyte (EG2) and 
semiquantitative scoring of positively stained cells on the different tissues. For that, frozen tissue sections 
were fixed in acetone for 10 minutes, washed in TBS buffer and incubated with (1:1000) mouse anti- human 
ECP/EPX monoclonal antibody (Pharmacia & Upjohn Uppsala, Sweden) for 1 hour. Then, the slides were 
incubated with (1:50) rabbit anti-mouse IgG for 10 minutes and developed with (1:100) alkaline phosphatase 
anti-alkaline phosphatase (Dako, Glostrup, Denmark) for 10 minutes at room temperature. Signal detection 
was performed using the New Fuchsin Substrate System, following the manufacture’s instructions (Dako, 
Glostrup, Denmark). Semiquantitative scoring was performed by a pathologist, who was blinded for the 
clinical data, on a four-point scale adapted from an already validated system of semiquantitative evaluation. 
Zero represented the lowest and three the highest score. The analysis included all areas of the biopsies and a 
global score was given for each parameter.  
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Immunohistochemical staining for prostanoid and leukotriene receptors 
 
Frozen tissue sections were fixed in acetone for 10 minutes at room temperature and washed in 1x TBS 
buffer. Endogenous peroxidase activity was blocked with 0.3 % hydrogen peroxidase (VWR International, 
Pennsylvania, USA) in PBS containing 0,001 % NaN3 for 20 minutes at room temperature. Sections were 
than washed for 10 minutes with 1x TBS and incubated with foetal bovine serum during 30 minutes. 
Sections were then incubated for 1 hour at room temperature with primary antibodies: (1:250) rabbit IgG 
polyclonal Antibodies for (1:250) EP1 receptor, (1:250) EP2 receptor, (1:200) EP3 receptor, (1:250) EP4 
receptor, (1:50) CysLT1 and (1:50) CysLT2, purchased by Cayman Chemicals, MI, USA. Signal was 
detected with LSAB+ kit (HRP Rabbit/Mouse/Goat) purchased from Dako, using the AEC+ High Sensitivity 
Substrate Chromogen Kit (Dako, Glostrup, Denmark). Number of inmunoreactive cells was determined by 
semiquantitative scoring of positively stained cells on the different tissues as described above. 
 
Statistical data analysis 
 
All data was analyzed using the MedCalc software version 6.0 (Mariakerke, Belgium). Results are presented 
in Box- and- Whisker plots, where the central box represent the values from the lower and upper interquartile 
range, and the middle line the median. Data comparison within different patient groups was performed using 
the Kruskal-Wallis test (H-test). The Wilcoxon test (or Mann-Whitney U test) for unpaired samples was 
applied to evaluate the statistical differences between two patient groups. Spearman’s rank correlation 
analysis was performed to determine statistical significance of differences between two parameters in a 
classification group. P values equal or less than 0.05 was regarded as significant. 
 
RESULTS  
 
mRNA expression of eicosanoid receptors by real time PCR 
 
Expression of leukotrienes and prostanoid receptors analyzed by quantitative real time PCR showed an up- 
regulation of CysLT1 and CysLT2 receptors in CRS patients compared to controls, but only CysLT1 was 
significantly higher in CRS-NP in comparison to CRS patients as showed in figure 1a. In contrast, the four 
EP receptors showed an up- regulation of EP2 and EP4 mRNA in both CRS groups when compared with 
normal subjects. In contrast, EP1 and EP3 expression was similar in controls and CRS patients but 
significantly down-regulated in the CRS- NP group (Figure 1b). Concentrations of BLT1 and BLT2 receptors 
were similar in the three groups of patients (data not shown). In addition, mRNA expression profile for the 
four EP and the two CysLTs receptors were analyzed in each individual group of patients as showed in 
figures 2 and 3. In the control group, the expression of EP receptors did not show any differences. However, 
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in the CRS and CRS-NP we observed a down- regulation of EP1 and EP3 receptors compared to EP2 and EP4 
and this difference was more accentuated in the CRS- NP subjects. On the other hand CysLT1 and CysLT2 
mRNA levels were similar in CRS and normal mucosa, however significantly higher concentrations of 
CysLT1 were observed in the CRS-NP group. 
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Figure 1.  mRNA levels of eicosanoids receptors in nasal mucosa; a) CysLTs receptors, b) 
prostaglandin E receptors. Controls: healthy subjects, CRS: chronic rhinosinusitis, CRS-NP:  chronic 
rhinosinusitis/ nasal polyps. P: p value after unpaired Mann-Whitney U test. 
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Figure 2.  Balance of mRNA levels of prostanoid E receptors in nasal 
mucosa P: p value (unpaired Mann- Whitney U test).
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Eicosanoid production and eosinophil inflammatory markers   
 
Levels of eicosanoids were quantified by Enzyme immunoassays. While concentrations of LTC4/ D4/ E4, 
were significantly higher in CRS-NP compared to CRS and controls, no differences were observed in LTB4 
levels between the groups. PGE2 concentrations however, were similar in CRS and control (p> 0.10) but 
statistically lower in the nasal polyp tissue (p= 0.001) as showed in table 2. Real time PCR for sol- IL-5αR 
showed a significantly increase in CRS-NP subjects compared to CRS and in CRS compared to control 
subjects. Accordingly sol- IL-5αR protein was also statistically higher in the CRS- NP compared to CRS and 
in this group compared to control tissue. ECP was significantly increased in CRS compared to the control 
group (p< 0.05) and even more in CRS-NP (p< 0.02), as showed in table 2.  
 
Immunohistochemistry results demonstrated a strong infiltration of inflammatory cells in the nasal polyp 
compared to the CRS and inferior turbinate tissues (data not shown) and the median score for EG2 positive 
cells was significantly higher in NP tissue compared to the control and CRS tissues as summarized in table 2. 
 
 
Table 2. Concentration of eicosanoids and eosinophilic inflammation markers in chronic rhinosinusitis 
patients. Results are expressed as median and interquartile ranges (IQR). §: p < 0.05 is due to differences 
between the three sample groups; (¶): p < 0.05 is due to differences in the levels between CRS-NP and 
controls and CRS patients. N.S: No statistical differences, p value > 0.05. CRS: Chronic rhinosinusitis, CRS-
NP: chronic rhinosinusitis/nasal polyp, Controls: inferior turbinate tissues from healthy subjects. 
 
 Controls CRS CRS-NP Kruskal 
Wallis- test 
Eicosanoids  
LTC4/ D4/ E4 (ng/ ml) 1.16 (IQR: 0.85- 1.68) 3.34 (IQR: 2.70- 5.35) 7.24 (IQR: 4.65- 
12.40) 
P < 0.01 § 
LTB4 (ng/ ml) 25.25 (IQR: 8.26- 
63.91) 
21.95 (IQR: 9.40- 
31.90) 
19.44 (IQR: 12.80- 
29.71) 
N.S 
PGE2 (ng/ ml) 180.63 (IQR: 101.44- 
258.86) 
199.83 (IQR: 59.10- 
223.52) 
55.00 (IQR: 40.59- 
67.87) 
p = 0.02 ¶ 
Eosinophilic inflammation markers 
ECP (µg/ L) 602.51 (IQR: 309.90- 
894.30) 
2090.00 (IQR: 1437.60- 
5442.40) 
11880.00 (IQR: 
1862.70- 17920.74) 
p  < 0.01 § 
IL-5Rα  protein (ng/ 
ml) 
20.62 (IQR: 15.77- 
26.43) 
50.95 (IQR: 28.62- 
67.78) 
175.24 (IQR: 37.11- 
309.67) 
P < 0.05 § 
sol- IL-5Rα mRNA 14757.50 (IQR: 
12493.97-  23015.35) 
159065.30 (IQR: 
45909.00- 185796.90) 
458449.55 (IQR: 
267447.00-  
796387.30) 
p = 0.02 § 
EG2 positive cells 1,00 (IQR: 1,00- 1,15) 1,05 (IQR: 1,00- 1,40) 2,10 (IQR: 1,90- 
2,25) 
p  < 0.01 ¶ 
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The Spearman’s rank correlation analysis showed a strong correlation between both CysLTs receptors 
mRNA with IL-5R protein concentrations (CysLT1: r = 0,574, p = 0.01; CysLT2: r = 0,523; p < 0.05), ECP 
(CysLT1: r = 0,544, p = 0.02; CysLT2: r = 0,413; p = 0.03) and the total number of activated eosinophils 
(CysLT1: r = 0,546, p = 0.02; CysLT2: r = 0,614; p = 0.03).  No correlations were found between the levels 
of these receptors and eosinophilic inflammation markers with exception of EP1 that inversely correlated 
with the number of activated eosinophils (r = 0,636; p = 0.01). 
 
Immunohistochemical staining for prostanoid and leukotriene receptors 
 
Immunohistochemical staining for CysLT1 and CysLT2 receptors in the nasal tissue is represented in figure 
3. Immunoreactivity of both CysLTs receptors was observed in inflammatory cells in the lamina propria in 
both CRS groups. In addition, these receptors were expressed in the sub-epithelial layer of the nasal mucosa 
and to a lesser extend in the epithelium. Prostanoid E receptors were mainly expressed in the epithelium and 
in mucosal glands. In inflammatory cells, immunoreactivity for EP1 and EP3 was higher compared to EP2 and 
EP4 as showed in figure 4. 
CysLT1 
CysLT2 
Isotype negative 
control 
Inflammatory cells 
Epithelium and 
subepithelium 
Glands and blood 
vessels 
Figure 4.  Representative photomicrography (original magnification 20X) of nasal polyp 
specimens immunostained for CysLT1 and CysLT2 receptors in inflammatory cells, 
epithelium, glands and blood vessels. 
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Inflammatory cells 
Epithelium and 
subepithelium Glands and blood vessels 
Isotype negative 
control 
EP1 
EP2 
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EP4 
Figure 5. Representative photomicrography (original magnification 20X) of nasal polyp specimens 
immunostained for EP1, EP2, EP3 and EP4 receptors in inflammatory cells, epithelium, glands and blood 
vessels. 
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DISCUSSION 
 
Several studies have suggested changes in the eicosanoid regulation patterns as one of the factors involved in 
the pathophysiology of chronic rhinosinusitis and nasal polyposis; however, the effect of eicosanoids in the 
tissue, greatly dependents of the differential expression of the distinct subtypes of their receptors. 
 
In this study, we confirmed that CysLT1 and CysLT2 receptors are up- regulated in chronic rhinosinusitis and 
nasal polyp patients. Interestingly, the balance of these receptors was similar in healthy and chronic 
rhinosinusitis subjects, in contrast to the nasal polyp group where expression of CysLT1 was significantly 
higher when compared to CysLT2. Furthermore, we evaluate the link between these receptors and 
eosinophilic inflammation and we observed that both CysLT1 and CysLT2 correlated with markers of 
eosinophil activation like IL-5αR, ECP and the number of activated eosinophils. These results are in line 
with previous results showing that eosinophils are one of the most important sources of these receptors in 
inflamed upper airways (25, 26); and that CysLT1 maybe involved in several stages of eosinophil 
differentiation, recruitment and maturation (27-29). In other hand, we did not found any changes in LTB4 or 
BLTs receptors between controls and disease groups. These findings correspond with previous studies 
performed in aspirin intolerant nasal polyp patients (13) and with perennial allergic rhinitis (30).  However 
are in contrast with other reports showing increased levels of this eicosanoid in allergic versus non- allergic 
nasal polyp patients (31). Accordingly, there are no clear evidences about the role of this molecule in chronic 
rhinosinusitis and nasal polyposis and following our results; we question its role in these diseases.  
 
As well as leukotrienes, prostaglandins and especially PGE2 play an important role in the regulation of the 
inflammatory process observed in chronic rhinosinusitis patients (28, 29). Little is known about the function 
and distribution of these receptors in airways and there are no studies reporting the action or regulation of 
these receptors in upper airway tissue 
 
We show for the first time that mRNA profile of prostanoid E receptors differs between chronic 
rhinosinusitis with and without polyps, again being different from healthy controls. We also observed that 
EP2 and EP4 receptors are up- regulated in chronic rhinosinusitis and nasal polyp tissue compared to control 
subjects; however, EP1 and EP3 transcripts were statistically decreased only in the nasal polyp patients.  
 
It has been reported, that action of PGE2 via EP1 and EP3 receptors has been reported to be mediated by an 
increase of intracellular cAMP (33). In inflammatory cells, this phenomenon is associated with an inhibition 
of effector’s cell functions such as activation, or response to certain stimulus (33). Accordingly, we can 
assume that down-regulation of these receptors may increase functionality and susceptibility of inflammatory 
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cells to inflammatory stimulus like IL-5 and LTs contributing to the chronic inflammation observed in these 
diseases. Controversially, interaction of PGE2 with EP1 and EP3 variants is translated in an increase of 
intracellular calcium inducing immune cell activation (33).   This last action may be of great importance in 
chronic rhinosinusitis/ nasal polyposis due to increase of intracellular calcium may induce the activation of 
cytosolic phospholipase A2 leading to the production of leukotrienes. However, this contradicts our previous 
hypothesis that PGE2/ EP1/ EP3 interaction may has anti- inflammatory action. 
 
An in vitro study performed on inflammatory cells demonstrated that eosinophils express high levels of EP2 
and EP4 mRNA in comparison with EP1 and EP3, which were almost not present in these cells (34). In 
addition, interaction of PGE2 with these receptors may induce cellular cAMP production that can contribute 
to CysLTs production that has been reported to be mediated by EP4 activation (34). Levels of EP2 and EP4 
receptors in the chronic rhinosinusitis and chronic rhinosinusitis/ nasal polyp groups did not correlate with 
eosinophil number or activation but it was increased in the disease groups compared to controls. In addition, 
CysLTs synthesis was also enhanced in the chronic rhinosinusitis patients compared to chronic 
rhinosinusitis/ nasal polyps and healthy subjects. These results may suggest the existence of important 
sources other than eosinophils expressing these receptors and contributing to inflammation in these patients.  
In addition, the lack of correlation and the similar mRNA levels of these receptors between the disease 
groups may be because regulation and functionality of these receptors greatly depend of post-transcriptional 
regulation mechanisms. Here we were not able to analyze the protein expression of these molecules to 
confirm our PCR results.  
 
Finally, it has also been suggested that deficiency of PGE2 production may up-regulate the expression of EP2 
and EP4 receptors (34). We have previously reported that concentrations of PGE2 are decreased in chronic 
rhinosinusitis/ nasal polyp compared to chronic rhinosinusitis patients (25) that could explain the high levels 
of the receptors observed in the patients. However, of interest, expression of these receptors is similar 
between the two chronic rhinosinusitis groups, suggesting again the role of post- transcriptional events in the 
functionality of these receptors. 
 
Summarizing, we here describe that mRNA pattern of prostanoid E receptors is different in chronic 
rhinosinusitis from chronic rhinosinusitis/ nasal polyp patients. In the last group a down- regulation of EP1 
and EP3 receptor was observed suggesting that these molecules may have some implications in polyp 
development. This is a descriptive preliminary study which opens the door to more specific experiments 
including protein regulation and functional studies that will reveal more information about the role of these 
receptors in chronic rhinosinusitis diseases. 
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CHAPTER 6 
 
IMPLICATION OF STAPHYLOCOCCAL SUPERANTIGENS ON 
EOSINOPHILIC INFLAMMATION 
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Introduction 
 
Infection with staphylococcus aureus is a common feature in patients suffering from chronic rhinosinusitis 
and nasal polyposis. The implication of the enterotoxins (SEs) released from this bacterium in the 
pathogenesis of these diseases has been extensively suggested. In this study, we wanted to investigate 
whether the immune response triggered against S. aureus enterotoxins could be associated with clinically 
documented aspirin intolerance and how these two criteria are linked to eosinophilic inflammation. We here 
demonstrated that patients with aspirin intolerance showed an exacerbated eosinophilic inflammation 
compared to tolerant and healthy subjects and an up-regulated immune response against SEs in terms of 
specific IgE antibodies to these enterotoxins. There was not direct association between this response and the 
manifestation of aspirin intolerance to aspirin; suggesting that eosinophilic inflammation and response to SEs 
both contribute to the pathophysiology of this syndrome in an independent manner. 
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CHAPTER 7 
 
ROLE OF STAPHYLOCOCCAL SUPERANTIGENS IN THE 
REGULATION OF EICOSANOID PRODUCTION IN NASAL 
TISSUE AND STRUCTURAL CELLS 
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Introduction 
 
Several authors have suggested the implication of bacterial superantigens in the regulation of arachidonic 
acid cascade. These enterotoxins have been shown to induce leukotrienes and affect several immune-
modulatory cell functions. In the previous chapters we suggested that the presence of a S. aureus induced  
immune response may increase eosinophilic inflammation in nasal polyp patients, and showed that IgE-
antibodies to SEs was significantly increased in aspirin- intolerant subjects. We also showed that the up-
regulation of the arachidonic acid cascade runs parallel with the severity of inflammation. Based on these 
findings, we here aimed to study the tissue regulation of eicosanoid production in nasal polyp patients and its 
possible relation to an immune response to S. aureus enterotoxins. In this study, we found that leukotriene 
and lipoxin pathway is up- regulated in nasal polyp patients with an immune response to SEs and this seems 
to be correlated to the inflammatory reaction probably derived by these enterotoxins. 
  
Furthermore, it has been demonstrated that SEs influence the regulation of the airway remodeling process in 
both upper and lower airway diseases. That is why we aimed to investigate the capacity of SEs to regulate 
the production of COX- 2 and PGE2, in fibroblasts isolated from nasal tissue. Furthermore, we evaluated the 
capacity of these molecules to influence basic cell functions like cell growth and migration. This preliminary 
work showed for the first time that SEB down- regulate COX- 2 expression, endogenous PGE2 release and 
migration capacity but blocks cell growing. Of interest, it seems that this enterotoxin may influence nasal 
fibroblast metabolism by interacting with the MHC-II (classical binding) and also by an alternative 
mechanism independent of these molecules. This study open a new door to the implication of superantigens 
in the regulation of the remodelling process in upper inflammatory airway diseases. 
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ABSTRACT 
 
Background: Staphylococcus aureus derived enterotoxins (SEs) have been implicated in the pathogenesis of 
airway inflammatory diseases, esp. nasal polyposis. However, the exact role of these molecules in the 
regulation of eicosanoid synthesis in this pathology remains unexplored. Objective: We studied the possible 
impact of SE-induced immune responses on the eicosanoid production in nasal polyp (NP) patients. 
Methods: Tissue sample homogenates from NP patients, with (NP-SEs(+)) and without detectable IgE-
antibodies to SEs (NP-SEs(-)) (ImmunoCap system), were assayed for IL-5, MPO, LTC4/D4/E4, LTB4, 
LXA4, total IgE and ECP. Results: Inflammatory makers, eicosanoids and total IgE were significantly 
increased in NP-SEs(+) compared to NP-SEs(-) tissues, with the exception of MPO, which was similar in 
both groups. Eicosanoid concentrations correlated to IL-5 and ECP, however, only cys-leukotriene levels 
correlated with IgE-antibodies to SEs, independently of allergy and asthma. Conclusions: Eicosanoid 
synthesis is up- regulated in polyp tissue of patients with immune response to SEs and seems to be related to 
the inflammatory reaction induced by these enterotoxins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
ECP :   eosinophil cationic protein 
IgE-abs to SEs :   IgE antibodies to S. aureus enterotoxins 
IL-5:   interleukin- 5 
LTB4:   leukotriene B4 
LTC4/ D4/ E4:  leukotriene C4/ D4/ E4 
LXA4:   lipoxin A4 
MPO:   myeloperoxidase 
NP:   nasal polyps/ nasal polyposis 
NP-SEs(-):  nasal polyp patients without IgE to SEs 
NP-SEs(+):  nasal polyp patients with IgE to SEs 
SAgs:   superantigens 
SEs:   S. aureus enterotoxins  
Key words: 
 
Nasal polyposis, S. aureus enterotoxins, eosinophilic inflammation, leukotrienes, lipoxin A4, IgE   
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INTRODUCTION 
 
In the normal population, 30% of individuals are long-term carriers of Staphylococcus aureus (1). This 
Gram- positive bacterium can often be found in the normal microflora of the human skin, but also in the 
upper respiratory and intestinal tracts (2), and constitutes an important cause of community- and hospital-
acquired infections (3). S. aureus pathogenicity is generally related to the production of coagulase enzymes; 
however, these organisms are also able to secrete a variety of cellular antigens and toxins named 
enterotoxins, which have potent superantigenic properties (4). S. aureus enterotoxins (SEs) may influence 
the activity of both immuno- modulatory and pro-inflammatory effector cell types, and therefore may have a 
potentially important role in the pathogenesis of chronic inflammatory disease, including eosinophil-related 
airway diseases (5). It has previously been shown that local application of superantigens (SAgs) to the 
airways in mice develops a unique inflammatory immune response, characterized by T cells and eosinophils 
influx, increased levels of IL-4 and marked macrophage activation resembling intrinsic asthma (5). In 
addition, in humans, recent studies performed in nasal polyp patients and asthma have demonstrated that an 
increased colonization and/or a local immune response to enterotoxins, including the formation of polyclonal 
IgE-antibodies, is related to disease severity and eosinophilic inflammation (6- 9). 
 
The implication of bacterial superantigens in the regulation of inflammatory pathways such as the 
arachidonic acid cascade has also been suggested. Stimulation of basophiles from patients with atopic 
eczema with staphylococcal enterotoxins has been shown to induce the release of histamine and leukotrienes, 
indicating a role for these toxins as possible allergens in this group of patients (10). Additionally, incubation 
of permeabilized human polymorphonuclear granulocytes with staphylococcal toxic shock syndrome toxin 1 
and streptococcal erythrogenic toxin A resulted in the up-regulation of signal transduction pathways (release 
of LTB4) in these cells, affecting immune-modulatory functions (11). Finally, studies done in plasma 
samples from mice challenged with SEB showed that incubation with this enterotoxin resulted in an increase 
of 5-hydroxyeicosatetraenoic acid and LTD4 production, suggesting that these metabolites may be important 
in SEB- induced illness and shock (12).  
 
Previous research from our group suggested that the presence of a S. aureus induced immune response may 
increase eosinophilic inflammation in nasal polyp patients, and the finding of IgE-antibodies to SEs was 
significantly increased in aspirin-sensitive subjects (7, 8). This report has consequently been confirmed by 
Suh et al (9). We also showed that the up-regulation of the arachidonic acid cascade runs parallel to with the 
severity of inflammation and disease (13). Based on these findings, we here aimed to study the tissue 
regulation of eicosanoid production in nasal polyp patients and its possible relation to an immune response to 
S. aureus enterotoxins. 
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MATERIALS AND METHODS 
 
Patients  
 
Study subjects were selected based on a documented medical history, visible polyps upon endoscopy, and a 
positive CT- Scan. Samples from ethmoidal and maxillary sinuses were collected during routine functional 
endoscopic sinus surgery (FESS) at the Department of Othorhinolaryngology in the Ghent University 
Hospital. The patients were later classified into 2 groups: subjects with nasal polyps with IgE to SEs (NP-
SEs(+), n= 10) and nasal polyp without IgE to SEs (NP-SEs(-), n= 10). Patients undergoing septoplasty or 
conchotomy due to anatomical variations were considered as controls (n= 10). All patients gave informed 
consent before their participation and the study was approved by the ethical committee of the Ghent 
University Hospital.  
 
Table 1. Characteristics of patients groups 
 
 
 
 
 
 
 
 
 
Clinical diagnosis of nasal polyposis 
 
Clinical diagnosis of nasal polyposis was performed following the guidelines of the American Academy of 
Otolaryngology, Head and Neck Surgery. It was based on a documented medical history, typical symptoms 
and the presence of endoscopically visible bilateral polyps growing from the middle nasal meatus into the 
nasal cavities, and affecting ethmoidal and maxillary sinuses according to a computed tomography (CT)- 
Scan of the paranasal sinuses. Diagnosis of asthma was based on the clinical history, and pathological lung 
function tests, following the Global initiative for asthma (GINA) guidelines. Atopy was evaluated on the 
basis of the results of a skin prick test performed for a panel of allergens including: house dust mites, grass 
and tree pollen, cat dander and moulds. The use of any medication related to the disease, including systemic 
glucocorticoids, antibiotics and anti-leukotrienes, was stopped in all subjects 4 weeks before surgery. The 
use of topical glucocorticoids was interrupted 2 weeks before surgery. Patient’s characteristics are 
summarized in table 1. 
 
 Controls NP- SEs (-) NP- SEs (+) 
Number of patients 10 10 10 
Sex (female/ male) 2/ 8 1/ 9 2/ 8 
Age, years (mean + standard error) 36 (± 4.3 years) 40 (± 4.1 years) 51.7 (± 2.5 years) 
Number of patients with asthma 0 3 6 
Number of patients with aspirin sensitivity 0 2 4 
Number of patients positive for specific IgE to SEs 0 0 10 
Number with positive skin prick test 0 3 5 
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Sample preparation 
 
Tissue specimens were collected from the inferior turbinate for control patients, and from the paranasal 
sinuses from polyp patients during routine septal and sinus surgery and snap frozen until use. All tissue 
specimens were weighed, and 1 ml of 0.9% NaCl solution was added per every 0.1 g tissue. The tissue was 
then homogenized with a mechanical homogenizer (B. Braun, Melsungen, Germany) at 1000 rpm during 
5 min on ice. After homogenization, the suspensions were centrifuged at 1500 rpm for 10 minutes at 4 °C, 
and the supernatants separated and stored at -80°C until analysis.  Supernatants were collected and stored at -
80°C until use. For measuring eicosanoids levels, specific sample extraction procedures were applied as 
described bellow. 
 
Quantification of Total and Specific IgE  
 
Screening for total IgE and IgE antibodies was performed by using the UniCAP system (Pharmacia 
Diagnostics, Uppsala, Sweden). For IgE to SEs measurements, we used a mix of three SEs (SE A, SE C and 
TSST-1) coupled to a solid phase, using a cut- off of 0.35 kUA/L. Non- specific binding of IgE was evaluated 
using an ImmunoCAP coated with glycine- human serum albumin. 
 
Levels of Eicosanoids  
 
Concentration of cysteinyl leukotrienes (LTC4/ D4/ E4), LTB4 and LXA4 were measured by Enzyme Linked 
Immunoassays (ELISAs) purchased from Oxford BioMedicals (Oxford, USA). Sample extraction procedures 
for protein removal and eicosanoid stabilization were performed according to the provider’s instructions. 
Briefly, nasal tissues were first homogenized in ethanol (5 ml/g) and then centrifuged for 5 minutes at 3,000 
rpm at 4°C. Supernatants were diluted in water, pH 3.5 and processed by using C18 Sep-Pak light column 
(Waters Corporation, USA) following manufacturer’s directions (Oxford BioMedicals, Oxford, USA). The 
assays have a detection range between 0.04 and 10 ng/ ml and a sensitivity of about 0.2 ng/ ml. The intra- 
and inter- assay coefficient of variation was less than 10% for all assays.  
 
Markers for inflammation 
 
IL-5 and MPO concentrations were measured tissue homogenates by ELISAs purchased by R&D Systems 
(Minneapolis, USA) and OxisResearch (Portland, OR, USA), respectively. The detection range was 7.8- 500 
pg/ ml and the sensitivity < 3 pg/ ml for IL-5, and 1.6 - 100 ng/ ml and 1.5 ng/ ml for MPO, respectively. The 
intra- and inter- assay coefficient of variation was less than 10% for all ELISAs. Quantification of Eosinophil 
Cationic Protein (ECP) was carried out on supernatants obtained after homogenization of NP tissues by the 
UniCAP system (Pharmacia & Upjohn, Sweden), with a detection limit of < 0.2 µg/L. 
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Statistical data analysis 
 
All data were analyzed using the MedCalc software version 7.6 (Mariakerke, Belgium). Results are 
presented in Box-and-Whisker plots or Bars. In the Box and Whisker plots, the central box represents the 
values from the lower to upper quartile (25 to 75 percentile or interquartile range (IQR)), the middle line 
represents the median and line extends from the minimum to the maximum value, excluding "outside" and 
"far out" values. In the bars chart, the height represents the median and the errors bars represents the values 
from the lower to upper quartile (25 to 75 percentile or interquartile range (IQR). Data comparison within 
different patient subgroups was performed using the Kruskal-Wallis test (H-test). The Wilcoxon test (or 
Mann-Whitney U test) for unpaired samples was applied to evaluate the statistical differences between 
patient groups. Spearman’s rank correlation and multiple regression analyses were performed to determine 
statistical significance of differences between two parameters in a classification group. P values equal or less 
than 0.05 were regarded as significant. 
 
RESULTS 
 
Levels of total and specific IgE  
 
Nasal polyp patients were divided in two groups according to the presence of IgE-antibodies to SEs. Patients 
with IgE antibodies to SEs above 0.35 kUA/L were considered to be previously or currently exposed to SEs. 
Subjects containing no IgE antibodies or concentrations of less than 0.35 kUA/L were considered as SE 
negative. Levels of total IgE were significantly higher in the NP- SEs(+) patients compared to the NP-SEs(-) 
and control subjects as shown in table 2. 
 
Concentrations of eicosanoids and inflammatory markers  
 
Concentrations of eicosanoids are summarized in figure 1. Levels of LTB4, LTC4/D4/E4 and LXA4 were 
significantly higher in NP-SEs(+) compared to NP-SEs(-), p < 0.05 and control groups. The inflammatory 
markers ECP and IL-5 were also significantly increased (p < 0.05) in NP-SEs(+) compared to NP-SEs(-) and 
healthy subjects, however, MPO concentrations were comparable in both disease groups, and significantly 
higher than in control patients (table 2). 
 
DISCUSSION 
 
Bacterial colonization have been suggested as possible triggers of the inflammatory events in the 
development of nasal polyposis (2, 6- 9). It has been demonstrated that S. aureus enterotoxins are capable of 
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reacting with T- lymphocytes, and that these lymphocytes are stimulated to produce Th2 cytokines, with the 
consecutive increase of eosinophil survival and IgE synthesis (14). The possible influence of SEs on 
eicosanoid release has been described in atopic eczema (10). The purpose of this study was to investigate the 
possible impact of an immune response to S. aureus enterotoxins on the regulation of the eicosanoid 
pathway, which is clearly implicated in the pathophysiology of upper airway diseases, and the development 
of inflammation (13). We here show  that eicosanoid production in terms of LTC4/D4/E4, LTB4 and LXA4 is 
up- regulated in nasal polyp tissue of patients with IgE-antibodies to S. aureus enterotoxins, and the levels of 
these mediators correlated to eosinophilic inflammation markers and specific IgE to SEs.  
 
Table 2. Median and interquartile ranges (IQR) for inflammatory markers in tissue nasal polyp samples with 
and without immune response to S. aureus enterotoxins. (*): p < 0.05 is due to differences between the three 
sample groups; (**): p < 0.05 is due to differences in the levels between control and NP patients. (***): p < 
0.05 is due to differences between the control and NP-SEs(-) compared to NP-SEs(+) groups. 
 
 
 
Eicosanoids are important mediators of inflammatory reactions in sinonasal diseases. These mediators are 
released locally from most inflammatory cells present in, or recruited to the airways, by a variety of 
biological signals (15, 16). In this study, leukotrienes LTC4/D4/E4 were significantly higher in the nasal polyp 
tissue from NP-SEs(+) patients and correlated with levels of IgE-abs to SEs and markers of eosinophil 
activation (ECP) and survival (IL-5). So far, there is no evidence that SEs can directly influence the 
leukotriene regulatory pathway; however, it is known that these enterotoxins can induce the synthesis of IL-5 
and modulate eosinophil functions (17), and IL-5 can activate cytosolic phospholipase A2, resulting in the 
translocation and activation of 5- lipoxygenase enzyme, and hence in the induction of cysteinyl leukotriene 
synthesis (18). LTB4 is known to be synthesized by activated neutrophils, monocytes and alveolar 
macrophages with neutrophils representing the main source in inflammation. In this study, increased 
concentrations of LTB4 did not correlate with myeloperoxidase (marker for neutrophil activation), which 
levels were similar in both NP groups, suggesting that neutrophils might not be the main source of this 
eicosanoid. S. aureus superantigens have been suggested to induce neutrophil migration and activation (19) 
 Controls NP- SEs (-) NP- SEs (+) Kruskal- Wallis 
test 
Eosinophil cationic protein (µg/ L) 602.5 (IQR: 309.9- 
894.3) 
9806.9 (IQR: 1686.5 - 
17673.8) 
25583.0 (IQR:  
17226.0 - 29870.3) 
p < 0.01 (*) 
Interleukin- 5 (pg/ ml) 20.9 (IQR: 16.9- 25.0) 81.5 (IQR: 38.9- 291.9) 327.9 (IQR: 106.2- 
385.5) 
p < 0.01 (*) 
Myeloperoxidase (ng/ ml) 4882.8 (IQR: 3007.1- 
7015.0) 
8013.90(IQR: 4912.1- 
11476.0) 
9705.2 (IQR: 7426.1- 
17427.1) 
p = 0.01 (**) 
Total IgE (kU/ L) 1.9 (IQR: 1.9- 1.9) 323.9 (IQR: 67.2- 387.5) 1564.0 (IQR: 739.1- 
2039.7) 
p < 0.01 (*) 
IgE to SEs (kUA/ L) 1.9 (IQR: 1.9- 1.9) 1.9 (IQR: 1.9- 1.9) 8.6 (IQR: 6.3- 17.0) P < 0.01 (***) 
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and LTB4 has been demonstrated to be a potent neutrophil, but a weak eosinophil chemoattractant, which 
partially seem to contradict our results. However, other studies have also shown that the responsiveness of 
eosinophils to this eicosanoid may be increased in the presence of IL-5 (20) which is clearly increased in the 
NP-SEs(+) patients.  
 
Table 3. Spearman’s correlation analysis between arachidonic acid metabolites, inflammatory markers and 
specific IgE to SEs in nasal polyp groups. (*): p values less than 0.05; r: correlation coefficient. 
 
 
 
Additionally, activated mast cells can also considerably regulate leukotriene synthesis via IgE and cytokine 
mediated mechanisms (21). Although we did not measure any marker of mast cell degranulation in this 
study, previous research from our group showed no differences in the levels of tryptase and histamine in 
nasal polyp tissue from patients with and without specific IgE to SEs (6) which suggests that leukotriene 
production may not mainly derive from these cells.  
 
Furthermore, contribution of the 15-lipoxygenase- derived eicosanoids such as lipoxins is receiving 
increased attention in the field of inflammatory diseases.  These compounds are synthesized during cell-cell 
interactions between infiltrating leukocytes and tissue-resident cells, such as cytokine-primed endothelial or 
epithelial cells (16). Of interest, although lipoxins have been defined as anti- inflammatory lipid mediators, 
severity of asthma has been associated with an increase and activation of 15-LOX enzymes, collagen 
deposition and eosinophil accumulation (22), and lipoxins have been reported to increase chloride secretion 
in human bronchial epithelial cells (23). In this study, tissue levels of LXA4 were increased in NP-SEs(+) 
compared to NP-SEs(-) and correlated with ECP and IL-5, but not with IgE-abs to SEs in the NP groups. 
Accordingly, we can suggest that the eosinophilic infiltration observed in NP-SEs(-) and even more in the 
NP-SEs(+) group, may crucially account for the high levels of lipoxins observed. The role of this eicosanoid 
in the pathogenesis of nasal polyposis remains unclear.  
 
 LTB4 (ng/ml) LTC4/D4/E4 (ng/ml) LXA4 (ng/ ml) 
IgE to SEs (kUA/L) r = 0.63, p = 0.02 (*) r = 0.60, p = 0.01 (*) r = 0.26, p = 0.27 
total IgE (KU/L) r = 0.39, p = 0.12 r = 0.61, p = 0.01 (*) r = 0.37, p = 0.11 
Interleukin-5 (pg/ ml) r = 0.72, p = 0.01 (*) r = 0.59, p = 0.01 (*) r = 0.60, p = 0.01 (*) 
Eosinophil cationic protein (µg/ L) r = 0.62, p = 0.01 (*) r = 0.58, p = 0.02 (*) r = 0.77, p < 0.01 (*) 
Myeloperoxidase (ng/ ml) r = 0.06, p = 0.79 r = 0.14, p = 0.56 r = -0.19, p = 0.44 
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Figure 1. Concentrations of eicosanoids: LTB4, cysteinyl leukotrienes (LTC4/D4/E4) and lipoxin A4, in 
nasal polyp tissue from patients with (NP-SEs(+)) and without (NP-SEs(-)) immune response to S. 
aureus enterotoxins. P: p value after Mann-Whitney test for independent samples. 
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Finally, the possible impact of allergy and asthma on eicosanoid levels was studied. This issue was difficult 
to address due to the limited number of patients per group. We did not observe any differences in eicosanoid 
levels between NP-SEs(+) and NP-SEs(-), asthmatics and non- asthmatics, or allergic and non- allergic 
patients, with the exception of LXA4, which was increased in asthmatics. In addition, no correlation was 
found between local mucosal levels of IgE to SEs and skin prick positivity, confirming previous results 
indicating that the local immune response to SEs may be unrelated to allergy (6, 7). 
 
In conclusion, we show in this study that tissue leukotriene and lipoxin synthesis is significantly up- 
regulated in nasal polyp patients with an IgE involving immune response to S. aureus enterotoxins. In 
addition, this increase of eicosanoids seems to be correlated to the inflammatory reaction derived by SEs 
immune response and seems to be unrelated to asthma and allergy conditions. This work is a preliminary 
evidence of the possible impact of S. aureus infection in the regulation of inflammatory mechanisms like 
eicosanoid pathway, playing an important role in the pathophysiology of upper airway diseases.  
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ABSTRACT 
 
Background: Superantigens have been identified to interact with T-cells, granulocytes and structural cells to 
orchestrate inflammatory processes, and are likely to amplify airway diseases such as nasal polyposis and 
asthma. With the strength of inflammation, the release of anti-inflammatory prostanoids is reduced. So far, a 
direct mechanism by which enterotoxins could modify the prostanoid metabolism and related functions of 
the cells is unknown.  Objective: We studied the possible role of S. aureus enterotoxin B (SEB) on COX-2 
expression, PGE2 release, and basic cell functions like growth and migration in fibroblasts isolated from 
nasal tissue. Methods: Fibroblasts were isolated from inferior turbinate tissue and cultured in the presence of 
different concentrations of SEB. Pre-incubation with IFN-γ was performed to induce the expression of 
MHC-II receptors, facilitating the interaction with SEB. PGE2 production was assayed by Enzyme Linked 
Immunoassays. Expression of COX-2 and HLA-DR genes was assayed by real-time PCR. Migration and 
growth tests were performed, and the localization of SEB within the cells was assayed by confocal 
microscopy. Results: Nasal fibroblasts express high baseline levels of PGE2. Stimulation with SEB failed to 
induce any change in COX-2 expression or PGE2 release. However, after pre- incubation with IFN-γ, the 
enterotoxin significantly down-regulated PGE2 synthesis and COX-2 mRNA expression. In addition, the 
migration capacity of the fibroblasts was increased after SEB stimulation with, but not without IFN-γ pre-
stimulation. Cellular growth was blocked by the enterotoxin, and this effect was inhibited by IFN-γ. 
Conclusion: We here show that SEB down-regulates COX-2 mRNA expression, PGE2 release, and growth, 
and increases cell migration in nasal fibroblasts. SEB partially acts via the HLA complex, but also directly 
translocates into the cells. 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS: 
 
COX-2:  cyclooxygenase- 2 
HLA-DR: major histocompatibility complex, class II, DR alpha 
IFN-γ:  interferon gamma 
MHC-II: major histocompatibility complex, class II 
PGE2 :  prostaglandin E2 
SEB :  staphylococcus aureus enterotoxin B 
SEs:  staphylococcus aureus enterotoxins 
SAgs :  superantigens 
Keywords 
 
Nasal fibroblasts, cell growth, cell migration, staphylococcus aureus enterotoxin B, PGE2, 
COX-2, interferon gamma.  
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INTRODUCTION 
 
Fibroblasts are important sentinel cells of the immune system playing a critical role in chronic inflammation 
and tissue repair (1). However, the implication of these cells in the regulation of immune responses has been 
considered during a long time as relatively unimportant. Recently, several studies have demonstrated that 
fibroblast can interact with CD40 receptors. This interaction induce the activation of the transcription factor 
NF-κB and stimulate fibroblasts to synthesize high levels of cytokines (e.g. IL-6, IL-8), adhesion molecules 
(e.g. ICAM-1, VCAM-1) and cyclooxygenase metabolites (2, 3). In the airways, fibroblasts play a crucial 
role in the remodelling process where they are the primary cellular source of collagens I and III as well as of 
growth factors (4). Additionally, prostanoids, metabolites of arachidonic acid have been suggested to be 
crucial molecules in the control of remodelling process (5- 6).   
 
Moreover, recent studies have suggested the possible implication of bacterial superantigens (SAgs) in the 
pathogenesis of inflammatory airway diseases (7- 8). In vitro experiments, have demonstrated that 
staphylococcal enterotoxins (SEs) can selectively induces the production of interstitial collagenase over the 
expression of the tissue inhibitor TIMP in fibroblasts; and that phenomenon maybe mediated in part by PGE2 
and cyclooxygenase production (9). In addition, staphylococcal enterotoxin A (SEA) can selectively induce 
the secretion of stromelysin (MMP-3) from synovial fibroblasts, suggesting the role of bacterial SAgs in the 
regulation of articular destruction observed in inflammatory joint disease (10). More recently, in a study 
performed in bovine mononuclear cells, SEA and SEB induced PGE2 production, which had a modulating 
role on the proliferative response of bovine CD4+ and CD8+ T cells (11).  
 
Role of superantigens in the pathogenesis of upper airway diseases has become an important issue in the last 
years (6, 7). In a previous study, we showed that immune response to SEs was linked to an exacerbation of 
eosinophilic inflammation and up- regulation of leukotrienes and lipoxins within the nasal polyp tissue (19).  
Based on those findings, we aimed with this study to investigate the capacity of S. aureus enterotoxin B to 
regulate the production of PGE2 release, growth and migration processes in nasal tissue fibroblasts. 
 
MATERIALS AND METHODS 
 
Samples  
 
Fibroblasts were isolated from inferior turbinate tissue obtained from patients (n= 5) undergoing septoplasty 
or rhinoseptoplasty due to anatomical variations, and not suffering from any sinus disease. Surgery was 
performed in the the Department of Othorinolaryngology at the Ghent University Hospital. All patients gave 
informed consent before their participation and the study was approved by the ethical committee of the 
Ghent University Hospital.  
  
  
 
- 148 - 
Reagents 
 
Dulbecco’s Phosphate Buffered Saline (PBS), Penicillin-Streptomycin (5000 IU/ml and 5000 µg/ml), 
Tryptan Blue (0.4 % solution in phosphate buffered saline) were obtained from Invitrogen, Merelbeke, 
Belgium. Minimum essential medium (MEM), Opti-MEM I Reduced Serum Medium (Optimem I), L-
glutamine (200 mM), Trypsin- EDTA (1X) and Foetal Bovine Serum (FBS), qualified, origin USA) were 
purchased from GIBCO BRL (Life Technologies, Grand Island, NY. 5% Ultroser G were obtained from 
Biospera (Cergy- Saint- Christophe, France). Recombinant human IFN-γ was from R&D Systems, 
Minneapolis, USA and S. aureus enterotoxin B (SEB) were obtained from Sigma- Chemicals, MO, USA. 
SYBR Green I Master mix, Aurum total RNA and the Script cDNA synthesis Kits were obtained from Bio-
Rad laboratories (CA, USA).  
 
Fibroblast isolation from nasal tissue  
 
Nasal tissues  obtained during surgical operations were rinsed several times with Opti-MEMI suplmented 
with 5 % FBS, 5 % Ultroser G, 2 mM glutamine, 50 IU/ ml Penicillin- 50 µg/ ml Streptomycin and cut into 
small pieces (approximately 1 mm2). Diced specimens were then plated (density of 9 pieces/ 6 well tissue 
culture dishes) and incubated in a humidified atmosphere containing 5% CO2 at 37°C until a monolayer of 
fibroblast-like cells was observed to be confluent. Then, the explanted tissues were removed, cells were 
trypsinized, and replated into 250 cm2 tissue culture falcons at a final volume of 5 ml. The medium was 
changed every 3 days for 2 to 3 weeks until 90% confluence was obtained. Subsequently, the cells were split 
and passaged. The cells were characterized with antibodies against vimentine, cytokeratin and alpha- smooth 
muscle actin using the Peroxidase- anti- peroxidase technique. Stimulated cell cultures were centrifuged at 
4°C and the supernatants were collected and stored at -20°C until use. Subsequently, cells were trypsinized, 
washed, resuspended in Opti-MEM I, and then centrifuged. After the supernatants were removed one part of 
the cells were resuspended in lysis buffer for posterior RNA extraction and another part was stored at -80°C.   
 
Cell stimulation 
 
Cells were stimulated with 0.01, 0.1 and 1 µg/ ml of SEB or 10 ng/ ml of IL-1β for 24 hours at 37°C and 5% 
CO2.  To induce the MHC-II receptors cells were pre- treated with IFN-γ (10ng/ ml) during 24 hours at 37°C 
and 5% CO2  and then were stimulated with 0.01, 0.1, 1 and 1 µg/ ml of SEB during 24 hours at 37°C and 
5% CO2. We used a negative control per sample in each experiment that consisted in cells incubated only 
with culture medium ( MEM ). 
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Enzymatic immunoassays 
 
Concentration of PGE2 were measured by Enzyme Linked Immunoassays (ELISA’s) according to the 
manufacturer’s instructions (Oxford BioMedicals, Oxford, USA) with an intra- and inter- assay coefficient of 
variation for all ELISAs was less than 10%.  
 
Quantitative real- time PCR  
 
Cell cultures were centrifuged and pellets containing 1x106 cells were disrupted and homogenized in Lysis 
solution  and total RNA was extracted using the Aurum total RNA Mini Kit. cDNA was synthesized from 
1µg of total RNA by using the Script cDNA Kit following the manufacturer’s instructions. Amplification 
reactions were performed on an iCycler iQ Real-Time PCR Detection System with the following primers set: 
Fw- (HLA-DR1α): 5’- CATCAAGGGAGTGCGCA-3’ and Rev (HLA-DR1α): 5’-CTCCATGTGCCTT-
ACAGAGGC-3’ (product size: 64 bp, Genbank accession number: NM_019111) and Fw (COX-2): 5’-
GCTGGAACATGGAATTACCCA-3’ and Rev (COX-2): CTTTCTGTACT-GCGGGTGGAA (product size: 
88 bp and Genbank accession number: XM_051899). PCR reactions contained 20 ng of cDNA from cultured 
cells, 1x SYBR Green I Master mix and 300 nM of each primer. PCR protocol consisted of 1 cycle at 95°C 
for 10 minutes followed by 45 cycles at 95°C for 30 seconds and at 62°C for 1 minute. Ubiquitin C (UBC) 
and Hypoxanthine phosphoribosyl-transferase 1 (HPRT1) were used as internal control genes for 
normalization. Primer sequences for these genes were obtained from the Real Time PCR Primer and Probe 
Database from the Dept. of Medical Genetics from the University of Ghent 
(medgen.ugent.be/rtprimerdb).The relative number of molecules of each gene was expressed in relative 
expression units quantified per 20 ng of cDNA sample and was determined by the ∆CT value method.  
 
Growth curve assay 
 
Confluent cells in a 25 cm2 falcon were trypsinized with preheated trypsin- EDTA and resuspended in 5 ml 
of Opti-MEM I. Living cells were counted using a Neubauer counting chamber and seeded (10.000 
cells/well) in a 24-well plate and incubated with Opti- MEM I, IFN-γ (10 ng/ml) or SEB (0.1 µg/ ml) at 
37°C, 5 % CO2 for 24, 48 and 72 hours. Per each time point, cells were again trypsinized with pre- heated 
trypsin-EDTA and resuspended in 1 ml Opti- MEM I and number of living cells (per each time point) were 
quantified with Tryptane blue using the Neubauer counting chamber. 
 
Cell migration and wound healing assays 
 
Fibroblasts were seeded in a 35 mm diameter 6 well plate and incubated at 1x105 cells/ well in serum free 
medium MEM and allowed to grow until confluency during 7 days. Then, the medium was replaced by 1x 
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Dulbecco’s Phosphate Buffered Saline and cells were incubated at 37°C, 5 % CO2 for 5 minutes. The 
monolayer was wounded by pressing a sterile razor blade down onto the well making a sharp visible 
demarcation at the wound edge. The blade was then gently moved to one side to remove a part of the cell-
monolayer. Two separated 15- 20 mm wounds were made in the same well. The wounded layers were 
washed two times with Opti-MEM to remove the cell debris and incubated with Opti-MEM I and  IFN-γ (10 
ng/ml) or SEB (0.1 µg/ ml) at 37°C, 5 % CO2. Migrating cells were counted after 24 and 48 hours using a 
counting- eyepiece with grid graticule (10 mm x 10 mm). The first line of the grids falls together with the 
sharp beginning demarcation of the wound. Ten different places of each wound were counted. 
 
Statistical Analysis 
 
All data was analyzed using the MedCalc software version 6.0 (Mariakerke, Belgium), and presented as 
median and interquartile range (IQR). Data comparison within different patient subgroups was performed 
using the Kruskal-Wallis test (H-test). The Wilcoxon test for unpaired samples (or Mann-Whitney U test) 
was applied to evaluate the statistical differences between patient groups. Spearman’s rank correlation 
analysis was used to determine statistical significance of differences between two parameters in a 
classification group. P values equal or less than 0.05 were regarded as significant. 
 
Cell localization of SEB  
 
Cell localization of SEB was assayed by immuno-fluorescence confocal microscopy. Cryostat (Shandon) 
sections from nasal tissues (7 to 8 µm thickness) were prepared and collected on poly-D-lysine-coated glass 
slides, air dried for 24 hours at room temperature and stored at –20°C.  Tissue  sections  were  fixed  in  
acetone  for 10 minutes at 4°C and blocked using 0.4% fish skin gelatin/ 1X PBS for 2 hours at room 
temperature. The sections were then incubated with (1: 500) polyclonal antibody anti- SEB (Sigma, MI, 
USA) for 1 hour and with the secondary antibody (1:2000) anti- rabbit Alexa Fluor 526 (Molecular Probes, 
Leiden, The Netherlands) for 1 hour  at  room  temperature;  both  primary and  secondary  antibodies were 
diluted in 0.4% fish skin gelatin/ 1X PBS. The sections were then counterstained with 4', 6-diamidino-2-
phenylindole (DAPI) (Molecular Probes, Leiden, The Netherlands) for 5 minutes and mounted in 
Vectashield mounting medium (Vector Laboratories, CA, USA). The localization of the protein was 
evaluated using a Bio- Rad Radiance 2100 Laser Scanning Confocal Microscope System with the 4- line 
Argon primary laser, Green HeNe laser and the Blue Laser Diode. Analysis was performed using Adobe 
Photoshop (version 7.0) and Confocal Assistant (version 4.02, Todd Clark Brelje) software programs. 
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RESULTS 
 
Effect of SEB on PGE2 production  
 
Nasal tissue fibroblasts cultured in MEM in absence of stimulus produced significant baseline concentrations 
of mRNA of COX-2 and PGE2. Stimulation with SEB without pre- incubation with IFN-γ did not induce any 
change on PGE2 production or COX-2 mRNA expression. Only IL-1β increased significantly the release of 
these molecules (data nor shown). Induction of the expression of MHC-II molecules in fibroblasts after 
stimulation with IFN-γ was verified by real-time PCR, which showed an expression of the HLA-DR1α genes 
in all IFN- γ pre- stimulated compared to non-stimulated cells (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre- incubation with IFN-γ lead to a significant decrease of endogenous PGE2 and COX-2 mRNA (Figure 2) 
compared to non- stimulated cells. Interestingly, this down- regulation was acentuated after incubation with 
SEB at 0.1 and 1 µg/ml, but in a dose independent manner (Figure 2). In addition, incubation with IL-1β 
significantly increased the expression COX-2 and PGE2 release. 
PCR Amp/Cycle Graph for SYBR-490 
HLA-DR1α mRNA expression 
 
Figure 1. Curve after real- time PCR for HLA-DRα gene in nasal tissue fibroblasts showing amplification of the 
gene after pre- incubation with IFN-γ (red curves) and no amplification in cells without pre- incubation with the 
cytokine (black curves). After Mann-Whitney test  for independent samples: *: p <0.05 in comparisson to MEM, *§: 
p < 0.05 in comparisson to MEM and IFN-γ. 
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Furthermore, expression of the transcripts expressing the genes encoding for prostanoids E recptors (EP1, 
EP2, EP3 and EP4) was analyzed. Real time PCR results showed no changes in expression of EP1 and EP3 
receptors (Figure 3) but a SEB dose dependent down- regulation of EP2 receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of SEB on growth and migration 
 
Results of growing test were expressed as number of living cells after 24, 48 and 72 hours. Number of cells 
per each stimulus was compared to cells cultured only in MEM, which were considered as controls for 
normal growing. Cells in MEM showed a significant increase in proliferation after 24, 48 and 72 hours. The 
same pattern was observed in cells stimulated with IFN-γ and IL-1β (Figure 4). When cells were incubated 
with SEB however, no differences were observed between the number of cells after 24, 48 and 72 hours. The 
number of living cells after 24 and 48 hours was similar in cultures containing IFN-γ and stimulated with 
SEB, but significantly increased after 72 hours. Cell number however, was similar for all cultures after 24 
and 48 hours only at 72 hours a stattistical difference was only observed between plates containing SEB 
when compared with the other cultures. 
 
Furthermore, migration test results show the number of cells reaching a line (L2) situated at 240 µm from the 
culture wound after 24 (L2D1) and 48 hours (L2D2) of incubation with SEB, IFN-γ, IL-1β or MEM (Figure 
4).  
Figure 2. mRNA levels of COX-2 and concentrations of PGE2 in nasal tissue fibroblasts after stimulation with IL-1β, IFN-
γ, and SEB (0.01, 0.1 and 1 µg/ ml). (*): statistical differences compared with IFN-γ and SEB stimulated cells; (*§): 
statistical difference compared with non- stimulated cells (MEM); p value < 0.05 after Mann-Whitney test for independent 
samples.   
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This test showed that pre- incubation with IFN-γ did not change migration capacity of the cells. However, 
SEB in absence of the cytokine significantly induced cell migration (Figure 5). In addition, stimulation with 
SEB after pre- incubation with IFN-γ attenuated the effect of SEB. IL-1β as expected increased migration in 
fibroblasts and this effect was statistical significant compared to the one obtained with SEB.  
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Figure 3. mRNA levels of E prostanoid receptors (EP1, EP2 and EP3) in nasal tissue fibroblasts after stimulation with 
IL-1β, IFN-γ, and SEB (0.01, 0.1 and 1 µg/ ml). (*): statistical differences compared with IFN-γ and SEB stimulated 
cells; (*§): statistical difference compared with non- stimulated cells (MEM); p value < 0.05 after Mann-Whitney test 
for independent samples.   
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Figure 4. Growth curve for nasal tissue fibroblasts after incubation with SEB, IFN- γ and IL-1β. P: p value after 
Mann-Whitney test for paired samples (comparing samples within a group):  
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Figure 5. Migration test for nasal tissue fibroblasts after stimulation with SEB, IFN-γ and IL-1β. (*): statistical 
difference compared to non- stimulated (MEM), IFN-γ, SEB and IL-1β stimulated cells; p value < 0.05 after 
Mann-Whitney test for independent samples.  Graph shows the number of cells that migrating 240 µm from the 
wound site after 24 hours (L2D1) and 48 hours (L2D2). 
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Cell localization of SEB  
 
Cellular localization of SEB was assayed by confocal microscopy. Confocal images of nasal fibroblasts after 
incubation with 0.1 µg/ ml of SEB showed that the enterotoxin was localized in the cytoplasm but also in 
some regions of the nucleous of the cell. Of interest the same effect was observed after pre- incubation with 
IFN-γ followed by stimulation with 0.1 µg/ ml of SEB. However, in this case the enterotoxin was more 
localized in the periphery of cell cytoplasm and around the nucleous. Also in some cells nuclear localization 
was oberved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Fibroblasts have been demonstrated to be key cells in the remodelling process in airway diseases. These cells 
are ubiquitous and provide mechanical strength to tissues by providing a supporting framework of 
extracellular matrix. It has recently postulated that fibroblasts from different anatomic regions display 
characteristic phenotypes that are remarkably stable even after prolonged culture in vitro (12). In this study 
we confirm that nasal tissue fibroblasts can spontaneously express the COX-2 enzyme and release PGE2. In 
addition, we found that SEB down- regulated the expression of these molecules, stops the growth and 
increased the migration capacity of these cells.  
 
PGE2 is the major prostanoid product of fibroblasts in upper and lower airways (13) and is a potent inhibitor 
of important functions in these cells including cell proliferation and chemotaxis, collagen synthesis, and 
growth factors expression (14, 15). The role of PGE2 in airways has been mainly related to anti- 
inflammatory actions, where this prostanoid blocks collagen synthesis and attenuates inflammatory cell 
b a c
Figure 5. Confocal microscopy image (magnification 40X) performed in nasal tissue fibroblasts (a) non-
stimulated, (b) stimulated with SEB (0.1 µg/ ml) during 24 hours, and (c) stimulated with SEB (0.1 µg/ ml) during 
24 hours after pre-incubation with IFN-γ. The figure shows that SEB is internalized in the nasal fibroblasts and 
can be localized in the cytolpams and in the nucleous (white arrow) of the cell.   
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activation (18). However, Liu et al., (17) have reported a rich vascularity around COX-2 mRNA positive 
fibroblasts in nasal polyp tissue; and suggested that inducible COX-2 and probably PGE2 may contribute to 
nasal polyp development by promoting vasodilatation (17). In contrast, deficient production of this 
eicosanoid has been observed in fibroblasts from asthmatic patients and especially in the ones having aspirin 
intolerance (16). And this study is in line with the one reporting a PGE2 down- regulation in homogenates 
from nasal polyp and aspirin intolerant patients (20). Although the contribution of this prostaglandin in 
airways diseases remains unclear, we here suggest that staphylococcal enterotoxins may contribute to the 
pro- inflammatory reactions observed in upper airway diseases by down- regulating PGE2 release. 
 
In this study, SEB failed to induce changes in the cyclooxygenase pathway in cells that were not pre- 
incubated with IFN-γ. IFN-γ is the only cytokine able to induce both mRNA and protein expression of MHC- 
II molecules via the HLA-DR gene. In cultures containing IFN-γ, the cytokine significantly reduced the 
mRNA expression of COX-2 and the release of PGE2. Interestingly, SEB acentuated the effect of this 
cytokine but in a partial dose dependent manner. These results suggest that SEB may influence this pathway 
by acting via the classical binding to MHC-II. IFN-γ is released in response to infection by bacteria or 
parasites. The implication of this cytokine in upper airway diseases like chronic rhinosinusitis and nasal 
polyposis is not yet clear. In several studies, IFN-γ has been observed to be highly expressed in nasal polyp 
tissue and has been shown to induce expression of COX-2 in nasal polyp explants (21). Here we hypothesize 
that IFN-γ may provide the binding site allowing the SEB enter the cell and regulate PGE2 synthesis.  In 
addition, the existence of a possible alternative superantigen binding molecule (p85) in monkey renal 
fibroblasts was reported in 1995 by Rogers and col. (22). The binding of SEB to this site had an affinity 
equivalent to SEB binding by MHC-II, but at a site which does not permit recognition by the TCR. 
Although, no further studies have been done regarding this molecule we cannot exclude the presence of this 
site allowing the entrance of the enterotoxin to the cell.  
 
Finally, accumulation of fibroblasts is an important event in tissue response to injury and can occur via 
chemotactic recruitment accompanied by local proliferation of these cells. The second aim of this study was 
to investigate if SEB could affect the growing and migration capacity of nasal tissue fibroblasts. Of interest, 
this molecule blocked the growing process of these cells after 72 hours and in absence of IFN-γ. This effect 
seems to be independent of IFN-γ and is in contradiction with the findings of COX-2 and PGE2 in these cells. 
Increase of PGE2 has been reported to inhibit cell proliferation. According to our data, it seems that SEB may 
regulate fibroblast’s growing by a PGE2 independent mechanism. In addition, this stop in growing may be 
due to a toxic effect from the enterotoxin. The changes in this process were induced after 48 and 72 hours 
that may suggest a long period of incubation. However, this was partiallly confirmed with the confocal 
staining showing that SEB is internalized by the cell in absence of IFN-γ;  maybe by altering cell membrane 
permeability?. Accordingly, although some asumptions can be made suggesting an alternative binding of the 
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enterotoxin to fibroblasts, studies evaluating different time points of incubation will give a better vision of 
the interaction and toxicity of these molecules. 
 
Finally, cell migration is one of the steps involved in wound healing process in the airways and constitute a 
subject of interest since patients with nasal polyp and chronic rhinosinusitis patients often suffer of fibrosis 
and healing problems after surgery. Cell migration of nasal fibroblasts was significantly enhanced after 
stimulation with SEB only in cultures pre- incubated with IFN-γ. Surprisingly, it seems that there is a 
synergistic effect between thes two molecules due to no changes compared to non-stimulated cells were 
observed in cells incubated with the cytokine or SEB separately. Of interest, the number of cells that 
migrated but not the number that proliferated increased with the time. This suggests that SEB may has a 
primary effect on the rate of migration in these cells. The rate of migration of a cell depends on several 
interacting factors, including the ability of the cell to polymerize cytoskeletal elements resulting in protrusion 
of cytoplasmic processes at the cell edge, to adhere to subjacent matrix at the leading edge, and detach from 
substrate at the trailing edge (23). Influence of any of these processes by the enterotoxin could result in an 
increased rate of nasal fibroblasts migration by the enterotoxin. 
 
In summary, the current study demonstrates for the first time that SEB decreases COX-2 expression, PGE2 
release and stops growing but increase migration processes in human nasal tissue fibroblasts. The mechanism 
behind this action was not the objective of this work however, it seems that there are mechanisms other than 
the conventional binding via MHC-II that allows the enterotoxin enter the cell and influence its metabolism. 
This study has to be completed with experiments using PGE2, and MHC-II inhibitors that can add  more 
information to the regulatory mechanisms acting in these cells. This work add a new clue to the implication 
of superantigens in the development of upper airway diseases. 
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Chronic sinus diseases constitute one of the most common respiratory tract conditions in humans with a 
prevalence of 4- 15% in the general population and representing a considerable socioeconomic problem.  
Chronic rhinosinusitis has been understood as one disease that can be linked to different clinical appearances 
like nasal polyps. However, recent studies based on clinical parameters, release of cytokines, and regulation 
of inflammatory pathways lead to the thinking of considering it as a heterogeneous group of diseases with 
different underlying etiologies and pathomechanisms.  During the last decade, extensive studies have been 
performed on the field of eicosanoid metabolism and its regulation in chronic rhinosinusitis. These studies 
have shown the importance of this pathway in the balance of pro- inflammatory mechanisms operating in 
this disease. More recently, the idea of infection as an important disease modifier has been suggested. Both 
viral and bacterial infections have clear implication on the clinical picture of chronic rhinosinusitis. In this 
work, we aimed to find a link between eosinophilic inflammation, imbalance of eicosanoid metabolism and 
the possible role of S. aureus enterotoxins in the regulation of these processes. 
 
Quantitative real time PCR for gene expression analysis in chronic Rhinosinusitis/ Nasal polyposis 
 
Chronic rhinosinusitis with bilateral nasal polyps are characterized by abundant eosinophilic infiltration 
activation, and high amounts of IL-5 and eotaxin. IL-5 is one of the main cytokines detected at mRNA as 
well as at protein level in nasal polyp tissue (Bachert et al., 1997; Hamilos et al., 1998). The biological signal 
of this cytokine is mediated through its receptor consisting of a specific IL-5-binding α-chain, and a signal-
transducing common β-chain (Tavernier et al., 1992). 
 
Function and expression of this receptor can be regulated through splicing events generating two different 
transcripts: one encoding a membrane-anchored protein through alternative splicing, and a second one 
encoding a soluble form of this receptor, by normal splicing events (Tavernier et al., 1992). Adequate tools 
to investigate the regulation of the hIL-5Rα expression in vivo are mandatory to understand the 
pathomechanisms involved as well as to design future therapeutic approaches for eosinophil inflammatory 
diseases. However, no sensitive technique was available for the quantification of the small differences at the 
transcription level of this receptor. 
 
Real time PCR is increasingly used to quantify physiological changes in gene expression due to its large 
dynamic range of quantification and its high sensitivity. With the methodology established, we could 
quantify the hIL-5Rα splice isoforms in human peripheral blood and eosinophilic chronic rhinosinusitis 
tissue with an efficiency ranged between 95% and 97% for both splice variants. Specific amplification and 
coefficients of variation less than 2% for CT values and 25% for calculated quantities demonstrated the 
accuracy of the technique. We also showed an up-regulation of both isoforms in nasal tissue and blood from 
eosinophilic chronic rhinosinusitis patients compared to healthy subjects. Additionally, a significant over-
expression of the soluble isoform in peripheral blood from chronic rhinosinusitis patients compared to 
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control subjects was also found, which confirmed previous studies reporting an up- regulation of this isoform 
at protein level in subjects with nasal polyposis (Gevaert et al., 2003). Finally, the development of this assay 
will greatly help in the study of the regulatory mechanisms of this receptor in other eosinophil- related 
diseases such as asthma, atopic dermatitis, and hypereosinophilic syndrome, and hence will contribute to the 
development of future therapeutic strategies for eosinophilic inflammatory diseases. 
 
Internal control genes and RNA quality in expression studies in chronic rhinosinusitis/ nasal polyposis 
 
To ensure the accuracy and reliability of gene expression studies it is necessary to guarantee the quality of 
the starting material, and the selection of a good reference gene to normalize for differences in RNA quantity 
and cDNA synthesis efficiency. RNA degradation constitutes a major problem for gene quantification 
analysis specially when working with biological samples resulting in misinterpretations of the results. 
However, although this problem has been extensively discussed, control of RNA integrity is often not 
performed due to the limited availability of samples or the lack of the adequate methodology. In addition, 
stability of reference gene expression is an issue that has been only addressed in a few studies and none of 
them in tissues from upper airways.   
 
Reference genes are expressed constitutively in every cell. However, it has been demonstrated that their 
expression can vary according to cellular proliferation, cellular composition, and by individual genetic 
background (Glare et al., 2002). Our results show for the first time that the stability of reference genes is 
different in chronic rhinosinusitis and nasal polyp mucosa (as can be expected because of the differences in 
cellular origin). Additionally, gene-specific variation was always higher in degraded versus intact samples, 
with more pronounced differences in chronic rhinosinusitis compared with nasal polyp tissue. In non- 
degraded tissue samples from chronic rhinosinusitis without polyps, HMBS, SDHA, GAPD and ACTB were 
the most stable reference control genes, whereas in the chronic rhinosinusitis/ nasal polyp tissue: ACTB, 
TBP, SDHA and HPRT1 showed the highest stability. Furthermore, although not included in the article, 
analysis of the most stable references genes for normal nasal mucosa (inferior turbinate tissue) was also 
performed.  Of interest, these samples suffered a much less degradation compared to specimens obtained 
from nasal polyp and chronic rhinosinusitis tissue and showed indeed a different stability pattern for internal 
control genes compared to the other tissues studied. In this case, HMBS, TBP, ACTB and RPL3A were the 
most stable genes. Furthermore, genNorm analysis performed for the three different sample groups showed 
that HMBS, SDHA, GAPD and ACTB are the most suitable genes for normalization.  Among the most used 
reference genes used in gene expression analyses in chronic rhinosinusitis and nasal polyps we found B2M, 
GAPD, ACTB and HPRT1 (Song et al. 2003; Rhyoo et al., 1999 and Mullol et al., 2002). From these genes, 
only GAPD and ACTB were found to show a high stability. However, it is important to remark that as stated 
before, stability of these genes may vary according to the sample treatment and the type of sample, so we 
cannot fully exclude these genes as stable genes in the samples analysed.  
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According to these results, we can conclude that HMBS, GAPD, ACTB, and SDHA are the most suitable 
genes for normalization in gene expression analysis performed in samples from chronic rhinosinusitis with 
and without polyps and inferior turbinate tissue. Additionally, we strongly recommend performing RNA 
integrity analysis for each sample before carrying out gene expression studies.  
 
Regulation of eicosanoid metabolism and eosinophilic inflammation  
 
The arachidonic acid (eicosanoid) cascade is one of the most important pathways regulating the balance of 
pro- and anti- inflammatory reactions in the human body. As we described before this cascade contains two 
major different pathways that lead to the formation of prostaglandins, leukotrienes and lipoxins (Funk et al., 
2001; McMahon et al., 1995). As we already known, changes in these pathways have been described in 
chronic rhinosinusitis patients with antrochoanal polyps (Jang et al. 2000), allergic rhinitis and cystic fibrosis 
(Wurm et al., 2001). More importantly, altered balance of these eicosanoids has been thought to be the main 
cause of the occurrence of the aspirin intolerance syndrome. In the second part of this study we analyzed the 
local tissue eicosanoid regulation in terms of leukotrienes, prostaglandins and lipoxins production and their 
receptors in three subgroups of patients with chronic rhinosinusitis and we evaluated its possible correlation 
with the severity of eosinophilic inflammation and the clinical manifestation of aspirin intolerance. The 
results discussed in this section are summarized in figures 7, 8 and 9. 
  
CysLTs and LTRs have been described as potent inducers of airway smooth muscle contraction, vascular 
vasodilatation and vascular permeability, which are pivotal processes for the recruitment of leukocytes to the 
site of inflammation (Holgate et al., 2003). Concentrations of these eicosanoids as measured by means of 
ELISA, were significantly increased in chronic rhinosinusitis/ nasal polyp versus chronic rhinosinusitis and 
control subjects. This increase was in parallel with the up- regulation of the mRNA transcripts and protein of 
5-LOX and LTC4S enzymes. Additionally, CysLT1 receptor mRNA was also increased in chronic 
rhinosinusitis/ nasal polyp versus chronic rhinosinusitis and control subjects. Interestingly CysLT2 transcripts 
were similar in both chronic rhinosinusitis groups and higher than control subjects. In the chronic 
rhinosinusitis groups we found a direct link between lipoxygenase pathway and the severity of eosinophilic 
inflammation. These patients showed a high infiltration of activated eosinophils in the epithelium and tissue 
lamina propria (data not shown); and the number of these cells together with eosinophil mediators ECP, IL-5 
and IL-5Rα directly correlated with the levels of CysLTs. Furtherly, we analysed the activation of this 
pathway in aspirin intolerant patients which showed a significant enhance in the tissue expression of CysLTs 
and their enzymes: LTC4S and 5-LOX. 
 
Eosinophils are one of the principal cell types recruited to and activated at sites of inflammation, and are 
capable of elaborating high amounts of lipid mediators, including leukotrienes. The enzymatic pathways by 
which eosinophils synthesize CysLTs have been established (Bandeira- Melo et al., 2003), but the 
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mechanisms that physiologically regulate their biosynthesis remain to be elucidated. Potentially ‘‘activated’’ 
eosinophils may elaborate greater quantities of LTC4. Some known priming stimuli like eotaxin, PAF and 
IL-5 may participate in the recruitment and activation of these cells to sites of inflammation and induce 
CysLTs production by inducing the formation of lipid bodies in these cells (Bandeira- Melo et al., 2003). In 
addition, IL- 5 has been shown to induce translocation of 5- LOX to the nucleus in normal human blood 
eosinophils resulting in the activation of the enzyme and enhancing the capability of cysLTs synthesis in 
these cells (Cowburn et al., 1999).  Additionally, eosinophils also constitute one of the major sources for 
CysLT1 in the nasal mucosa (Sousa et al., 2002), which suggests a possible autocrine regulation of the 
leukotrienes synthesis able to maintain the high levels of these eicosanoids in the chronic rhinosinusitis 
tissue. Alternatively, CysLTs are known to be chemotactic for eosinophils and to promote eosinophilic 
inflammation through their ability to promote adhesion molecule P-selectin and CCR3 expression and to 
inhibit eosinophil apoptosis (Zhu et al., 2001). Accordingly, we speculate that the enhanced presence of 
CysLTs in chronic rhinosinusitis tissues might be in part a result of an increased infiltration and activation of 
eosinophils. Consequently this leukotriene up- regulation acts as a paracrine and autocrine factor for survival 
and chemotaxis of these cells (Figure 7).  
 
Together with CysLTs, LTB4 and LTB4 receptors (BLTs) were assayed. We found that protein levels of 
LTB4 and mRNA for BLT1 and BLT2 did not differ between the disease groups and normal nasal mucosa. 
Leukotriene B4 is thought to be an important mediator of inflammation as it is a potent activator and 
chemotactic agent for human neutrophils (Beeh et al., 2003). Of interest, controversial results regarding the 
regulation of this eicosanoid in upper airways diseases have been reported, difficulting the understanding of 
its role in these pathologies. Elevated concentrations of LTB4 have been found in nasal polyp patients with 
allergy in comparison to non-allergic subjects (Pinto et al., 1997) and in aspirin sensitive patients compared 
to healthy subjects, but without differences with the tolerant subjects (Sousa et al., 2002).  Production of 
LTB4 depends of the action of LTA4 hydrolase enzyme on its metabolite LTA4. However, LTA4 is a 
ubiquitous molecule that serves also as substrate for LTC4S, 12-LOX and 15-LOX. We found that levels of 
this eicosanoid were similar in all our patient groups and we hypothesize that it may be due to intrinsic 
regulatory mechanisms operating in chronic rhinosinusitis that lead to a switch to the CysLTs pathway 
instead to the LTB4 formation. Furthermore, it has been suggested that in some diseases the differences in 
eicosanoid levels between group of patients is due to the differences in number of the cells producing them 
an not due to a differential cellular synthesis. LTB4 is mainly produced by neutrophils which were present in 
the same extend in our patients groups. In this study, we did not investigate why the levels of LTB4 and 
BLTs are equal in all groups; this issue requires more investigation to be elucidated.  
 
Cyclooxygenases (COX-1 and COX- 2) catalyze the initial step in the formation of biologically important 
prostanoids, such as prostaglandins and tromboxanes. As leukotrienes, prostaglandins play a central role in 
ing, wound healing and immune responses.   
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Figure 7. Autocrine and paracrine effects of leukotrienes on eosinophil activation and recruitment.  
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The role of these eicosanoids in airway diseases have been mainly described in rhinosinusitis- aspirin 
intolerant patients. It has been demonstrated that in this group of patients, blockage of COX-2 reduce 
asthmatics symptoms and CysLTs release contrary to COX-1 inhibition that precipitates asthmatic attacks 
(Szczeklik et al., 2001). Additionally, it has been found that COX-2 expression is down- regulated in nasal 
mucosa of aspirin-intolerant patients (Picado et al. 1999; Szczeklik et al., 1999) and this is associated with a 
decrease and activation of the NF-κβ transcription factor, which modulates activation of several genes 
involved in inflammation including that of COX-2 (Picado et al. 1999).  
 
We first showed that COX-2 mRNA and PGE2 concentrations were significantly decreased in chronic 
rhinosinusitis/ nasal polyp tissue and even more in patients with aspirin intolerance. Of interest, PGE2 
concentrations were also significantly decreased in chronic rhinosinusitis/ nasal polyp patients without 
aspirin intolerance. These findings are in line with the ones reported by Gosepath and col. (Gosepath et al., 
2004), where COX-2 was found down- regulated in epithelial cells of nasal polyp tissue compared to normal 
nasal mucosa. Furthermore, we found an inverse correlation of PGE2 and eosinophilic inflammation markers 
Figure 8. Profile of the arachidonic acid metabolism in patients with chronic rhinosinusitis, chronic   
rhinosinusitis/ nasal polyp and chronic rhinosinusitis/ nasal polyp- aspirin intolerance. 
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such as ECP and IL-5 in the subgroups of chronic rhinosinusitis patients; which is in line with a study 
performed in sensitized mice showing an increase of eosinophil infiltration into the airway wall and 
eosinophil number in bronchoalveolar lavage fluid in COX-2 deficient mice (Nakata et al., 2005). Taking all 
together, we can suggest that down- regulation of COX-2 and PGE2 may play an important role in the 
maintenance of eosinophilic inflammation and hence in the high levels of CysLTs produced in chronic 
rhinosinusitis/ nasal polyp patients. However, the related pathomechanisms may not be exclusive for aspirin 
intolerance.  
 
In addition, evaluation of the expression of EP receptors, showed an increase in EP2 and EP4 receptors 
mRNA in chronic rhinosinusitis compared to control subjects whereas EP1 and EP3 were dramatically 
decreased in the nasal polyp patients. Until now, this is the first study reporting the gene regulation of these 
receptors in upper airway tissue. It has been demonstrated that EP2, EP4, and one isoform of the EP3 receptor 
can increase intracellular cAMP, which may be associated with inhibition of inflammatory cell functions 
(Tilley et al., 2001). On the other hand EP1, as well the EP3 variant can also increase intracellular calcium 
levels inducing activation of immune cells (Tilley et al., 2001). Down- regulation of PGE2 production may 
increase the expression of EP2 and EP4 receptors (Mita et al., 2002). Prolongation of eosinophil survival by 
PGE2 seems to be mediated by EP4 receptors (Peacock et al., 1999), which are highly expressed together 
with EP2 in eosinophils and inflammatory cells from asthmatic patients leading to the production of pro- 
inflammatory cytokines (Ying et al., 2004). The high levels of EP2 and EP4 receptors in the chronic 
rhinosinusitis and nasal polyp groups, together with the increase in eosinophil inflammation compared to 
healthy subjects support these previous results. However, remains unclear why the expression of these 
receptors is similar between the two chronic rhinosinusitis groups when the degree of eosinophilic 
inflammation is clearly higher in the nasal polyp group. Additionally, action of PGE2 on EP1/EP3 receptors 
showing induction of airway and pronounced allergic inflammation in asthmatics mice lacking EP3 receptor 
has been reported (Tilley et al., 2003). These findings together with the down-regulation of EP1 and EP3 
receptors and the low concentrations of PGE2 observed in chronic rhinosinusitis and even more in nasal 
polyp patients suggest that PGE2- EP3 interaction may play an important role in regulating allergic and 
inflammatory mechanisms in upper airways inflammatory diseases. 
 
Furthermore, eicosanoids produced by 12/ 15-LOX enzymes, the lipoxins, have been implicated in several 
airway inflammatory conditions (McMahon et al., 2004). However, knowledge on the expression and role of 
15-LOX and lipoxins in upper airways diseases is quite limited and controversial. In general, lipoxins (LXA4 
and LXB4), are associated with anti- inflammatory effects (Kantarci et al., 2003). However, there are in vitro 
experiments showing that LXA4 is able to induce a dose-dependent increase of the hyper- adhesiveness of 
human umbilical vein endothelial cells, leading to an increase in the binding of neutrophils to these cells 
(Bratt et al., 1995). In addition, it has been observed that patients with localized aggressive periodontitis 
produce more LXA4  compared  to  healthy  subjects,  suggesting  the possible  link of  this molecule with the  
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inflammatory process in these patients (Kantarci et al., 2005). Additionally, certain 15- HETEs, intermediate 
metabolites of the lipoxygenase pathway, may have some pro-inflammatory action, specifically neutrophilic 
chemotaxis and severity of asthma has been associated with increased expression and activation of 15- LO 
enzymes, collagen deposition and eosinophil accumulation (Chu et al., 2002). 
 
We here found an up-regulation of 15-LOX mRNA and LXA4 levels in the chronic rhinosinusitis patients 
compared to control subjects and a down-regulation in aspirin intolerant patients compared to tolerants. In 
addition, 15-LOX enzyme was localized in the epithelium and sub- epithelium of chronic rhinosinusitis and 
even more in nasal polyp tissues (data not published) confirming its expression in the nasal tissue. Chopped 
human nasal polyps have been shown to have a high capacity of producing LXA4 in presence of 
polymorphonuclear granulocytes (Edenius et al., 1990), which was confirmed in this study. The high amount 
of activated eosinophils infiltrating the nasal mucosa together with the strong immunohistochemical signal 
for 15-LOX observed in the epithelium of chronic rhinosinusitis and even more in the nasal polyp tissues, 
suggests that the increased levels of LXA4 may be related to a transcellular interaction between inflammatory 
(eosinophils) and tissue-resident cells, such as cytokine-primed endothelial or epithelial cells.  
Figure 9. Profile eicosanoid receptors in patients with chronic rhinosinusitis and chronic 
rhinosinusitis/ nasal polyposis 
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Lipoxin synthesis by eosinophils could be via transference of LTA4 to epithelial cells bearing 15-LOX 
enzyme or directly synthesis after stimulation by cytokines (e.g. IL-5) or other inflammatory mediators. 
However, the mechanism controlling the release of these mediators remains to be elucidated. 
 
Finally, contribution of these molecules in the pathogenesis of chronic rhinosinusitis/ nasal polyp remains 
unclear. In vitro studies performed in bronchial epithelial cells have shown that lipoxins can increase 
chloride secretion, which might affect water retention (Bonnans et al., 2003). Increased local release of 
inflammatory mediators causing sodium absorption and chloride permeability in epithelial from polyps 
leading to the recruitment of inflammatory cells have been also proposed as a phenomenon involved in the 
development of polyps (Bernstein et al., 1994). The role of these molecules and the mechanism operating in 
upper airway diseases will need further investigation. However, it seems that down-regulation of this 
molecule only in the aspirin-intolerant group maybe an important hallmark for this syndrome. However, 
what is contradictory and extremely interesting is why this reduced capacity of lipoxin production in patients 
with aspirin intolerance harboring abundant numbers of eosinophils and other inflammatory cells. 
Accordingly, it may be hypothesized that lipoxins are synthesized in chronic rhinosinusitis with and without 
nasal polyp as a natural response to balance the high levels of leukotrienes and to maintain tissue integrity 
and down- regulation in aspirin intolerant patients may be due to intrinsic changes (maybe in epithelial or 
endothelial cells as has been suggested) in this biosynthetic pathway unrelated to eosinophilic inflammation.  
 
Impact of superantigens on eosinophilic inflammation  
 
Eicosanoid regulation and eosinophilic inflammation, as we stated before, constitute important mechanisms 
in chronic rhinosinusitis and even more in nasal polyp and aspirin intolerance. Additionally pathogenesis of 
these diseases has been related to a number of factors such as fungi, allergy, bacterial infection, and most 
recently, superantigens. In 2001, work from our group showed an association between increased levels of 
specific IgE to S. aureus enterotoxins and eosinophilic inflammation in nasal polyps, pointing to the possible 
implication of bacterial superantigens in the pathophysiology of upper airway diseases (Bachert et al., 2001). 
Based on the previous findings we decided to evaluate the implication of S. aureus immune response on 
eosinophilic inflammation in patients with chronic rhinosinusitis/ nasal polyp and the manifestation of 
aspirin intolerance. Furthermore, we explorated the regulation of eicosanoid metabolism in terms of 
leukotrienes and lipoxins production in patients with IgE to staphylococcal enterotoxins and the correlation 
with eosinophil activation markers. Finally, we explorated the possible role of these enterotoxins in cellular 
process and eicosanoid release in strucutral cells. 
 
In our first study we found that concentrations of eosinophil-related markers such as IL-5 and ECP, as well 
as total IgE and IgE antibodies to SEs were significantly increased in nasal polyp patients compared to 
healthy subjects. In the nasal polyp tissue these eosinophilic markers strongly correlated with IgE antibodies 
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to SEs confirming our previous findings. Additionally, these mediators were also statistically higher in 
aspirin intolerant when compared to their tolerant counterparts. In these patient groups IgE to SEs was 
observed in 54% aspirin intolerant subjects and only 26% in the tolerant ones and these figures were un- 
related to the presence of allergy. Of interest, direct correlation between eosinophilic activation markers and 
IgE to SEs levels was only observed between patients with and without SEs immune response within the 
aspirin tolerant but not in the aspirin intolerant group. These results are partially supported by Suh et al., 
(Suh et al., 2004) who found that levels of ECP, total IgE, and specific IgE to SEs were higher in nasal polyp 
homogenates from aspirin intolerant compared tolerant subjects. However, on the contrary to our data these 
authors found a significant correlation between IgE to SEs and eosinophil activation markers in the aspirin 
intolerance patients.  
 
SEs act as superantigens by stimulating accessory or target T-cells by cross-linking the variable part of the β 
chain of the T-cell receptor but also can bind with MHC class II molecules in antigen presenting cells. 
Binding to T- cells, leads to a stimulation (20- 25%) of the naive T-cell population inducing multiclonal IgE 
synthesis and the release of Th1 and Th2 cytokines (e.g. IL-1, IL-3, IL-4, IL-5, IL-8) that may regulate 
eosinophil activation and apoptosis processes. Moreover, enterotoxins may also modulate eosinophil surface 
expression of CD9, CD11a, CD16, CD40, CD44, or CD63 receptors and hence modify important eosinophil 
functions (Wedi et al., 2002). It is not clear yet what is the real contribution of these enterotoxins in the 
pathogenesis of chronic rhinosinusitis/ nasal polyposis and aspirin intolerance syndrome. It is important to 
emphasize that chronic inflammation is the major problem in chronic rhinosinusitis and bacterial 
superantigens may act as disease modifier by continuously stimulate lymphocytes to produce the cytokines 
necessary for the maintenance of this inflammation. The link between eosinophilic inflammation and 
immune response to SEs may be due to the release of certain molecules like IL-5, GM-CSF and RANTES, 
which greatly contribute, to eosinophil chemotaxis, activation and survival.  Taking all together, we can 
hypothesize that staphylococcal superantigens may be a modulating factor of the local eosinophilic 
inflammation in chronic rhinosinusitis/ nasal polyp tissue. However, the contribution of this enterotoxin’s 
immune response to the clinical manifestation of aspirin intolerance remains unclear. Our data points that 
SEs may be a modifier more than a causative factor being dependent on a former damage of the nasal 
mucosa by unrelated mechanisms as suggested before (Bachert et al., 2001).  
 
Studies on the relationship between superantigens and eicosanoid metabolism  
 
Once infection occurs, a cascade of inflammatory events act as an amplified loop of immune reactions until 
the infection is contained. These early actions are later replaced by mechanisms that are more specific and 
eventually become redundant.  Thus, it is important for the inflammatory response to be limited and 
resolved. Many molecules like endogenous lipid-derived mediators (eicosanoids) play a crucial regulatory 
role in the maintenance or resolution stages of inflammatory response controlling its magnitude and duration. 
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Based in the later findings, we decided to investigate the role of these SAgs on eicosanoid release in chronic 
rhinosinusitis/ nasal polyp tissue and its relation with inflammatory process present in these patients. This 
study showed that eicosanoid production in terms of LTC4/D4/E4, LTB4 and LXA4 is up- regulated in nasal 
polyp tissue of patients with IgE-antibodies to S. aureus enterotoxins. Additionally, the levels of these 
mediators correlated to eosinophilic inflammation markers and specific IgE to SEs and were unrelated to 
asthma and allergy, which are clinical factors related to exacerbated eicosanoid release.  
So far, there is no evidence that SEs can directly influence the leukotriene regulatory pathway; however 
these enterotoxins can induce the synthesis of IL-5 which activates cytosolic phospholipase A2, resulting in 
the translocation and activation of 5-LOX enzyme, and hence in the induction of cysteinyl leukotriene 
synthesis (Cowburn et al., 1999). On the other hand, LTD4 which is secreted extracellularly may induce 
adhesion and behave as a potent chemoattractant for eosinophils which are recruited to the site of 
inflammation and then activated (Spada et al., 1994). Moreover, eosinophils may act as antigen presenting 
cells expressing the MHC-II surface molecules when activated with GM-CSF (Mawhorter et al., 1994), 
which can be expressed in high concentrations in the nasal polyp, resulting on cell activation and release of 
eosinophil granulocytes and pro- inflammatory mediators including leukotrienes. 
Additionally, it is important to emphasize that although eosinophils constitute an important cell type in 
eicosanoid release in upper airway diseases, activated macrophages may also greatly contribute to this 
pathway (Wehner  et al., 2001).  The role of these cells during mucosal inflammation involves events like 
pathogen clearance, antigen presentation, lymphocyte activation and its ability to produce cytokines and lipid 
mediators such as leukotrienes. Parallel studies from our group have shown an infiltration of activated 
macrophages in the nasal polyp tissue with S. aureus immune response. These cells expressing phagocytotic 
receptors such as mannose receptor have the ability of recognize microorganisms and subsequently activate 
secretion of inflammatory products that may include lipoxygenase derivate molecules.   
Another interesting observation of our study was that number of activated neutrophils did not differ between 
patients with and without SEs immune response. Activated neutrophils are important sources of LTB4 and 
LXA4 which concentrations were up- regulated in patients with IgE antibodies to SEs. S. aureus 
superantigens have been suggested to induce neutrophil migration and activation with subsequent release of 
LTB4. In addition, LXA4 have been shown to be secreted after bacterial infection and act as endogenous 
leukotriene antagonists and inhibitors of bacterial induced peripheral mononuclear cells recruitment in 
inflammation. The lack of correlation between LTB4 and activated neutrophils points to the existence of 
another source for the production of this eicosanoid such as eosinophils and macrophages, also bearing the 
enzymes necessary for its synthesis. On the other hand, the high levels of LXA4 may account not only from 
eosinophils but also from transcellular events between these cells containing LTA4 and endothelial cells 
synthesizing 15-LOX. LXA4 inhibits LTB4-induced neutrophil chemotaxis and migration of these cells 
across the endothelium, which can in part explain the similar numbers of neutrophils in the nasal tissues. 
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Accordingly, endothelial cells can express high levels of LXA4 receptor and may act as paracrine and 
autocrine factors regulating the expression of this eicosanoid in cell epithelium and circulating eosinophils 
and macrophages. However, the role of these molecules in the nasal polyp tissue of SEs positive patients is 
still a question mark; are they synthesized as natural counter- regulatory molecules or have some pro- 
inflammatory actions as has been suggested in periodontal diseases (Kantarci et al., 2005).  
 
Importantly, we cannot exclude that contribution of allergy and asthma conditions on eicosanoid levels and 
this issue was addressed in this study. Allergen inhalation in asthma induces the activation of mast cells and 
macrophages. Antigen processing and presentation by macrophages to undifferentiated T- helper cells may 
induce differentiation to the Th2 phenotype. This process results in the release of IL-4 and IL-5, causing IgE 
synthesis and eosinophil infiltration, respectively; which end in the release of pro- inflammatory mediators, 
including leukotrienes. Furthermore, activation of human lung mast cells with IgE has been shown to 
increase cytosolic free Ca2+. This results in the activation of Ca2+ dependent phospholipase A2 and the 
production of LTC4 provoking inflammatory cell influx into the airways and bronchial smooth muscle 
contraction (Cruse et al., 2005). Of interest, we did not observe any differences in leukotriene levels between 
SEs positive or negative subjects with and without asthma or allergic and non- allergic. These findings 
suggest that regulation of leukotriene production is a general phenomenon parallel to inflammation and may 
not be directly link to asthma or allergy conditions. However, surprisingly, LXA4 was significantly increased 
in asthmatics patients versus non- asthmatics with the highest levels in patients with IgE antibodies to SEs. 
Lipoxins have been identified in the bronchoalveolar fluid of patients with lung disease and found in 
decreased concentrations in patients with severe compared to subjects with mild asthma (Levy et al., 2005). 
However, in contrast to these previous results and partially in line with ours, Chavis et al., (2000) found that 
levels of lipoxins are the same in PBM from untreated and steroid dependent asthmatic patients, and that they 
are not synthesized in control subjects. Accordingly, these authors indicate that lipoxins can be produced at 
inflammation sites by transcellular metabolism associated to the inflammatory process operating in these 
patients. This made us suggest that lipoxins could be of interest as a biomarker to evaluate severity and the 
pathomechanisms not only in upper airway but also in lower airway diseases such as asthma.  
To confirm our findings in tissue, we decided to study the influence of SEs (SEB) in the eicosanoid pathway 
in nasal tissue fibroblasts due to their clear implication in the remodelling process in both upper and lower 
airways. Fibroblasts are the major source of extracellular connective tissue matrix, and the recruitment, 
accumulation, and stimulation of these cells are thought to play important roles in both normal healing and 
the development of fibrosis in airway remodelling. In the airways, PGE2 is mainly produced by smooth 
muscle cells, fibroblasts, and epithelial cells. In this study we demonstrated that nasal fibroblasts express 
high constitutive levels of PGE2 and COX-2 mRNA in culture.  
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Additionally, SEB failed to induce changes in COX-2 and PGE2 production when cells were cultured in 
absence of IFN-γ. Of interest, a significantly decrease in the levels of endogenous PGE2 and mRNA of COX-
2 was observed after stimulation with SEB in IFN-γ pre-treated cells. It is important to remark that in this 
study; cells were pre- incubated with IFN-γ to induce the MHC-II molecules, (which are normally not 
expressed in fibroblasts) and mimic the classical binding of superantigens to the cell. However, we cannot 
exclude the action of this cytokine on these cells. IFN-γ is present in elevated levels in upper airway 
inflammatory diseases and may induce the activation of lymphocytes and eosinophils within the tissue 
(Dellacono et al., 1997). This cytokine has been demonstrated to attenuate IL-1β induced PGE2 production in 
orbital fibroblasts (Han et al., 2005) and induce the synthesis and activation of cPLA2 protein in a human 
bronchial epithelial cell line (Wu et al., 1994). In line with these findings, our results show that IFN-γ 
induces COX-2 mRNA expression and PGE2 release in nasal fibroblasts. Additionally, staphylococcal 
enterotoxin A has been demonstrated to induce PGE2 production, COX-2 and cytosolic phospholipase A2 
(cPLA2) expression in IFN-γ treated fibroblast-like synoviocytes (Mehindate  et al., 1995),  however in nasal 
fibroblasts, SEB acted as an antagonist of this cytokine. Although there are no studies performed in nasal 
fibroblasts showing the effect of superantigens in PGE2 release, parallel results from our group have shown 
the presence of S. aureus and enterotoxins in epithelium of nasal polyps. It is known that interaction between 
fibroblasts and epithelial cells play a crucial role in the balance of eicosanoid levels via transcellular 
mechanisms. We here suggest that presence of SEB in chronic rhinosinusitis/ nasal polyposis may contribute 
to the exacerbation of inflammation in this disease by down- regulating fibroblasts PGE2 production.  
 
Moreover, staphylococcal superantigens have been shown to induce leukocyte infiltration that is dependent 
on the expression of ICAM-1 and TNF-α in mouse air pouches (Tessier et al., 1998). Additionally, 
stimulation of human alveolar macrophages with enterotoxin A (SEA) induced the synthesis and secretion of 
IL-8, which is a major neutrophil chemotaxin (Miller et al., 1996).  Of interest, enterotoxin B only induced 
migration in presence of IFN-γ and it seems that this cytokine somehow attenuate the effect of the 
enterotoxin. These controversial results can only suggest that SEB may act as a chemoattractant for 
fibroblasts however, this effect seems to be mediated by the binding of MHC-II. IFN-γ has been reported to 
increase the expression of both intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule (VCAM-1) in human lung fibroblasts (Spoelstra et al. 1999), which are molecules regulating the 
adhesion and migration processes.  Although it was not the objective of this work, it will be interesting to 
evaluate the expression of these molecules in our cell model to add more data about the possible mechanisms 
modulating the migration capacity of these cells. Finally, PGE2 has been reported to be involved in the 
regulation of the migration capacity of airway fibroblasts and hence modulate the wound healing process in 
the airways. Specifically, PGE2 is a potent inhibitor of fibroblast proliferation and collagen synthesis 
(Saltzman et al., 1982) and appears to inhibit fibroblast chemotaxis by modulating the rate of fibroblast 
migration (Kohyama et al., 2001.) We here showed that SEB blocks cell proliferation probably by entering 
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the cell by altering membrane cell permeabilization. However, its effect on rate migration was IFN-γ 
dependent but did not correlate with the release of PGE2.  This suggests that SEB may influence these 
processes by acting on different regulatory pathways as the ones involving this eicosanoid. 
 
In conclusion, we suggest that staphylococcal superantigens may influence significantly the pathogenesis of 
upper airway inflammatory diseases by not only modulating eosinophil activation but also by influencing 
fibroblast metabolism. The molecular mechanisms behind the action of these compounds remain unclear and 
futher studies are mandatory. The understanding of the regulatory mechanisms of important pathways like 
eicosanoid synthesis and cell migration by enterotoxins will surely be a pivotal element in our understanding 
of the role played by Staphylococcus aureus superantigens in upper airway diseases.  
 
Clinical relevance of the study 
 
Conventional medical treatment of chronic rhinosinusitis and nasal polyps consists of systemic 
glucocorticoids (decreasing doses), eventually associated with antibiotics, and then long-term use of 
intranasal steroids. The clinical efficacy of glucocorticoids depends mainly on their ability to reduce airway 
eosinophil infiltration and the concomitant massive plasma exsudation. Both topical and systemic 
glucocorticoids may affect the eosinophil function by reducing eosinophil viability and activation. 
Furthermore, they have been shown to reduce the secretion and release of chemotactic cytokines by nasal 
mucosa and polyp epithelial cells. However, a long-term use of steroids can induce severe side events 
including osteoporosis, growth retardation in children and thinning skin. Thus, in patients where 
corticosteroid treatment is contraindicated or induces side-effects, sinus surgery remains the only alternative. 
However, after surgery, some patients have been reported to have recurrency of polyp formation. This rate of 
recurrence is not only depending of technical skill of the surgeon, but also seems to be dependent of the type 
of nasal polyposis. Patients suffering from aspirin intolerance syndrome are more prone to have recurrences 
after sinus surgery. Our studies clearly demonstrated that patients suffering from nasal polyps with aspirin 
intolerance present different pathogenesis pathways and, subsequently, may differ in their clinical course. 
These evidences fully justify the urgent need for new alternatives in the management of chronic 
rhinosinusitis/ nasal polyposis and constitute a priority issue for research works related to these pathologies. 
The use of several 5-lypoxygenase inhitors and leukotriene receptor antagonists in the daily management of 
asthma and aspirin intolerance illustrates this trend. However, their use in chronic rhinosinusitis and nasal 
polyps is up till now limited.    
 
Our work will surely open new perspectives for alternative therapies in these diseases. These therapies may 
not only include corticosteroids and antibiotics but could also find a place for lipoxin analogs and 
lipoxygenases and leukotriene antagonists, which are known to have a modulating role in eosinophil and 
eicosanoid-derived inflammation.  
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FUTURE PERSPECTIVES 
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Based on the results discussed previously we intend to extend this work in the following directions: 
 
Regulation of the 15-LOX enzyme and its metabolites 15-HETE and LXA4 in upper airway diseases 
 
LXA4 has been considered to play a crucial role in resolving inflammation and stopping recruitment signals 
for neutrophils in the airways; however, the role of these metabolites in the regulation of inflammatory 
mechanisms in the airways is not yet fully understood. 15-LOX, the enzyme responsible for the synthesis of 
lipoxins exist in two isoforms, the 15-LOXa and the 15-LOXb. 15-LOX was shown in this work to be up- 
regulated in the diseases groups compared to controls, but down- regulated in the aspirin intolerant patients. 
Recent studies have shown the existence of three additional splice variants for 15-LOXb gene, which maybe 
have different regulatory (pro-) inflammatory functions (Bhatia et al. 2003).  Based on the later we will first 
develop a quantitative real time PCR protocol (in collaboration with Prof. Marek Kowalski from the Medical 
University of Lodz, Poland) together with a methodology for the detection of single nucleotides 
polymorphisms to study the expression of these splice variants in the nasal tissue. Furthermore, the cellular 
expression of these enzymes on inflammatory cells in the nasal tissue will be studied by double confocal 
microscopy staining.  This study will be performed in chronic rhinosinusitis with and without polyps and in 
cystic fibrosis patients, which have been reported to have a metabolic defect in this pathway. Furthermore, 
special attention will be focused in aspirin intolerant patients.  
  
Role of prostanoid receptors on inflammatory upper airway diseases 
 
We have demonstrated that prostaglandin E receptors mRNA is differentially regulated in chronic 
rhinosinusitis and nasal polyps compared to healthy nasal tissue. To extend this study we will evaluate the 
protein expression of these receptors by using western- blotting and double staining to identify their cellular 
localization. Furthermore, after the cellular source is identified, in vitro functional studies will be performed 
in cells isolated from peripheral blood and tissue of patients with chronic rhinosinusitis/ nasal polyposis. In 
this experiment, cells will be stimulated with different cytokines and pro- inflammatory mediators in 
presence of specific receptor antagonists to study the release of inflammatory molecules and the regulation of 
other eicosanoids like CysLTs. 
 
Mechanism of aspirin desensitization and the implication of AA cascade changes 
 
Aspirin desensitization is one of the most effective methods for patients with aspirin induced asthma with 
symptoms of chronic rhinosinusitis and recurrent nasal polyps. The regulatory mechanisms and eicosanoid 
metabolism during aspirin desensitization, has been a subject of very few studies to date. The implication of 
aspirin desensitization on the regulation of arachidonic acid cascade will be assayed in a double- blind study 
including chronic rhinosinusitis patients with and without aspirin intolerance. Here we will evaluate the 
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regulation of key enzymes and bioactive metabolites from the cyclooxygenase and lipoxygenase pathways 
including PGs, cysLTs and lipoxins. In addition, mRNA of eicosanoid receptor will be evaluated together 
with the incidence of polymorphisms in COX- 2 and LTC4S in these patients. This data will be furtherly 
related to clinical parameters on the lower and the upper airways. This study will be performed in 
collaboration with Prof. Andrew Szczeklik, from the Medical University of Krakow, Poland. 
 
Superantigens, eosinophilic inflammation and arachidonic acid pathway in upper airway diseases  
 
We have provide some evidences that SEs may be involved in the regulation of eicosanoid production in 
tissue and structural cells from patients with chronic rhinosinusitis/ nasal polyposis. Although the study of 
the splicit mechanisms was not the objective of this work, we have now a very wide view of the possible role 
that these enterotoxins may play in the pathogenesis of airway diseases. To further go on with this project we 
are currently studying the effect of SEB in the regulation of leukotriene and lipoxin pathways in peripheral 
blood from aspirin intolerant and tolerant patients (in collaboration with Prof. Marek Kowalski, Medical 
University of Lodz, Poland).  
 
In addition, our pre-liminar study on nasal  fibroblasts will be extended to define the mechanisms of SEB 
action on these cells. For that, we will first perform stimulation experiments at different time points to study 
the time dependent action of the enterotoxin. Subsequently we will perform inhibition studies with antibodies 
against MHC-II to verify the participation of this molecule in the binding of the enterotoxin to the cell. 
Parallel to this work we will evaluate the influence of the staphylococcal  enterotoxin in the regulation of 
other important mediators involved in fibroblasts metabolism like fibroblasts growth factors, adhesion 
molecules (VCAM-I, ICAM-I) and cytokines. Finally, we will evaluate the implication of SEB on the NF-κβ 
pathway. The nuclear factor kappa beta (NF-κΒ) is a transcription factor involved in the regulation of crucial 
mechanisms related to cytokine and lipid mediators’ release during inflammation. In this work, we will first 
study the mRNA expression of IκΒα and the IΚΚβ molecules, which are involved in the regulation of COX- 
2.  IκΒα is the endogenous inhibitor of NF-κΒ and IΚΚβ molecule is involved in the phosphorilation of 
IκΒα, and their balance is responsible for the activation and deactivation of the NF-κΒ activity. Furthermore, 
we will correlate the mRNA findings with activity assays and the release of PGE2 by the stimulated cells. 
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